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  Summary 
Multiple sclerosis (MS) is the most common cause of neurological disability in 
young population after trauma and represents a significant personal, social and 
economic public health burden. The clinical course and response to therapy of 
MS is highly heterogeneous, but most patients go from a relapsing-remitting 
disease course, where patients may respond to immunomodulatory drugs, to a 
steady progression and neurodegeneration that is unresponsive to any currently 
available treatment. Around 20% of MS patients present with the primary-
progressive form, for which there is no therapy. 
To date, reliable biomarkers that enable to distinguish among the different 
clinical forms of MS are lacking. Such biomarkers are highly desirable given the 
need to define which patients could evolve to progressive forms and the 
disappointing failure to stop primary and secondary progressive MS.  
Recent evidence 1 suggests that treatment failure with type I interferon (IFN) in 
hepatitis C may be linked to high dipeptydil peptidase (DPP) cleavage of one of 
its substrates, the chemokine IP10/CXCL10. Since MS is an organ-specific 
autoimmune disease in which type I IFN is the gold standard treatment to 
modify clinical course, we explored the role of DPP4 in MS pathophysiology. 
Our main objective was to identify blood biomarkers in MS through the following 
approaches: the identification of biomarkers that could discriminate between MS 
patients and healthy controls; biomarkers that could stratify MS patients and 
reflect pathophysiological differences according to their clinical form; and finally, 
the identification of biomarkers related with type I IFN signaling pathways that 
might help in the personalization of future therapeutic strategies for MS and 
provide mechanistic insight of MS pathophysiology. Secondly, we focused on 
the use of a combination of biomarkers using logistic regression for their 
predictive classification power achieving superior sensitivity and specificity.   
We studied 182 subjects (129 MS patients and 53 healthy controls) that were 
consecutively recruited during two years as two independent cohorts. The 
current investigation with an extensive multiplex set consisting of cytokines, 
chemokines, soluble receptors, growth and angiogenic factors, was evaluated 
using bead-based immunoassays (Luminex) and ELISA. The gene expression 
profiles of a vast array of genes related with type I IFN signature and MS 
 5 
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pathophysiology were studied in peripheral blood mononuclear cells (PBMCs) 
by BioMark technology. 
The data presented here show a significantly decreased expression of DPP4 
and DPP activity in the plasma of MS patients with respect to healthy controls, 
which might interfere in the chemokine immunoregulation in the central nervous 
system. In addition, DPP activity correlated inversely with clinical disability score 
in MS. On the other hand, our results demonstrate that the divergent clinical 
and histology-based MS forms are associated with distinct profiles of circulating 
biomarkers, mostly chemokines and growth/angiogenic factors (HGF, Eotaxin, 
MCP-1, Rantes, EGF, MIP-1β, VEGF and FGFb); and with different gene 
expression levels in their PBMCs (CLU, IRF2 and LDLR). Responder patients to 
type I IFN displayed high levels of plasma IP10 and MCP-1, and a specific 
expression pattern of IFN stimulated genes.  
In summary, this study has contributed to the identification of novel biomarkers 
and their combinations that might serve as useful tools for the classification of 
the different clinical forms of MS and to explore the pathophysiological 
differences between the progressive and the recurrent-remitting phase of the 
disease. 
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  Summary 
La esclerosis múltiple (EM) es la causa no traumática más común de 
discapacidad neurológica en adultos jóvenes y representa un significativo 
problema personal, social y económico para los que la padecen. La evolución 
clínica y la respuesta a la terapia es altamente heterogénea, pero la gran 
mayoría de pacientes pasan de una fase recurrente-remitente, donde los 
pacientes pueden responder a tratamientos inmunomoduladores, a una 
progresión y neurodegeneración continua que es intratable con los 
medicamentos de los que se dispone actualmente. Aproximadamente un 20% 
de los pacientes con EM debutan con la forma primaria progresiva, para la que 
hasta ahora no existe terapia. 
Por el momento, no existen biomarcadores que permitan distinguir con 
fiabilidad entre las distintas formas clínicas con EM. Tales biomarcadores 
serían altamente necesarios para definir aquellos pacientes que podrían 
evolucionar a formas progresivas de la enfermedad y el consiguiente fallo para 
detener la progresión en la EM primaria y secundaria. 
Evidencia reciente 1 sugiere que el fallo en el tratamiento con interferón de tipo 
I en la hepatitis C puede estar ligada a una mayor actividad enzimática 
dipeptidil peptidasa (DPP) en uno de sus sustratos IP10/CXCL10. Dado que la 
EM es una enfermedad autoinmune órgano específica, en la que el IFN de tipo 
I sigue siendo el tratamiento más utilizado para modificar el curso de la 
enfermedad, en este trabajo hemos querido investigar el papel de DPP4 en la 
fisiopatología de la EM. 
El principal objetivo de este trabajo fue el de indentificar biomarcadores de EM 
en sangre periférica mediante las siguientes aproximaciones: identificación de 
biomarcadores que pudieran discriminar entre pacientes con EM y controles 
sanos; biomarcadores que pudieran estratificar los pacientes con EM y reflejar 
diferencias fisiopatológicas según la forma clínica; y finalmente, la identificación 
de biomarcadores relacionados con la vía del IFN de tipo I que podrían ayudar 
a personalizar futuras estrategias terapéuticas para la EM y proporcionar 
información sobre los mecanismos de la fisiopatología de la EM. En segundo 
lugar, nos centramos en la combinación de biomarcadores mediante regresión 
logística para aumentar el poder de clasificación predictivo alcanzando mayor 
sensibilidad y especificidad. 
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Hemos estudiado 182 sujetos (129 pacientes con EM y 53 controles sanos) que 
fueron reclutados consecutivamente durante dos años como dos cohortes 
independientes. La presente investigación con un amplio set de citoquinas, 
quimiocinas, receptores solubles y factores de crecimiento solubles y 
angiogénicos, fue evaluada mediante inmunoensayos con microesferas 
(Luminex) y ELISA. Los perfiles de expresión génica de un amplio conjunto de 
genes relacionados con la señalización del IFN de tipo I y la fisiopatología de la 
EM, se estudiaron en células mononucleares de sangre periférica (PBMCs) por 
la tecnología BioMark. 
Los datos aquí presentados muestran una significativa expresión disminuida de 
DPP4 y de la actividad DPP en el plasma de los pacientes con EM con 
respecto a los controles sanos, lo que podría interferir en la inmunoregulación 
de quimiocinas en el sistema nervioso central. Además, la actividad DPP se 
correlacionaba inversamente con la escala de discapacidad clínica en EM. Por 
otro lado, nuestros resultados demuestran que las distintas formas clínicas de 
EM se asocian con distintos perfiles de biomarcadores clirculantes, en su 
mayor parte quimiocinas y factores de crecimiento/angiogénicos (HGF, Eotaxin, 
MCP-1, Rantes, EGF, MIP-1β, VEGF y FGFb); y con diferentes niveles de 
expresión génica en sus PBMCs (CLU, IRF2 y LDLR). Los pacientes 
respondedores a IFN de tipo I presentaban niveles elevados de IP10 y MCP-1 
en plasma, así como una expresión específica de los genes estimulados por 
IFN. 
En resumen, este estudio ha contribuido a la identificación de biomarcadores y 
de sus combinaciones que podrían servir como herramientas útiles en la 
clasificación de las distintas formas clínicas de EM y que permiten explorar las 
diferencias fisiopatológicas entre las fase recurrente-remitente y la fase 
progresiva de la enfermedad. 
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1.1. HISTORICAL PERSPECTIVE OF MULTIPLE SCLEROSIS 
The first description of multiple sclerosis (MS) dates from the XIV century 2, but 
it was in the XIX century when the first anatomopathological descriptions were 
made. Robert Carswell (1838) associated the presence of demyelinating lesions 
with clinical features and Jean Cruveilhier (1835) was the first to report clinical 
findings of a patient who would later develop demyelination 3. But it was some 
decades later, in 1868, when the French pathologist Jean-Martin Charcot 
formally describes the disease entity as “sclérose en plaques” and performs the 
first detailed correlation between clinical and post-mortem findings 4. 
Considered the founder of modern Neurology, Charcot‘s pictures illustrated the 
expansion of lesions from the ventricles into the cerebral hemispheres and he 
noted the accumulation of inflammatory cells perivascullary in brain and spinal 
cord white matter of patients 5, 6. The English physicians added the adjective 
“disseminated” due to the extension of lesions in the central nervous system 
(CNS) and the American neurologists the adjective “multiple” due to the multiple 
lesions and episodes of neurologic dysfunction 7. The French still conserve the 
original name given by Charcot, but the most used denomination of the disease 
is multiple sclerosis (MS). In 1933, Thomas Rivers was the first to induce 
experimental autoimmune encephalomyelitis (EAE), the animal model of MS, by 
injecting repeatedly brain emulsions and extracts from rabbits in primates 
provoking CNS demyelinating lesions. This immunization of mammals with CNS 
myelin suggests an autoimmune nature of the chronic inflammation present in 
the disease to self-antigens. In 1948, Elvin Kabat describes increments in 
oligoclonal immunoglobulins in the cerebrospinal fluid (CSF) of patients with 
MS, sustaining an inflammatory nature of the disease 8, 9. Nowadays, the 
etiology of MS remains elusive, but since the 1990s, several treatments 
available can modify the disease course of the relapsing form of MS, delaying 
neurological deterioration of MS, even if the mechanisms of actions of these 
drugs are not well understood. However, for the progressive forms of MS there 
is still no effective therapy. 
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1.2. EPIDEMIOLOGY OF MULTIPLE SCLEROSIS 
MS can be defined as a chronic inflammatory demyelinating disease of the CNS 
in which repeated episodes of inflammatory demyelination result in the 
formation of persistently demyelinated plaques of gliotic scar tissue associated 
with varying degrees of axonal loss 10. Anatomopathologically, it is 
characterized by the loss and disruption of the myelin sheath that surrounds the 
axons in brain and spinal cord, producing multifocal lesions in the CNS white 
matter 11 that can lead to axonal degeneration and to progressive neurological 
dysfunction. Common symptoms include visual disturbances, loss of balance 
and coordination, spasticity, sensory disturbances, bladder and bowel 
incontinence, pain, weakness, fatigue and paralysis.  
MS severely compromises the quality of life of the patient and their families, and 
has a huge adverse socioeconomic impact for MS patients, their families and 
society as a whole. 
1.2.1.         Incidence and Prevalence 
MS is the most common neurological disease that causes disability in young 
adults 7. The disease has an increasing prevalence worldwide that may be 
attributable to environmental factors or to a higher awareness and more 
accurate diagnosis.  
According to the Atlas of MS performed in 2008 by the World Health 
Organization (WHO), the median estimated incidence of MS in the world is 2.5 
per 100,000 (with a range of 1.1–4.0) 12. The estimated mean MS prevalence 
worldwide is 30 per 100,000 inhabitants (with a range of 5-200) (Figure 1). MS 
is more common in Europe, North America, Australia and New Zealand, with 
prevalences greater than 60 per 100,000. It is less common in Eastern 
Mediterranean (14.9), Central and South America (between 5 and 20 per 
100,000), the Western Pacific (5), South-East Asia (2.8) and Africa (0.3) 12. 
Data from continents like Africa must be taken with precaution as few countries 
provided data for this report. In Europe, the prevalence is the highest in the 
world: 80 per 100,000. Scotland has the highest prevalence rate with 200 13 and 
the Scottish Orkney islands with 402 14 per 100,000 inhabitants. Other countries 
with very high prevalences are: Hungary (176 per 100,000), Slovenia (150) and 
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Germany (149). Data from this atlas generally confirm the observation stated by 
the neurologist John Kurtzke, in 1975, of that MS prevalence increases the 
further countries are from the equator 15. A north-to-south gradient of declining 
prevalence of MS seems to be still present in Europe, but there are several 
exceptions to this rule. For instance, very close geographical regions like Sicily 
(>60 per 100,000) and Malta (4 per 100,000) have totally different prevalences 
16.  Southern European countries like Spain and Italy have also high MS 
prevalences, between 60 and 100 per 100,000 that have increased in the last 
years 16. In the United States of America and Canada, the prevalence is over 
130 per 100 000 12 (Figure 1). 
 
Figure 1 Multiple Sclerosis prevalence in the world. Figure taken from the Atlas of 
MS 2008 (World Health Organization). 
 
1.2.2.     Age of Onset and Sex Dimorphism in Multiple Sclerosis 
Although the disease has a broad range of age at onset (85% of cases occur 
between the ages of 14 and 55), the disease symptoms typically start at 
childbearing years, around 30 years of age. Globally, the average age of onset 
is 29.2 years, with an interquartile range of 25.3 and 31.8 years 12. Children can 
also suffer from MS, before the age of 16 years old, girls are more frequently 
affected than in MS adult-onset (female/ male ratio F/M=2.8 vs 1.8). Children 
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with MS take longer to arrive to a disabling progressive state of the disease but 
do so at a younger age 17. 
As observed in other autoimmune diseases 18-20, MS affects more frequently 
young women than men and the disease course is modified by pregnancy and 
decreases after menopause 21. During pregnancy, the frequency of MS relapses 
clearly decreases with a subsequent surge at postpartum 20, 22-25. The current 
F/M ratio is 2/1 worldwide 12 but some populations (Canadians, Japanese, 
Northern Finnish, Iranian, Sardinian) have reported a higher incidence in 
women over the last decades increasing the female/male ratio to more than 3/1 
26-30, while others populations have not (Swedish) 31. This rapid change in 
female incidence of MS in some populations is thought to be due to 
environmental factors rather than to genetic ones. Potential factors underlying 
the sex-bias in MS are the effects of sex hormones on immune responses 32-34 
and the differential distribution of sex hormones receptors in immune cell 
subsets 35, 36. 
1.2.3.        Environmental Factors 
The cause or causes of MS remain unknown. MS is now considered a complex 
disorder that is triggered in genetically susceptible individuals by different 
environmental and stochastic factors 37.  
1.2.3.1.  Migrations 
Several studies from migrations have demonstrated that the risk of developing 
MS depends on the place of residence in childhood. Children who migrate early 
in life from low-risk regions to high risk regions have an increased risk of 
developing MS 38. In the first generation, Asian immigrants’ children from 
countries with low incidence show a similar incidence of MS to the host country 
children 39, what reflects the importance of environmental factors rather than of 
genetic ones. 
1.2.3.2.  The Hygiene Hypothesis 
This hypothesis states that hygiene based reductions of cross infections during 
infancy explain the rise of autoimmunity or allergies as an adult 40. 
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In 1966 Leibowitz et al. observed that MS patients had lived in cleaner 
conditions during childhood than their contemporary controls 41. They proposed 
that a certain sanitary level early in life might represent a 'threshold' for the risk 
of developing MS later. They agreed with the hypothesis stated previously by 
Poskanzer et al. 42 that MS might be a manifestation of a subclinical infection 
acquired later in life by the individual when sanitary conditions were high during 
childhood. Given the similarity of the epidemiological patterns of poliomyelitis 
and MS, Poskanzer et al. suggested an enteric infection as cause of the 
disease. This is why the hygiene hypothesis was originally named the 
poliomyelitis hypothesis. Epidemiological studies have later observed an 
increase in the incidence of MS associated with a reduction in intestinal 
parasitic infections 43, 44. 
1.2.3.3.  The Human Herpes Virus Family   
Many epidemiological studies have searched for a causative infectious agent in 
MS and viruses have been widely associated with MS etiology. Human herpes 
viruses (HHV), especially herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) 
have been thoroughly studied in the last decades and suggested as possible 
triggers of MS disease. HHV are double stranded DNA (dsDNA) viruses 
ubiquitous and neurotropic that induce lytic, persistent and latent infections 45. 
HHV-6 is a T lymphotropic herpes virus expressed in neurons and glia from MS 
and normal brains 46, 47 but only in the oligodendrocytes from MS plaques and 
not in control brains, what suggests an active replication of the virus 46. HHV-6 
DNA and increased concentrations of IgG and IgM antibodies in blood and CSF 
have been found only in a minority of patients and seem to correlate with 
exacerbations in the relapsing-remitting phase of the disease 48-50. Furthermore, 
those MS patients without active replication of HHV-6 respond better to IFNβ 
treatment than those with active replication of the virus 51. Two polymorphisms 
in the gene MHC2TA (rs4774C and rs3087456G), gene that codes for the 
transcription factor CIITA involved in the regulation of HLA class II expression 
52, is associated with active replication of HHV-6 in MS 51, 53. 
EBV or HHV-4 virus is a B lymphotropic herpes virus transmitted primarily via 
saliva. EBV provokes a latent infection in B lymphocytes with permanent 
immunological stimulation through life 45. EBV infection is very common and 
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subclinical in children, but in adults it causes an acute febrile syndrome, known 
as infectious mononucleosis (IM). More than 99% of MS patients have an EBV 
infection compared to 86-95% in healthy controls 50, and the relative risk of MS 
for EBV-negative individuals is very low (OR, 0.06; 95% CI, 0.03–0.13) 54. 
Pediatric MS and EBV infection have been also associated. In a European 
cohort of children with MS, 99% were EBV-seropositive compared to 72% age-
matched controls 55, while in a North American pediatric cohort with MS, only 
86% were EBV-seropositive compared to a 64% in healthy controls 56. 
Therefore, children with MS seem to be infected at higher rates of EBV than 
their age-matched controls. In adults, MS patients who acquired EBV in 
adulthood, manifested as IM, had a twofold to threefold higher risk of MS 57, 58. 
Additionally, seroepidemiological studies have revealed that high levels of EBV-
antibodies were associated with higher risk of MS and the elevation of antibody 
titers to EBV nuclear antigen-1 (EBVNA-1) has been observed years before the 
first symptoms appear 59. In a large prospective study with 50 million serum 
samples from US military 60, only 5% were EBV-seronegative and 10 cases of 
MS occurred among these EBV-seronegative baseline subjects who developed 
first symptoms of MS several months after serological positivity for MS. In order 
to establish whether EBV infection is a putative causative agent of MS, those 
children EBV-seronegative with MS should be followed up to see whether they 
evolve to the classical MS adult disease. In addition, Lang et al. demonstrated 
the molecular mimicry between a myelin basic protein (MBP) and an EBV 
peptide, four DRB1* restricted T cell receptor peptide contacts are identical to 
both proteins, so the immune response to the virus would cross-react with self-
myelin and induce demyelination 61. Overall, EBV infection increases the risk of 
developing pediatric MS and in adult-onset MS, late EBV infection, presented 
as IM, is associated with MS. Molecular mimicry must be considered as a 
possible pathophysiological mechanism. 
In summary, up to date no virus has been isolated or directly linked with MS. 
However, different pieces of evidence suggest that the disease may be 
triggered by an infectious agent and evolve to an immune-mediated chronic 
disease.  
15 
 
  Introduction 
1.2.3.4.  Vitamin D 
The geographical distribution of MS correlates with the duration and intensity to 
sun exposure 62-64 . UVB radiation is the major source of vitamin D, although 
this vitamin can also be ingested with the diet (i.e. fatty fish) or from dietary 
supplements. There are some large longitudinal studies that support the inverse 
association between vitamin D and risk of MS. A prospective follow-up study for 
over 20 years of 182,000 female nurses documented 173 MS patients and 
found a MS risk 33% lower in those women who took the highest vitamin D 
intake (from food and supplements) than in those in the lowest quintile 0.67 
(relative risk [RR]=0.67, 95% CI = 0.40-1.12; p = 0.03). Specifically, women who 
took daily at least 400 IU of vitamin D from supplements, had a MS risk 41% 
lower than those with no vitamin D supplement intake ([RR]=0.59, 95% CI 0.38-
0.91; p=0.006) 65. Another nested case-control study in personnel of the US 
military 66 found that high levels of serum 25(OH) vitamin D levels (>99  nmol/L) 
in young non-Hispanic white adults had a 62% lower MS risk, with 
independence of vitamin D status in childhood. Lucas et al. studied cumulative 
lifetime sun exposure by measuring the degree of actinic damage in the dorsum 
of the hand and its association with a first demyelinating event (FDE) among 
216 MS patients and 395 matched controls from the same latitudes in Australia. 
Higher actinic skin damage was associated with decreased FDE.  
CYP27B1 is the enzyme that hydroxilates 25(OH) vitamin D to its active form 
1,25-dihydroxycholecalciferol (calcitriol). Homozygous carriers of nonfunctional 
mutations suffer from rickets type 1, a very rare disease, but in three patients 
studied in Norway with this disease during childhood, all of them developed MS 
as adults 67. Moreover, heterozygous carriers of mutations in CYP27B1 have 
lower levels of calcitriol and an increased risk of developing MS 68. 
1.2.4.          Genetics 
MS familiar studies have proven the relevance of genetic susceptibility to MS. 
Monozygotic twins of the index case have a ≈25% risk of developing MS, 
dizygotic twins a ≈5% and non-twin-siblings have a 20 to 40 fold increased risk 
69-71. Non-biological relatives living with affected patients and MS subjects who 
were adopted soon after birth have no higher risk than general population, 
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indicating that sharing the environment with MS is not a risk factor for acquiring 
the disease and that familial aggregation of MS is genetically determined 71. 
The major histocompatibility complex (MHC) exerts the most important 
contribution to MS susceptibility. The genetic association with MS and the MHC, 
a cluster of genes on the short arm of chromosome 6, was identified more than 
30 years ago 72, 73. As MHC molecules select the (autoreactive) T-cell repertoire 
and determine the ability of T-cells to respond to a specific antigen, this 
association highlights the central role of self-reactive T cells in MS pathogenesis 
74. The strongest and more replicated genetic association with MS is the DR15 
haplotype with the corresponding genotype DRB1*1501-DQA1*0102-
DRQB1*0602. This allele is very common in countries with high MS prevalence 
(14-30%) 75, and is present in all populations except for Sardinian and other 
Mediterranean groups in whom MS associates with DR3 and DR4 haplotypes 
(DRB1*0301-DQA1*0501-DRQB1*0201 and DRB1*0405-DQA1*0301-  
DRQB1*0302) 76, 77. Being heterozygous for the DRB1*1501 allele increases the 
risk of MS by three fold and homozygosity by over six fold 78. Interestingly, the 
haplotype DRB1*03 (ancestral haplotype 18.2) has been recently associated 
with MS and is restricted to patients with IgM oligoclonal bands (OB), a bad 
prognostic marker, conferring a risk similar to that caused by DRB1*1501 79. 
Interactions between different MHC-DRB1 alleles, called epistatic interactions, 
can either increase the risk or confer protection in MS 78.                                                    
Genome-wide studies involving large number of patients have identified 
protective effects endowed by HLA-C5 80 and HLA-DRB1*11 81, 82 and 
increased susceptibility in immunologically important risk alleles: IL-2RA 83, 
CD58 84, STAT3 85, IL-7RA 86. A recent large-scale meta-analysis of most of the 
genome-wide single nucleotide polymorphism (SNP) known for MS has 
validated the described SNPs and discovered three new loci of MS 
susceptibility and remarked the common presence of some SNPs in other 
autoimmune diseases and inflammatory conditions 87. The association of Non-
MHC II risk alleles is not as strong as with MHC II alleles. In the Spanish 
population, an association between MS susceptibility and a polymorphism 
located in the promoter of the tumor necrosis factor-alpha (TNF) gene, 
rs1800750 (TNF -376) has been described 88, 89. This polymorphism was later 
17 
 
  Introduction 
on found in a subgroup of Spanish MS patients characterized by the presence 
of oligoclonal IgM bands against myelin lipids (OCMB) restricted to the CSF 90. 
 
As it is summarized below, MS is a complex autoimmune disease with 
multiple internal and external factors that may trigger autoreactivity to self 
antigens in the CNS. The CNS interacts with the immune system and the rest 
of intrinsic and stochastic factors targeting the disease process 37. 
 
Figure 2 Multiple Sclerosis, a multifactorial disease. Ideas from 91. 
 
 
1.3. NATURAL HISTORY OF MULTIPLE SCLEROSIS 
1.3.1.         Clinical Course 
MS is a clinically heterogeneous disease that varies according to the location of 
plaques or lesions in the CNS. Most of the patients with MS (80%) present with 
an acute attack, called clinically isolated syndrome (CIS), which can affect one 
or several neurological sites of the organism 92 (Table 1). Neurological sites 
more usually affected in CIS include the optic nerve, spinal cord, brainstem or 
cerebellum and rarely a cerebral hemisphere 93. The most frequent symptoms 
include optic neuritis in one eye with visual disturbances; paresthesias in the 
extremities suggesting a spinothalamic abnormality and weakness in feet or 
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hands reflecting motor dysfunction of the spinal cord. If there are white matter 
lesions detected by magnetic resonance imaging (MRI), the risk of suffering a 
second relapse increases 94. New attacks occur with different frequencies, but 
rarely exceeding 1.5 per year 95. This clinical form is known as relapsing-
remitting MS (RR-MS), characterized by recurrent relapses with total or partial 
recovery and a disease inflammatory course that can be modified with therapy. 
After a median of 15 years from disease onset 92, progression evolves in around 
65% of patients and they enter in the secondary-progressive MS form (SP-MS). 
Around a 20% of patients have a progressive onset without relapses, known as 
primary-progressive MS (PP-MS) 95 (Figure 3). For the SP-MS and PP-MS 
evolutive forms, available treatments are unable to stop the progression of the 
disease. Older age at relapsing-remitting (RR) phase, high relapse frequency in 
the first two years of disease and short first-inter-relapse interval (< 6 years) are 
associated with higher risk of more rapid progression to SP-MS 92, 96.  
Some patients with RR-MS present with the mildest phenotype of MS called 
“benign” MS. These patients are not disabled after ten or more years of the 
disease course and have normal employment and domestic activities. However, 
this “benign” adjective does not imply that they have no disease symptoms but 
the disabling is slower and does not happen in all patients 97. 
 
Figure 3 Phenotypes and frequencies of the clinical forms of multiple sclerosis. 
Frequencies adapted from 95 and figure adapted from 98. 
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The Expanded Disability Status Scale proposed by Kurtzke in 1983 (EDSS) 
evaluates the degree of neurologic impairment in MS patients and classifies 
them in a scale from 0 to 10 as a numerical measure of the disease evolution 
throughout time. For instance, an EDSS=3 implies a moderate disability, 
whereas EDSS=6 aid for walking, EDSS=8 wheelchair, and EDSS=10 death 
from MS. The subdivisions (1.0, 1.5, 2.0 . . . 9.5, 10) correspond to the definition 
by Functional System grades which are: Pyramidal, Cerebellar, Brain Stem, 
Sensory, Bowel & Bladder, Visual, Cerebral, and the Sensory and Bowel & 
Bladder Systems 99. This scale is largely used as a standard measure to 
evaluate MS patients, but has some important disadvantages: it gives too much 
importance to the ability to walk and does not take into account the cognitive 
dysfunction in MS. 
 
1.4. DIAGNOSIS OF MULTIPLE SCLEROSIS 
The cornerstone of the MS diagnosis is based on clinical evidence from a 
detailed neurological history and physical examination. There are symptoms 
and signs of the motor, sensory, visual and autonomic systems, but many 
others can occur (Table 1). The lesions must be disseminated in place (at least 
two independent lesions in the CNS) and time (two or more episodes of 
neurologic dysfunction separated at least for 30 days) 95. There are two 
characteristic clinical symptoms of MS: Lhermitte’s symptom (electrical 
sensation that runs down the spine or limbs on neck flexion) and Uhthoff 
phenomenon (transient worsening of symptomatology when the body 
temperature increases, after for instance exercise or a hot bath) 95. When 
clinical manifestations are not sufficient for an accurate diagnosis, paraclinical 
features can help for the establishment of the diagnosis. 
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Table 1    Main symptoms and signs of multiple sclerosis. Adapted from the table 
“Symptoms and signs of multiple sclerosis by site” by 95. 
 
 
1.4.1.         Paraclinical Tests  
Paraclinical tests provide clinicians with more information that help establishing 
a correct and early diagnosis of MS.  
Magnetic Resonance Imaging  
Abnormalities of white matter are demonstrated in more than 95% of MS 
patients. MRI shows the anatomical dissemination of lesions and used serially 
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over time it can show new plaques in the absence of clinical episodes 95. MRI 
positivity by itself, without clinical manifestations, does not make a correct 
diagnosis because lesions are not exclusively characteristic of MS disease, but 
also non-specific white matter cerebral lesions appear in people without clinical 
signs of disease and in people older than 50 years. In contrast, lesions detected 
in the spinal cord are abnormal at any age 95. Gadolinium (Gd) is a contrast 
material and Gd-enhancement in T1 indicates active lesions, inflammation and 
evidence of breakdown of the blood-brain barrier 100. 
Cerebrospinal Fluid 
A lumbar puncture is performed so as to better elucidate the aetiology of the 
clinical episode. The detection of oligoclonal bands (OB) of IgG in the CSF and 
not in the serum of MS patients is the most important CSF test in MS, as OB 
are seen in most of the patients (>90%) 95. OB reflect intrathecal synthesis of 
immunoglobulins. However, the detection of OB is not exclusive to MS and it 
has diagnostic value once other CNS inflammation causes have been excluded 
101. There are complementary tests, as the Albumin quotient (QAlb=CSF 
albumin/serum albumin, QAlb>7*10-3 in 12% of patients), the IgG index 
(increased QIgG=CSF/ serum in 80% of patients) and cell count (50% with >4 
white cells/µl but only 1% with cell counts >35/ µl) 101 that help in the differential 
diagnosis of MS. 
Evoked Potentials 
Evoked potentials measure the CNS response to different stimuli (visual 
somatosensorial and auditory). The speed of response gives idea of the degree 
of demyelination.  
In summary, MRI and OB are the main paraclinical tools used in clinical practice 
95, 102 but imaging techniques and OB have shown weak clinical correlations so 
far and on the other hand, cannot be used to monitor the disease 103, 104. 
1.4.2.         Poser Criteria  
Poser criteria 105 allowed the classification of MS patients according to the 
number of attacks, clinical  and paraclinical evidence and CSF OB or increased 
IgG index. These guidelines define an attack or relapse as “the occurrence of a 
symptom or symptoms of neurological dysfunction, with or without objective 
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confirmation, lasting more than 24 hours”. The Poser classification divided MS 
patients in two major groups: “definite” and “probable” and these two as 
“clinically” and “laboratory-supported” (Table 2). 
 
Table 2    Poser diagnostic criteria for multiple sclerosis 105. 
 
The two clinical attacks must involve different locations of the CNS, must be 
separated for at least one month and last a minimum of 24 hours. One of the 
attacks must involve a different CNS site than the one demonstrated by clinical 
or paraclinical evidence. Clinical or paraclinical evidence of lesions must be 
separated in time for at least one month. 
These criteria enable a reliable but not very early diagnosis of the disease. Due 
to the importance of an early treatment of MS, another group of experts 
proposed new diagnostic guidelines based in the time and spacial 
dissemination of lesions provided by MRI 106. 
1.4.3.         McDonald Criteria 
Poser criteria were updated by the McDonald criteria 106 which underline the 
importance of MRI in the diagnosis of MS that allows earlier diagnosis of 
patients at their first clinical episode (Table 3). 
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These criteria included a scheme for the diagnosis of PP-MS, which lacks 
relapses from disease-onset. 
In the definition of attack or relapse, the authors added to the definition by 
Poser 105 that multiple episodes occurring over not less than 24 hours were 
considered also a relapse. In a prospective study of a cohort of patients with 
clinically isolated syndrome (CIS), McDonald’s criteria showed to have higher 
sensitivity, specificity, positive and negative predictive value and accuracy after 
one year than Poser criteria. One year after disease onset, McDonald’s criteria 
were able to detect half of the patients with MS, while only one fifth with Poser 
criteria 107. So these McDonald’s criteria (Table 3) have a higher predictive 
value than the former ones and help in establishing an early diagnosis of MS, 
without the need of waiting till the next clinical relapse occurs. The McDonald 
Criteria were revised in 2005 and the changes mainly focus on the use of T2-
weighted lesions and spinal cord imaging 108. 
MRI Evidence of Dissemination in Space  
In these criteria, MRI provides evidence in the diagnosis of MS of dissemination 
in space if at least three of the four criteria 109, 110 for brain abnormality are 
involved: one Gd-enhancing lesion or nine T2 hyperintense lesions if there is no 
Gd-enhancing lesion; at least one infratentorial lesion; at least one juxtacortical 
lesion; at least three periventricular lesions. 
MRI Evidence of Dissemination in Time 
In order to assess the dissemination of lesions in time these criteria must be 
fulfilled: a Gd-enhancing lesion in a scan done at least 3 months after the onset 
of clinical symptoms at a different site from the relapse; if there is no Gd-
enhancing lesion at 3 month scan, serial scans after additional 3 months must 
show Gd-enhancing lesions or new T2 lesions.  
MRI informs about the histopathology of MS lesions. The pathological hallmark 
of MS is focal demyelination in the lesions, with variable degrees of 
inflammation, demyelination, gliosis and axonal injury 100. The site of the lesion 
is very important for MS diagnosis, as MS lesions are commonly located in the 
brainstem, cerebellum and periventricular white matter 111. Typical MRI include 
T1-weighted (T1) with and without Gd administration, T2-weighted (T2), proton-
density (PD), and fluid-attenuated inversion recovery (FLAIR) 112. T2-weighted 
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scans show hyperintense lesions while T1-weighted scans show hypointensive 
lesions. T2, PD, and FLAIR demonstrate well most demyelinated lesions 112. In 
the acute phase, T1 hypointensity reflects edema and demyelination that 
disappears when inflammation attenuates. On the contrary, chronic foci of T1 
hypointensity (known as black holes) reflect persistent axonal loss 113. 
 
Table 3    McDonald Diagnostic Criteria for multiple sclerosis 106. 
*Criteria proposed in the previous paper by Thompson et al. 114 
aPositive CSF means positive OB detected in CSF and not in the serum or by a raised IgG index. 
bAbnormal visual evoked potential (VEP) seen in MS: delayed but well-preserved wave form. 
 
 
1.4.4.         Differential Diagnosis  
Due to the clinical heterogeneity of MS, there are many different diseases that 
should be well differentiated from MS diagnosis. Monophasic disorders affecting 
multiple separate sites, as acute disseminated encephalomyelitis; disorders 
affecting one site but with a relapsing-remitting or progressive course as 
tumors; systemic diseases with CNS involvement and a relapsing-remitting 
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course as systemic vasculitis; diseases of the brain and spinal cord with a 
progressive course as hereditary cerebellar ataxia; somatization disorders as 
MS Münchausen 95. CNS vasculitis, such as SLE, Sjögren’s disease, 
polyarteritis nodosa, syphilis, retroviral diseases and Behcet disease, may all 
produce multifocal lesions with or without a relapsing-remitting course. 
 
1.5. PATHOGENESIS OF MULTIPLE SCLEROSIS 
MS has classically been considered a white matter disease with characteristic 
focal and multiple demyelinated plaques in brain, spinal cord and optic nerve.  
Even if the “pioneers” in MS, Carswell and Charcot, already remarked the 
presence of lesions in the gray matter 6, 115, 116 little attention has been paid until 
recently to cerebral cortex gray matter, probably due to the lack of better 
immunohistochemistry methods and to better imaging techniques like double 
inversion recovery (DIR) that are now available 117, 118. Recent advances in MS 
pathology show that cortical demyelinated lesions with an inflammatory nature 
are present in early MS and may preceed white matter damage 117, 119-122.  
The demyelination observed in MS occurs through autoimmune inflammation 
mediated by T cells, B cells and macrophages. In many MS patients, there are 
meningeal follicles of B-cells with T-cells, plasma cells and follicular dendritic 
cells 121. These follicles in the cerebral meninges indicate a locally continued 
humoral response with the maturation of B-cells to plasma cells and intrathecal 
production of immunoglobulins that compose characteristic OB 123, 124. The 
cortical neurodegeneration associated with meningeal inflammation and 
lymphocyte infiltrates was evident in SP-MS patients and not in PP-MS patients 
125, 126. However, later studies have confirmed gray matter demyelination 
associated with meningeal inflammation at all stages of MS disease, including 
PP-MS patients 127, 128. In older patients, inflammation fades away and the 
degree of axonal injury is similar to age-matched controls 128. A trigger to B-cell 
proliferation has been attributed to EBV infection in the CNS, but this 
association remains in question because many groups have not found an 
excess of EBV-infected B-cells in MS CNS 121. Cognitive impairment and 
epilepsy are more common in those MS patients with multiple cortical lesions 
and atrophy 129, 130. In MS, the inflammation driven mainly by Th17 and Th1 
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lymphocytes and the defect of regulatory mechanisms induce the perivascular 
CD8+ cell infiltrates causing MS plaques that gather around the lateral 
ventricles, corpus callosum, cortex and subcortical white matter, optic nerves, 
brainstem and in the spinal cord 95. Pro-inflammatory cytokines secreted by T, B 
lymphocytes and macrophages amplify the pathological response recruiting 
naïve microglia 95 that additionally upregulate proinflammatory pathways 131. In 
demyelinated white matter lesions, oligodendrocytes upregulate anti-
inflammatory genes 131 and oligodendrocyte precursors surround lesions 132, so 
these cells probably have a role in the remyelination process 131, 133. The 
formation of remyelinated or shadow plaques has been found in a 20% of 
patients with early and progressive MS 134 and gray matter remyelinates more 
extensively than white matter 135. In the progressive stages of the disease, apart 
from demyelination there is also axonal rupture, neuronal degeneration 95 and 
accumulation of hyperphosphorilated  and insoluble tau 136, 137.  
Antigen specificity is still not clear in MS. Myelin proteins such as myelin basic 
protein (MBP), proteolipoprotein (PLP) and myelin oligodendrocyte glycoprotein 
(MOG), are implicated but not totally specific to MS as autoreactive clones of 
lymphocytes are also detected in healthy individuals 95. Antibodies to 
neurofascin, a neuronal protein in myelinated fibers at nodes of Ranvier, cause 
axonal injury and have been found in MS patients 138. Other autoantibodies 
detected in MS patients’ CSF, against αβ crystalline, have been found to 
suppress inflammatory pathways in the immune system and CNS 139. 
1.6.    IMMUNOPATHOPHYSIOLOGY OF MULTIPLE SCLEROSIS 
MS is a clinically heterogeneous disease whose clinical manifestations can be 
explained by the pathological changes observed in axons and neurons of 
affected patients. Whether neuronal pathology of gray matter is primary or 
secondary to white matter axonal damage is unclear 140.  
The RR-MS and PP-MS forms of MS present different clinical courses. RR-MS 
patients display a “two-stage” disease: a first stage with predominance of 
inflammation (relapses and remissions) and a second stage with more 
neurodegeneration and progression (demyelination and axonal loss) as SP-MS. 
However, neuroimaging studies have shown the coexistence of inflammation 
and neurodegeneration 141. Consequently, therapy strategies differ depending 
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on the target phase of the disease: immunomodulatory therapies combat 
inflammation in the inflammatory phase and neuroprotective agents fight 
against myelin/neural degeneration in the progressive phase (Figure 4). By 
contrast, PP-MS patients present with a steady progression and degeneration 
from the disease onset. 
 
 
Figure 4 Clinical evolution of relapsing-remitting MS to secondary-progressive 
MS (RR-MS to SP-MS). The clinical scale is represented by EDSS (red line); the frequency 
of inflammatory events when studied by MRI (T1 lesions with gadolinium enchancement 
showing blood-brain barrier opening (green arrows); T2 lesions load reflecting tissue 
damage (green line) and loss of brain volume with brain atrophy (blue line). Adapted from 37. 
 
Acute inflammation occurs during relapses and partial or complete 
remyelination happens during remissions, but the progressive degree of 
neurodegeneration leads to a higher brain volume loss and clinical disability. 
The etiology of MS is still unresolved and the nature of the disease has been 
proposed to be of autoimmune, infectious, genetic, metabolic, dietary or 
neurodegenerative origin. None of these hypotheses by itself can explain the 
clinical heterogeneity of the disease, so it is more probable that all of them may 
contribute to some extent to trigger and maintain the disease. Nonetheless, the 
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immune system plays an important role in MS pathophysiology. This is 
sustained by diverse facts:  
• Susceptibility to MS disease is linked to important genes of the 
immunological response. 
• MS plaques or lesions are crowed with inflammatory lymphocytes and 
macrophages. 
• Oligoclonal bands of immunoglobulins are present in the CSF of most of 
the patients with MS. 
• Immunomodulatory treatments modify the disease course and can stop 
inflammatory attacks but not progression once started. 
The contribution of the target organ, the CNS, has been almost completely 
ignored 37. Pathological and imaging studies 7, 142, as well as the research of the 
molecular aspects of the disease in the animal model of MS, EAE and in MS, 
provide now large evidence that CNS-specific factors are important 143, 144. 
The most accepted theory for MS onset is that autoreactive T lymphocytes 
against myelin peptides reach the CNS crossing the BBB and trigger the 
pathological events that lead to demyelination and axonal damage. This insult 
to axons can be mild and reversible or severe and irreversible, with transection 
and likely loss of neuronal function. The failure of immunoregulatory 
mechanisms, such as defective suppressive function of Treg 33, 145, 146 and the 
overexpression of β-arrestin 1, promoter of CD4+ T-cell survival 147, maintain 
autoreactive CD4+ T lymphocytes and their ongoing inflammatory recruitment of 
other activated leukocyte subsets. Active lesions of MS patients show a 
perivascular infiltration of oligoclonal T cells (CD8+>CD4+) α/β and ɣ/δ, 
monocytes, occasional B cells and few plasma cells 5. The degree of axonal 
transection is proportional to the number of macrophages and CD8+ T 
lymphocytes present in MS lesions 148. B lymphocytes are also relevant players 
in MS pathophysiology, as they are abnormally activated in meningeal follicles 
and differentiate to plasma cells that produce intrathecally immunoglobulins 
detected as OB in most of MS patients 124. Programmed cell death, apoptosis of 
immune cells, is also an important pathophysiological mechanism in MS 
inflammation. It regulates elimination of autoreactive T and B cells and 
macrophages from the circulation and prevents their entry into the CNS. 
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Dysregulation of apoptosis and other immune functions may lead to 
inflammation within the CNS tissue and subsequent development of tissue 
damage 149, 150. 
1.6.1. Important Players 
1.6.1.1.  Dendritic Cells  
Dendritic cells (DCs) are one of the main actors of MS disease pathophysiology. 
They are antigen-presenting cells (APC) that link innate and adaptive immunity 
and thus presumably responsible of activating autoreactive T cell clones and of 
initiating the disease. 
DCs are bone-marrow derived leukocytes that initiate and modulate the immune 
response by presenting endocytosed antigenic peptides on both MHC class I or 
class II molecules to naïve T lymphocytes. Small numbers of DCs are able to 
strongly stimulate T-cell responses with low levels of Ag, they are able to induce 
tolerogenic T cells to self-antigens and can capture Ag in the periphery and 
migrate to lymphoid organs to select optimal CD4+ and CD8+ T clones that clear 
the pathogenic Ag 151. DCs have different degrees of maturation depending on 
the antigen and microenvironmental signals. Resident-immature DCs are 
located in peripheral tissues, where they are specialized in the capture and 
processing of Ag of invasive pathogens but have low antigen-presenting ability. 
After the pathogen encounter, they start a program of maturation where they 
change phenotypically, express higher quantities of MHC class II, co-stimulatory 
molecules and cytokines and migrate from peripheral tissues to secondary 
lymphoid organs, where they present processed Ags in the MHC complex to 
naïve T lymphocytes 151-153. There are different subtypes of circulating DCs 
described in humans mainly: myeloid DCs (mDCs) and plasmacytoid DCs 
(pDCs). 
DCs have been found in the CSF of MS patients at clinical relapse and their 
circulating levels in the periphery are increased with respect to healthy controls 
154, 155. DCs coexpressing the ligands for CCR7, CCL19 and CCL21 have been 
found in MS lesions 156-158. In the periphery, the phenotype of mDCs and pDCs 
is altered. Nowadays, DCs are considered potential therapeutic targets in MS 
159. Specifically, tolerogenic DCs - induce T cell tolerance and secrete anti-
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inflammatory cytokines: IL10, TGFβ, IDO and PD-1 that induce Treg - have 
been proposed as therapy for their ability in restoring peripheral tolerance 160. 
Recently, Raïch-Regué and colleagues have generated semimature tolerogenic 
monocyte-derived DCs, in the presence of 1α,25-dihydroxyvitamin-D(3), loaded 
with myelin peptides that induced stable antigen-specific hyporesponsiveness in 
myelin-reactive T cells from RR-MS patients 161, what moves closer to the clinic 
the use of tolerogenic DCs. 
MS patients seem to have higher titers of mature (CD80+) proinflammatory 
(IL12 and TNFα producers) mDCs 162, while pDCs have also an altered 
phenotype that contributes to the immune regulation impairment seen in MS 163-
165. MS patients starting therapy with IFNβ-1a and low baseline circulating 
BDCA1+ mDCs (≤0.4%) have a 7 fold-risk of developing clinical activity 
compared to patients with higher baseline BDCA1+ mDCs levels. Furthermore, 
patients that responded to therapy with IFNβ-1a increased their proportions of 
mDCs while decreasing those of pDCs 166. Other authors found that non-
responder patients to IFNβ treatment had higher expression of CD86 on mDCs 
before initiation of treatment 167. These studies point to mDCs rather than to 
pDCs, the interferon-secreting cells, as responsible for the clinical response to 
IFNβ in MS. 
The humanized monoclonal antibody natalizumab, approved for MS therapy 
blocks the adhesion molecule very late activation antigen 4 (VLA-4) and 
reduces the number of DCs in the CNS 168 presumably by blocking the entrance 
of DCs in the CNS due to the gradually lower expression of the integrin VLA-4 
on their surface 169.  
1.6.1.2.  CD4+ T Lymphocytes  
The activation of autoreactive T CD4+ lymphocytes seems crucial in the 
induction of autoimmune disease 5. These autoreactive lymphocytes to myelin 
peptides are modestly increased in MS patients with respect to normal subjects 
170, 171. Therefore, something “extra” must happens to unleash autoimmunity in 
some individuals. The T cell receptor (TCR) from these autoreactive cell clones 
appears to be highly specific for immunodominant p85–99 epitope of MBP 5 and 
HLA-DR2+ restricted 172. However, when this peptide ligand is altered, the TCR 
conformation is also modified causing T cell cross-reactivity 5, 173. This would 
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partly explain why most MS patients have T cell reactivity to multiple myelin 
epitopes 172. Moreover, viral epitopes can trigger autoreactive T cell clones 61, 
174, evidence that would support the theory that microbial antigens cross-
reactive with myelin can trigger MS disease 175. MCH class II alleles (HLA-DR) 
specifically confer risk in MS 37, what reflects again the importance of antigen 
(Ag) recognition in the pathophysiology of MS disease. Windhagen  et al. found 
an upregulation of B7.1 and IL12 in early white matter lesions of MS patients 
and in inflammatory cerebral infarcts 176, suggesting that inflammation in MS 
lesions has an important T cell activation component.  
Leukocytes patrol continuously different organs including CNS for damaging 
insults that disrupt homeostasis 177. Resident T cells found in the CSF of healthy 
individuals are predominantly central memory T cells (CD4+CD45RA-
CD27+CD69+) that express high levels of CCR7, CXCR3, L-selectin and P-
selectin 178, 179. In response to a pathological or inflammatory insult, 
proinflammatory cytokines such as interleukin-1 (IL-1), tumoral necrosis factor- 
α (TNFα) and interferon-gamma (IFNɣ) induce an increase in the adhesion 
molecules, E-selectin, intercellular adhesion molecule 1 (ICAM-1) and vascular 
cell adhesion molecule (VCAM-1), and other adhesion molecules that facilitate 
the entrance to human brain have been found in the vessels and subarachnoid 
space of human brains 178, 180. Once activated, T cells have enough surface 
molecules to cross the BBB and reach the CNS parenchyma, capture and 
adherence of Th1 T cells occurs thanks to the interaction of the integrin very 
late antigen-4 (VLA-4) present in Th1 T cell and the VCAM-1 present on 
endothelial cells 169, 177. The transendothelial migration across the venule wall is 
mediated by the leukocyte function associated antigen (LFA-1) 181. Matrix 
metalloproteinases (MMPs), especially MMP-2 and MMP-9 that degrade 
extracellular matrix and help in the recruitment of autoreactive T cells are also 
present in MS lesions 182, 183. Th17 migration is known from the animal models. 
In EAE, Th17 cell migration depends on the chemokine receptor CCR6 on Th17 
cells that binds to CCL20 constitutively expressed by the choroid plexus 
epithelium 184 and others have reported that the earliest CNS entry of CD4+ T 
cells in EAE occurs at the fifth lumbar level of the spinal cord with a high CCL20 
chemokine expression of CCL20 in the dorsal root vessels 185. 
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1.6.1.3.  CD8+ T Lymphocytes  
CD8+ T lymphocytes have been less studied in MS than CD4+ T lymphocytes 37. 
However, they are more probably directly involved in the CNS tissue damage 
due to their effector functions than CD4+ T lymphocytes 37. Indeed, CD8+ T cells 
are more abundant in the active lesions of MS patients 5, 186, oligoclonal 
expansion of memory CD8+ T cells have been found in the CSF 187 and CD8+ T 
cells clones can persist for years in the CSF and blood of MS patients 188. Of 
note, oligodendrocytes and neurons can only express MHC class I, so they can 
only be recognized by CD8+ T lymphocytes 189, 190. Furthermore, cytokine 
production by CD8+ T cells correlates with tissue destruction determined by MRI 
191. The CD8+ cytotoxic response to MBP is increased in MS patients 192 and 
CD8+ myelin-specific T lymphocytes secrete chemokines (CCL3/MIP-1α, 
CCL4/MIP-1β, IL-16 and CXCL10/IP10) that chemoattract CD4+ myelin-specific 
T lymphocytes, being this chemoattraction mainly mediated by CXCL10/IP10, 
perpetuating the immune response 193. All these pieces of data sustain the 
important role of CD8+ T lymphocytes in MS pathophysiology.  
1.6.1.4.  B Lymphocytes 
The intrathecal production of oligoclonal Igs in most MS patients is the most 
important evidence of the role of B lymphocytes in MS pathophysiology 124. B 
cells cross the BBB once the inflammation process has started 37, the activation 
of B lymphocytes to plasma Ig producing cells can occur because of activation 
with self or foreign antigens, through a random effect during inflammation in MS 
plaques or by superantigen stimulation 37. In addition, B lymphocytes can 
contribute to MS pathophysiology in different ways: they can act as APC for 
autoreactive T lymphocytes; they can provide costimulation to T lymphocytes 
and produce myelin-specific antibodies that mediate the myelin destruction with 
plaques 37.  
1.6.1.5.  Regulatory T Lymphocytes 
The CD4+ regulatory T lymphocytes or Treg are a minor subset (5-10% of total 
CD4+ T cells) essential in maintaining immune tolerance to self-antigens and in 
avoiding harmful immune responses to the host. Functionally mature Treg can 
be produced in the thymus (naturally occurring or naïve: nTreg) or can be 
induced from naïve T lymphocytes in the periphery (induced: iTreg). nTreg are 
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specialized in the immune suppression of autoreactive T lymphocytes and the 
absence of this population cause severe autoimmune diseases in humans 
(IPEX syndrome: immune dysregulation, polyendocrinopathy, enteropathy, X-
linked syndrome) 194 and animals 195. Treg can also be induced or converted 
during inflammatory processes by certain cytokines (IL 10 and TGFβ) 196, 197 198 
or by the action of tolerogenic DCs 199, 200. iTreg have a more limited TCR 
repertoire than nTreg, so they are more specific for particular cell types, tumors 
or foreign antigens 201. 
In 1995, Sakaguchi and coworkers identified the molecule CD25 (the IL-2 
receptor α chain) as a putative surface marker of Treg 202. nTreg are memory 
lymphocytes (CD45Ro+) that persist in the periphery controlling not only 
pathogenic self-reactive T cells but also immune responses to quasi-self-
antigens (autologous tumor cells) and non-self-antigens (microbres and 
allografts) 203. nTreg specifically express the nuclear transcription factor FoxP3 
(forkhead box P3) and human mutations in this gene cause IPEX syndrome in 
humans 194. FoxP3 is crucial in nTreg function as its transduction upregulates 
the expression of CD25, cytotoxic T cell associated antigen-4 (CTLA-4) and 
glucocorticoid-induced TNF receptor family-related gene (GITR), and it 
suppresses the production of IL-2, IFNγ and IL4 203, clue cytokines in Th1 and 
Th2 responses. In humans, FoxP3 is also detected in iTreg, whereas in mice it 
is detected only in nTreg 204. As FoxP3 is expressed intracellulary, the isolation 
for investigations of CD4+ nTreg was limited due to the lack of specificity of the 
other surface markers (CD25, CTLA-4, GITR). Nonetheless, nTreg express 
constitutively a higher density of CD25 205 and low levels of the antigen CD127 
(the IL-7 receptor α chain) 206-208. This enabled a more specific isolation of 
nTreg characterized as CD4+CD25+CD127low. 
Treg lymphocytes from MS patients show a defective suppressive function 
compared to those from healthy controls 33, 145, 209. In early MS patients the 
nTreg thymic output is diminished compared to those of healthy controls 208. 
Similar Treg frequencies in the periphery have been found in RR-MS patients 
and healthy controls 145, while others have found decreased expression of 
FoxP3 levels in Tregs from MS patients and decreased function 210, 211. In the 
CNS, CD4+ Treg are found at higher frequencies than in peripheral blood during 
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relapses 212-214, what suggests an active recruitment of these cells to the central 
compartment in order to control the inflammation. Results from our group show 
that CD4+ Treg cells express higher intracellular expression of perforin than their 
blood counterparts what points out a relevant role of this molecule in the 
suppressive effects CD4+ Treg in MS 214. Furthermore, CSF CD4+ Treg cells 
were more abundant in women than in men reflecting the sexual dimorphism 
present in MS 214. Treatment with IFNβ expands Treg frequencies and restores 
its suppressive function 208, 215. 
Treg have different suppressive mechanisms of the immune response 216 that 
are constantly being investigated. The most important suppressive mechanisms 
are mediated by CTLA-4 217-219; by direct cell to cell contact suppressing the IL-
2 production of responder T cells 220 or competing for IL-2 221; by perforin 
mediated suppression 222 that is influenced by the sexual hormone estradiol 36; 
by apoptosis induction 223 or by the lymphocyte activation gene 3 (LAG-3 or 
CD223) mediated suppression 224. 
1.6.2. The Innate Immune System 
1.6.2.1.  Toll-Like Receptors 
Our innate immune cells are able to detect pathogens through pattern 
recognition receptors (PRRs) that recognize pathogen-associated molecular 
patterns (PAMPs) present on the surface of pathogens 225. Toll-Like Receptors 
(TLRs) were the first PRRs to be described. The PAMPs recognized by the 
TLRs include pathogenic molecules from bacteria, parasites and virus 226. 
TLR1, TLR2, TLR4, TLR5, TLR6 are on the cell surface, whereas TLR3, TLR4, 
TLR7, TLR8, TLR9 are intracellularly expressed 227. There are five TLRs: TLR-
3, TLR-4, TLR-7, TLR-8 and TLR-9 that induce type I interferon production 
(Figure 5). TLR3 is the only TLR that does not require the adaptor molecule 
myeloid differentiation primary response protein 88 (MyD88) for the recruitment 
of the IRAK family protein kinases and to the activation of TRAF, NF-ĸb and 
final production of inflammatory cytokines. TLR4 and TLR3 use the adaptor 
protein TRIF for the activation of the transcription factor IRF3 and subsequent 
production of type I interferons 227. The main producers of type I IFN are 
monocytes (via TLR-4 and TLR-8), plasmacytoid dendritic cells (pDCs) (via 
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TLR-7 and TLR-9) and myeloid dendritic cells (mDCs) (via TLR-3). TLRs are 
also expressed by microglia and astrocytes playing an important role in the 
central surveillance and homeostasis 177, 228. Microglia express a wide range of 
different TLR family members, while astrocytes and oligodendrocytes express 
TLR-2 and TLR-3 229. Neurons express TLR-2, -3, -4 and -8 230 and in the 
peripheral nerves, Schwann cells express high levels of TLR-3 and TLR-4 231. 
Although most of these TLRs are redundant in host defenses against most 
microbes, some of them are vital for natural immunity within the CNS. For 
instance, TLR-3 deficient patients suffer from Herpes Simplex Encephalitis, a 
potentially fatal manifestation of herpes simplex virus-1 (HSV-1) infection 232-234. 
These monogenic primary immunodeficiencies have provided new insights on 
the relevance of the production of IFN-α/β and IFN-λ after infection by 
neurotropic viruses of the CNS. A large body of evidence highlights the 
importance of TLRs in the modulation of CNS responses to inflammation or 
injury. 
In MS, there is evidence of viral infections triggering CNS autoimmunity both in 
the animal model and in the clinical setting. In MS patients, it is frequently 
observed that after infections or fever, patients suffer changes in their 
neurological function that seem to be related to a clinical relapse called 
pseudoexacerbations 235. Some patients with urinary tract infections caused by 
bacterial agents as Escherichia coli, require steroids to recover from their 
clinical symptoms and sometimes do not recover completely. It has been 
suggested that these bacterial agents may stimulate the innate immune 
response via TLRs and activate autoreactive T cells that provoke MS 
exacerbations 236. Microglia and astrocytes may be implicated in the 
pathogenesis of MS when they are activated by pathogenic molecules that bind 
and activate continuously their TLRs, leading to an abnormal activation of 
effector myelin-self T cell clones in the CNS 237, 238. In EAE, MyD88 knockout 
mice do not develop active EAE, reflecting the importance of the TLRs-
dependent pathways in EAE pathophysiology 239. Stimulation of TLR1, TLR2, 
TLR4 and TLR9 in the presence of myelin peptides is important in the induction 
and modulation of EAE 236, whereas TLR3 stimulation through the MyD88-
independent pathway ameliorates the disease. For instance, the synthetic TLR3 
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ligand polyinosinic:polycytidylic acid (poly I:C) added as an adjuvant with myelin 
peptides does not induce active EAE 240. Treatment with poly(I:C) suppresses 
the development of EAE, increasing the production of endogenous IFNβ 241. 
TLR3 and TLR4 type I IFN production pathways seem to play an important role 
in EAE, as type I IFN receptor and TRIF knockout mice develop a more severe 
disease, with an increased endogenous IL17 production and Th17 driven 
inflammation 242. Moreover, the synthetic cannabinoid R(+)WIN55,212-2 has 
recently been identified as a novel regulator of TLR3 signaling via IRF3 
activation and IFNβ endogenous production 243. All this body of evidence 
indicates that TLRs play an important role in the modulation of EAE disease and 
need to be further investigated in MS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5    Cellular localization and main ligands of TLRs with intracellular pathways 
that lead to the stimulation of type I IFN and proinflammatory cytokines. Taken from 
the review by Netea et al. 227. 
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1.6.2.2.  Mast Cells 
Elevated numbers of mast cells have been found in MS plaques 244 and the 
chemokine Rantes/CCL5 is a potent chemoattractor for mast cells that is 
elevated in MS lesions 37. Mast cells can augment leukocyte infiltration in the 
CNS increasing their recruitment, adhesion and rolling through their mediators 
(histamine and tryptase) and cytokines (lymphotactin, IL-16, TNFα and IL-1) 37.  
1.6.2.3.  NK Cells 
Circulating frequencies of NK cells are significantly reduced in MS 245.  The 
subset CD56bright which is expanded in vivo in MS patients under therapy with 
daclizumab (humanized monoclonal antibody against the IL-2 receptor α chain), 
has immunoregulatory functions, as their increased perforin expression 
correlates with a reduction in the inflammatory activity and the direct lysis in 
vitro of CD4+ T lymphocytes via perforin and grazyme K 246. 
1.6.2.4.  Nitric Oxide Synthase 
Granulocytes and macrophages present the enzyme inducible nitric oxide 
synthase (iNOS) that generates nitric oxide (NO), a short-lived and bioactive 
free radical with antimicrobial properties 37. NOS has been found in MS lesions 
247 but its role in MS lesions is uncertain 37. 
 
1.7. BIOMARKERS IN MULTIPE SCLEROSIS DISEASE 
MS is a heterogeneous disease not only in its clinical manifestations and forms, 
but also in the disease course and response to therapy. The search for reliable 
biomarkers that help in the diagnosis, stratification, treatment response and 
prediction of MS clinical disability has increased greatly in the last years and is 
strongly needed. Putative biomarkers need to be validated for clinical use and 
this is the main obstacle in biomarker discovery for MS, as very few candidate 
biomarkers have been validated for its clinical use 248 except for the oligoclonal 
bands (OB), the neutralizing antibodies to IFNβ in non-responder patients to 
IFNβ and the antibody response to the JC virus as a predictor of those patients 
who would develop progressive multifocal leukoencephalopathy (PML) when 
receiving natalizumab (anti-α4 integrin monoclonal antibody) 249. 
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The definition of biomarker or biological marker encompasses “a characteristic 
that is objectively measured and evaluated as an indicator of either normal 
biological processes, pathogenic processes or pharmacologic responses to a 
therapeutic intervention 250 (Figure 6).  
In MS, biomarkers can be classified depending on their proposed use 251 as: 
• Predictive for the risk of presenting the disease 
• Diagnostic 
• Classifiers of the staging and clinical form of the disease 
• Predictive for the natural history of the disease or treatment response 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 6    Characteristics of the ideal biomarker for MS. Adapted from 251. 
 
 
1.7.1. Cytokines as Biomarkers in Multiple Sclerosis 
Cytokines are very important in the regulation of the activity and function of 
immune cells; they have a clear role in MS pathogenesis and have been 
thoroughly studied as potential biomarkers.  
Cytokines as Biomarkers for Disease Activity 
Hagman et al. have recently found in a prospective study that serum Fas and 
MIF (macrophage migration inhibitory factor) are candidate biomarkers of 
neurological worsening in progressive neurodegeneration, while serum TNFα 
and MCP-1/CCL2 could be for PPMS patients 252. Increased levels of the 
proinflammatory cytokines TNFα, IL-12, IL-17 and IFNɣ and decreased of the 
anti-inflammatory cytokine IL-10 are found in the CSF and blood of MS patients 
IDEAL MS BIOMARKER 
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Detected in an easily accessible 
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at relapse 248, giving an idea of the nature Th1 and Th17 of the immune attack. 
Indeed, systemic IL-12 production, that stimulates the production of other 
proinflammatory cytokines, is prior to MS relapses and correlates with clinical 
activity 248. 
Cytokines as Biomarkers for Treatment Response 
Several cytokines have been studied for monitoring the treatment efficacy to 
disease modifying therapies (DMTs) and prediction of its response. For 
instance, IFNβ responder patients had lower serum IL-10 253 and lower baseline 
IL-12p35 mRNA in blood than non-responders 254, while serum IL-17F levels 
were higher in non-responder patients to IFNβ 255.  
1.7.2. Chemokines as Biomarkers in Multiple Sclerosis 
Chemokines and their receptors have an important role in the pathophysiology 
of MS given the organ-specific nature of MS. They can act as chemoattractants 
through the recruitment of autoreactive cells from the periphery to the CNS and 
induce the secretion of proinflammatory cytokines, which promote the final 
demyelination and neuronal loss 256, 257. The chemokines CXCL8, Rantes/ 
CCL5 are increased in the CSF and serum of those patients at relapse 258 and 
the levels of CXCL13 in those patients with clinical disease activity 259, 260. The 
interferon gamma-induced protein 10 (IP10) or CXCL10, whose secretion is 
enhanced after exposure to IFNs 261, and its receptor CXCR3 are expressed 
widely by a variety of cells (including immune cells and astrocytes). The levels 
of IP10 have been reported to be elevated in the CSF and serum of MS patients 
during the active phase of the disease compared to NIND controls 262-264, 
possibly due to its production by astrocytes in demyelinating lesions 265. On the 
other hand, MCP-1/CCL2 levels are decreased at relapse 258, 262. CXCR3 and 
CCR5 expression on peripheral blood lymphocytes increases during relapses 
266 and in progressive patients 265. The frequency of CD8+CXCR3+ correlates 
with MRI measures of MS inflammatory activity and tissue destruction 267. 
Additionally, polymorphisms in Rantes and CCR5 have been found to be 
associated with axonal loss and MRI measures of disease severity 268. Most of 
the β-chemokines or CC chemokine ligands (CCL) genes are clustered in 
chromosome 17q11.2-12, a location that has been associated with MS in 
40 
 
  Introduction 
different studies 269-271. In a model of EAE, increased levels of Eotaxin/CCL11 
were associated with milder disease phenotype, tighter blood brain barrier, 
reduced antigenic specific response and an anti-inflammatory Th2 phenotype 
272. 
1.7.2.1.  sDPP4 and Multiple Sclerosis 
Dipeptidylpeptidase 4 (DPP4, also known as CD26) is a multifunctional 
molecule that has been implicated in autoimmune pathophysiology with a 
putative immunoregulatory role. DPP4 is the prototypic member of a family of X-
prolyl dipeptidylpeptidases, a family of  multifunctional serine proteases whose 
role depend on the cell type and local conditions in which it is expressed 273. 
DPP4 is a 110-kD transmembrane glycoprotein constitutively expressed as a 
dimer on epithelial cells of the liver, hepatocytes, kidney and intestinal tissues, 
as well as in some endothelial cells, fibroblasts and lymphocytes 274. It also 
exists in a soluble form (sDPP4), and is present in different biological fluids 
such as serum, plasma, seminal fluid and in low amounts in the CSF 274, 275. 
DPP4, also known as adenosin-deaminase (ADA) binding-2 protein, binds ADA 
on the surface of T cells 276, and provides a co-stimulatory signal 277, 278 that 
increases T cell proliferation and induces the production of Th1 cytokines 278. 
DPP4 is involved in the regulation and migration of T cells 279 and thymocytes 
280. The DPP4hi T cell subset shows an effector-memory phenotype 
(CD45RO+CCR7low) 281, 282, induces a Th1 and Th17 profile of cytokines and 
their DPP4 expression is upregulated under inflammatory conditions 274. Indeed, 
Th17 cells that can be found in sites of inflammation (e.g., active lesions of 
inflammatory bowel disease) show the highest expression of DPP4, which is 
enzymatically active and may regulate Th17 cell migration to inflamed tissues 
by modulating chemokine gradients 283. DPP4 cleaves NH2-terminal dipeptides 
from polypeptides with either L-proline or L-alanine at the penultimate position 
284. In many instances, this results in regulation of the substrate, inactivating the 
ligand activity or altering its function (e.g., generating dominant negative forms 
of the protein). Biologically important substrates for DPP4 include several 
chemokines, gastrointestinal hormones and neuropeptides 275, 285. Chemokines 
regulated by DPP4 (reviewed by 275, 285, include but are not limited to: MIP-1α/ 
CCL3, MIP-1β/CCL4, Rantes/CCL5, Eotaxin/CCL11, Mig/CXCL9, 
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IP10/CXCL10, I-TAC/CXCL11 and SDF-1α/CXCL12. Recent findings by 
Casrouge et al. that IP10 cleavage by DPP4 generates a truncated form with 
negative function have yielded a new understanding of the processes governing 
leukocyte migration and a changing paradigm of the regulatory circuit of 
inflammatory responses 1.  
Prior studies in MS patients have focused on the role of DPP4 expression on T 
cells. Hafler et al. were the first to describe an increase in the subset of DPP4+ 
T (named as Ta1+) cells in the peripheral blood and in the cerebrospinal fluid 
(CSF) of MS patients with progressive forms of the disease 286. Subsequent 
studies presented conflicting results 287, 288, but it was eventually confirmed that 
circulating DPP4+ T cells correlate with clinical and magnetic resonance 
imaging (MRI) disease activity scores in MS 289-291. Krakauer et al. 
demonstrated that the memory CD4+CD45RO+DPP4hi cells in MS patients 
contained the largest fraction of Th1 cells coexpressing markers linked with MS 
disease (e.g. CCR5, CXCR3 and VLA-4hi) and correlated with clinical MS 
disease severity 281. The frequency of circulating DPP4- and CD71-expressing 
CD8+ T cells decreases after interferon-β (IFNβ) immunomodulatory therapy, 
whereas interleukin IL-10 and IL-13 CD8+ producing T cells increased in 
frequency 292. Indeed, IFNβ treatment as well as endogenous type I IFN activity 
reduced the expression of CD49d integrin (subunit of VLA-4) on CD4+DPP4hi T 
cells 293. Narikawa et al. found increased levels of soluble DPP4 (sDPP4) in the 
CSF of a small series of relapsing neuromyelitis optica and MS patients 
compared to patients with non-inflammatory neurological diseases (NIND) 294. 
All this body of evidence suggests that DPP4 expression may have an 
important role in MS pathophysiology that has been scarcely explored. 
1.7.3. Growth Factors as Putative Biomarkers in Multiple 
Sclerosis 
Different growth factors have relevance in the CNS disorders. The hepatocyte 
growth factor (HGF) is a multifunctional protein in the CNS that is produced by 
microglial cells, oligodendroglial progenitor cells, astrocytes and neurons 295-298. 
The receptor for HGF, c-Met, is the tyrosine kinase product of the c-Met proto-
oncogene 299, 300 and both HGF and its receptor c-Met are present during brain 
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development and persist in adulthood with important neurotrophic functions 301, 
302. Besides, peripheral HGF shows immunomodulatory effects: promoting the 
adhesion of B cells 303, migration of T cells 304 and recruitment of dendritic cells 
(DCs) 305, 306. HGF has been found to be increased in CNS diseases, including 
MS and in prototypic neurodegenerative diseases, such as Alzheimer’s disease 
307. However, other studies have found decreased HGF CSF levels in patients 
with MS 308, 309 or unaltered levels of plasmatic HGF between MS patients and 
healthy controls 308. The epidermal growth factor (EGF) has positive effects in 
the proliferation and differentiation of neurons, astrocytes and oligodendrocytes 
310, 311 and its co-administration with growth hormone (GH) in EAE improved the 
clinical score and survival rate of mild and severe EAE forms 312. In MS 
patients, EGF in CSF has been found to be significantly lower than in other non-
inflammatory neurological diseases 313. Also, the basic fibroblast growth factor 
(FGFb or FGF-2), is a key regulator of the growth, differentiation, migration and 
survival of CNS glial progenitors 310, and its expression is enhanced in active 
MS lesions 314.  FGFb has a controversial role in MS. It has been associated 
with demyelination and inhibition of myelin production by oligodendrocytes in 
vivo 315, 316 while with the induction of myelination in oligodendrocytes in vitro 
317. Recently, the knockout mouse of FGFb revealed rather a neuroprotective 
role for this growth factor in the animal model of MS 318. 
1.7.4. Humoral and Antibody Biomarkers 
Detection of two or more IgG oligoclonal bands (OB) in the CSF and not in the 
serum of a patient with clinical signs of MS provide very useful diagnostic value, 
as more than 95% of MS patients present with positive OB 319. OB are the most 
commonly used MS biomarker 248. They are detected since disease onset and 
persist during the disease regardless of disease activity. However, they are not 
specific of MS, as they are also detected in other inflammatory disorders and 
infections affecting the CNS 319.   
The presence of IFNβ neutralizing antibodies (NAbs) has been found in 
patients at relapse. When there are persistent high titres of IFNβ NAbs, the 
physician might consider stopping treatment with IFNβ as it may not be effective 
320 in a high percentage of patients who do not have a satisfactory clinical 
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response to this therapy. In patients with low or middle titers of NAbs, the 
induction by IFNβ of the protein myxovirus resistance protein A (MxA), encoded 
by the MX1 gene can provide additional information of IFNβ response to 
therapy 320.  
Finally, elevated kappa free light chains in the CSF may correlate with 
disability prognosis 321 and elevated Epstein-Barr virus nuclear antigen 1 
(EBNA-1) IgG correlates with gadolinium-enhancing lesions 322. 
1.7.5. Biomarkers for Interferon-β Therapeutical Response  
IFNβ remains the most widely prescribed treatment for RR-MS, with positive 
effects in reducing disease activity. However, there is still a high proportion of 
patients (up to 40%) who do not respond to this therapy 323. IFNβ is a type I 
interferon that binds to the heterodimeric receptor IFNAR1 IFNAR 2 and 
activates the JAK-STAT pathway with phosphorilation of STAT1 and STAT2, 
which bind IRF9 and finally translocate to the nucleus and bind IFN-stimulated 
response elements (ISREs) in DNA to initiate the transcription of type I IFN-
stimulated genes (ISGs) 324. There has been an intensive search for specific 
biomarkers predictors of therapeutic response to IFNβ. Baranzini et al. found 
nine blood sets of gene triplets whose expression at baseline (before starting 
IFNβ therapy) could predict the response to IFNβ with an accuracy > 80% 325. 
Another group described that nonresponder patients to IFNβ had a baseline 
overexpression of some type I IFN genes and that their expression did not vary 
significantly during  IFNβ treatment, while responder patients strongly 
upregulated these genes 167. Recently, Bustamante et al. have found that 
nonresponder patients to IFNβ have decreased expression levels of 
endogenous IFNβ in their PBMCs and increased IFN receptor 1 (IFNAR1) 
expression in monocytes compared to responder patients and controls. 
Moreover, they found that the baseline expression of interleukin-1 receptor-
associated kinase 3 (IRAK3), a negative regulator of TLR4 signaling, was 
significantly decreased in responder compared to nonresponder patients. This 
study links TLR4 and endogenous type I IFN signaling pathways and 
endogenous production of IFN with the clinical response to IFNβ therapy 326. 
Finally, the chemokines IP10/CXCL10 and MCP-1/CCL2 and have also been 
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described as biomarkers for the positive clinical response to IFNβ treatment 327.  
IP10/CXCL10 levels are higher in patients under treatment with IFNβ 327-329 and 
IP10/CXCL10 and MCP-1/CCL2 have been proposed as biomarkers for IFNβ 
response 327, 329. 
1.8. MULTIPLE SCLEROSIS TREATMENTS 
Available first-line MS treatments act in the RR stage of the disease (IFNβ, 
glatiramer acetate and Natalizumab) and partially in the SP stage of the disease 
(Natalizumab), but not in the PP-MS. Fingolimod or FTY720 is the first oral 
treatment for RR-MS that has recently been approved and has greater efficacy 
compared to IFNβ-1a 330. Up to now, PP-MS continues with no effective 
treatment to stop disease progression. 
The main MS treatments are summarized below according to their mechanisms 
of action: 
Immunomodulatory Properties 
In the 1990s, IFNβ and glatiramer acetate (GA) were the first disease-modifying 
therapies (DMTs) to be approved. Nowadays, they are still the most used first 
line treatments for RR-MS.  
IFNβ has different formulations: IFNβ-1a (Avonex® and Rebif®) and IFNβ-1b 
(Betaseron® and Extavia®). IFNβ has multiple immunomodulatory properties: It 
increases Th2 cytokines (IL4 and IL10) while decreases Th1 cytokines (IL12, 
IFNɣ and TNFα) 331, 332; diminishes T-cell expansion and differentiation; 
increases T-cell apoptosis 333, 334; downregulates MHC-II expression 335 and 
antigen presentation; inhibits MMPs secretion and migration of immune cells 
across the BBB 336; expands blood Treg and enhances Treg function 146, 166 and 
normalizes ex vivo T lymphocyte apoptosis that is increased in active MS 
patients 337. IFNβ is usually well tolerated, with some patients experiencing flu-
like symptoms, myalgia and less frequently depression, anemia, leukopenia, 
and thrombocytopenia 338. The main problem with IFNβ is its immunogenicity 
(IFNβ-1a is more immunogenic than IFNβ-1b and Rebif® more than Avonex®). 
A mean of 25% of patients develop neutralizing antibodies (NAbs) to IFNβ, and 
this is a factor that contributes to non-responsiveness to this treatment 338. 
Glatiramer acetate (Copaxone®) was discovered in the 1960s relatively by 
chance. Scientists were looking for encephalitogenic copolymers to induce EAE 
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and they found the opposite with the copolymer randomly composed of L-
alanine, L-lysine, L-glutamic acid and L-tyrosine, in a molar ratio of 
4.2:3.4:1.4:1.0 339. In humans, GA is administered daily as a subcutaneous 
dose of 20 mg and is able to reduce relapse rate and disability in MS. GA 
modulates peripherally autoreactive T cells as it competes for the MHC-II with 
myelin peptides and induces a Th2 antiinflammatory profile (IL4, IL5, IL10 and 
TGFβ) while reducing Th17 cells. Moreover, GA ameliorates the function and 
frequencies of regulatory T cells in the CNS and in the periphery and has 
neuroprotective properties 339. 
Inhibition of lymphocyte migration 
Natalizumab (Tysabri®) is a humanized monoclonal antibody (mAb) that binds 
to the adhesion molecule VLA-4 or CD49d and diminishes greatly lymphocyte 
migration through the BBB. VLA-4 is expressed by all white blood cells except 
neutrophils. Tysabri’s more severe adverse event is progressive multifocal 
leukoencephalopathy (PML), a life-threatening brain infection caused by JC 
virus that is extremely severe in immunodeficient subjects 340. Natalizumab is 
administered every four weeks in IV perfusion of 300 mg. 
Fingolimod (Gilenya®) or FTY720 is an immunosuppressive metabolite 
obtained from the fungus Isaria sinclairii 341. It is a sphingosin-1 phosphate 
receptor agonist and the first oral treatment approved for MS treatment. During 
fingolimod administration, lymphocytes are recruited within the lymph organs, 
inhibiting their migration to the CNS but without impairing their activation or 
proliferation 330. The lymphopenia observed with fingolimod is reversible once 
the treatment is stopped. Fingolimod is a lipophilic molecule able to directly 
enter the CNS. Direct neurobiological effects are also under investigation 330. 
Immunosuppressive properties 
Alemtuzumab (Campath-1H) is a humanized mAb against CD52, antigen 
expressed on T and B lymphocytes, NK cells, DCs, most monocytes and 
thymocytes 342. This treatment is also approved to treat leukemia as it rapidly 
depletes CD52+ cells 343. Alemtuzumab is administered intravenously and 
reduces relapse rate and accumulation of disability greater than IFNβ-1a in 
untreated patients and in patients that relapsed after IFNβ or GA 344, 345. 
Patients under treatment with Alemtuzumab are more susceptible to herpes 
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infections, thyroid disorders than with IFNβ-1a and a few (1%) had immune 
thrombocytopenia 344, 345. 
Azathioprine is an off-label therapy for MS in most countries, except in Germany 
346. Azathioprine is a purine antimetabolite immunosuppressor that affects DNA 
replication and impairs correct T lymphocyte function 347. It has been used for 
decades but nowadays it is only recommended as prophylactic for those 
patients who do not tolerate first-line treatments. A continued use increases the 
risk of developing malignancies. 
Depletion of T lymphocytes 
Daclizumab is a humanized mAb against the IL-2 receptor alpha chain (IL-2RA 
or CD25). The main mechanism of action of daclizumab is the enhancement of 
regulatory NK cells CD56high rather than the restraint of the expansion of 
autoreactive T CD25+ cells 348. Several small phase II clinical trials have tested 
daclizumab in patients with RR-MS, SP-MS and in RR-MS patients that did not 
respond to IFNβ. Although the number of patients in these trials is low, the 
efficacy seen is very promising and there are no serious adverse effects 
reported 348. 
Depletion of B lymphocytes 
Several mAbs that bind to the antigen CD20, present on pre-B and mature B 
lymphocytes but not in plasma cells have been tested for MS treatment. 
Rituximab (Mabthera ®), ocrelizumab and ofatumumab bind to different 
epitopes of CD20 and have been tested in small phase I and II clinical trials for 
MS therapy. There are reported rapid beneficial effects of these drugs, but 
larger phase III clinical trials are warranted to determine the best efficacy/safety 
dose 349. 
Promising new drugs 
Cladribine is a purine nucleoside analog that produces lymphospecific toxicity 
and depletion through the inhibition of DNA synthesis and cell death. Phase III 
studies with oral cladribine have been completed and it has been authorized for 
the treatment of RR-MS in Russia and Australia 350. 
Laquinimod is an immunomodulatory quinolone, orally administered, that is 
believed to favor Th2/Th3 cytokine production, interferes with VLA-4 binding,  
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and inhibits immune cell transmigration to the CNS (Phase III clinical trials 
ongoing) 351. 
Teriflunomide is an inhibitor of the enzyme dihydroorate dehydrogenase 
(DHODH), key enzyme in pyrimidine synthesis. Teriflunomide inhibits de novo 
synthesis of pyrimidine, which is required for the proliferation of activated 
lymphocytes, thus preventing clonal expansion of T and B lymphocytes, but 
does not induce lymphopenia (Phase III completed) 352. 
Cannabinoids have neuroprotective and immunomodulatory properties that 
have been shown to be beneficial in the animal models of MS and are now 
being evaluated to assess their impact in slowing the development of disability 
in progressive patients with MS (SP-MS and PP-MS) (Cannabinoid use in 
progressive inflammatory brain disease-CUPID-trial) 353. 
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2. AIMS 
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 Multiple sclerosis is characterized by a variable clinical course and response to 
therapy that may represent divergent etiologies, given the distinct pathological 
patterns that the different clinical forms exhibit. To date, there are no reliable 
serum biomarkers for MS, which would be necessary for an improved diagnosis 
and evaluation of disease activity and treatment response. Early identification of 
the clinical forms of MS, especially the primary progressive form, remains a 
challenge for clinicians. The fact that progressive forms of the disease have still 
no available therapies to stop neurodegeneration and clinical disability makes 
more urgent the need for biomarkers that can anticipate the onset of 
progression. Identification of such biomarkers of MS in the individual patient is 
an important issue and would allow more personalized therapies for MS.  
 
The purpose of this thesis work was to identify reliable blood biomarkers that 
could distinguish between MS patients and healthy controls and reflect 
pathophysiological differences in MS clinical forms. 
 
Specific Aims: 
 
I. Identify blood biomarkers that discriminate between MS patients and 
healthy controls.  
II. Characterize the expression of DPP4 in MS to test the hypothesis 
that this enzyme is an important feature in the pathophysiology of the 
disease, given the role of DPP4 as key chemokines immunoregulator 
and the organ-specific nature of MS. 
III. Identify blood biomarkers that stratify MS patients according to their 
clinical form. 
IV. Identify biomarkers related with type I interferon signaling pathways 
that could help to develop personalized strategies in MS and provide 
mechanistic insight of MS pathophysiology. 
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3. POPULATION OF STUDY AND METHODS 
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3.1. STUDY DESIGN 
A cross-sectional and observational study was carried out in 182 MS patients 
and healthy controls. Two independent cohorts of MS patients diagnosed by 
McDonald’s revised criteria 106, 108 by the same neurologist at the Neurology 
Service in the University General Hospital Gregorio Marañón were included. 
Patients were informed about the study and recruited by their hospital 
neurologist. The only patients who were hospitalized at the moment of 
sampling were those undergoing a clinical relapse, the rest were consecutively 
appointed in the Neurology Service to participate in this observational study. 
The majority of patients with a progressive and more disabling stage of the 
disease were recruited from the Center Alicia Koplowitz for Multiple Sclerosis 
of the Community of Madrid, where they and their families were informed and 
gave written consent to participate in the study. The group of sex- and age-
matched healthy controls came from the Blood Donor Bank of the University 
General Hospital Gregorio Marañón. This project was approved by University 
Hospital Gregorio Marañón Ethics Committee in Madrid and all subjects gave 
written informed consent.  
There were two independent cohorts of patients and healthy controls studied, 
with the objective to find reproducible differences which correlate with a 
defined clinical outcome and to minimise the influence of experimental bias, 
overfitting and stastitical chance:  
• Cohort 1: the Pilot cohort was recruited from November 2010 to 
February 2011 and consisted of 81 subjects: 65 MS patients (47 
women and 18 men) and 16 HC (9 women and 7 men), adjusted by age 
and sex. 
•  Cohort 2: the Validation cohort was recruited from June 2011 to June 
2012 and consisted of 101 subjects: 64 MS patients (38 women and 26 
men) and 37 HC (20 women and 17 men), adjusted by age and sex. 
 
The Validation cohort was designed and used to confirm the findings in the 
cohort 1 and to increase the number of patients in the different clinical MS 
groups, incrementing the statistical power of the results. 
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The total number of subjects included in this study was of 182 subjects: 129 
MS patients (85 women and 44 men) and 53 healthy controls (29 women and 
24 men). 
The experiments were divided in three main parts: 
1) Screening of plasma analytes that are differentially expressed in all MS 
patients as a whole with respect to healthy controls. 
2) Screening of plasma analytes that are differentially expressed in the 
different clinical forms of MS and that can discriminate between 
inflammatory and neurodegenerative. 
3) Study of the genetic expression of a vast array of different genes 
related with MS pathogenesis and the interferon signature in the 
different clinical forms of MS. 
Functional experiments with freshly isolated peripheral blood mononuclear 
cells (PBMCs) and additional flow cytometry analysis were performed so as to 
go further in the research of the biomarkers described. 
Due to the number of putative biomarkers proposed in each section of the 
results, the results of each biomarker and its known role in MS pathogenesis 
will be shortly introduced in the results section so as to facilitate the 
comprehension of the study. 
3.2. SUBJECTS AND PERIOD OF STUDY  
The study included 182 subjects: a total of 129 (85 women and 44 men) 
patients with MS diagnosis defined by McDonald’s revised criteria 106, 108 were 
consecutively recruited for this study from November 2010 to June 2012, at 
the Unit of Multiple Sclerosis of the University Hospital Gregorio Marañón and 
from Center Alicia Koplowitz for Multiple Sclerosis of the Community of Madrid. 
A group of 53 sex- and age-matched healthy controls (HC) (29 women/ 24 
men; age: 37 (31-43) (median years: 25th-75th percentiles) from the Blood 
Donor Bank of the University Hospital Gregorio Marañón was also included.  
Patients were characterized based on the 7 defined groups of MS patients: 
- Recurrent-remitting MS patients in remission (RR-MS Remission). 
- RR-MS patients with active disease (RR-MS Active). 
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- Patients at clinical exacerbation or relapse (RELAPSES). 
- RR-MS patients under treatment with IFNβ for a minimum of 6 months 
defined as long-term IFNβ responders (RESPONDERS). 
- RR-MS patients that had not previously responded to IFNβ (NON-
RESPONDERS). 
- Secondary-progressive MS patients (SP-MS). 
- Primary-progressive MS patients (PP-MS). 
In the RESPONDERS group, response to IFNβ treatment was defined as the 
absence of relapses or progression (increase in EDSS score) during the time 
of treatment with IFNβ. All the patients included in this study as 
RESPONDERS have been followed-up in our institution and they continue 
with IFNβ therapy and clinically stable. Samples were drawn at 36-48 hours 
after injection of IFNβ. NON RESPONDERS were defined as RR-MS patients 
that suffered relapses or increased their progression (EDSS) during the period 
when they were treated with IFNβ and and were going to start other disease-
modifying therapy (DMT). 
In order to evaluate the effects of IFNβ ex vivo after the first injection of IFNβ, 
a small subset of four RR-MS Active patients who started therapy with IFNβ, 
were studied before, after 10 hours, after 32 hours and after 1 month (post 10 
hours from injection). 
Except for the long-term IFNβ RESPONDERS group and the group of four 
patients previously mentioned, the rest of the patients had not received any 
glucocorticoid treatment, immunosuppressive or DMT before blood sampling 
for this study in the three months prior to study entry.  
Most of the patients of the RR-MS Remission group were benign forms of MS 
(17 out of 23) that had been symptom-free for years.  
Relapse was defined as the appearance or reappearance of one or more 
neurological abnormalities that persisted for at least 24h and which had been 
preceded by at least 30 days of stable or improved neurological state, without 
any underlying infectious disease, blood samples were drawn from relapse 
patients before initiation of glucocorticoids treatment. RR-MS Active patients 
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were defined as patients diagnosed with RR-MS that were eligible to start a 
DMT because they had clinical and paraclinical activity of the disease and they 
were studied at least 1 month after the end of a clinical exacerbation. Clinical 
disease severity and disability were scored according to the Kurtzke Expanded 
Disability Status Scale (EDSS). For detailed patient characteristics, see Table 
6 of the results section. 
3.3. CLINICAL VARIABLES STUDIED 
Clinical variables included from each patient were the following (Table 6): 
Epidemiological variables such as age, sex, disease duration and age at onset 
of the disease.  
Clinical disease progression was evaluated by the Expanded Disability Status 
Scale (EDSS) 99 at the study point. The progression index was determined as 
disability degree divided by the duration of the disease (EDSS/disease 
duration in years).  
Clinical disease activity was determined by calculating the number of relapses 
in the preceding two years.  
The patients in the groups of RESPONDERS to IFNβ (n=20) were the only 
group under treatment with disease modifying therapies (DMT) and their 
treatment duration when samples were drawn are depicted in Table 6. Eleven 
patients were under treatment with IFNβ-1b (Betaseron®) and nine with IFNβ-
1a (4 with Avonex® and 5 with Rebif®).  
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3.4. LABORATORY TECHNIQUES 
3.4.1.  Extraction and Blood Samples Processing 
Peripheral blood samples were taken by venous puncture and collected in 
sterile EDTA Vacutainers, heparin and serum dried tubes between 8:00 and 
10:00 a.m., and they were processed within 2 hours after extraction. The 
collected blood was allowed to clot for 30 minutes before separation. Serum 
(from dry tubes) and plasma samples (from EDTA tubes) were obtained after 
high speed centrifugation for 10 minutes at 3500-4000 rpm. Plasma samples 
were immediately aliquoted and frozen at -80ºC for its conservation. 
Anticoagulated blood from the EDTA tubes was used for flow-cytometry and 
for RNA extraction of their peripheral blood mononuclear cells (PBMCs). 
PBMCs were isolated from MS patients and healthy donors by density 
gradient centrifugation using Ficoll- Paque (Amersham Biosciences, RU) and 
then washed with phosphate buffered saline (PBS). 
3.4.2.  Extraction and Processing of CSF 
The extraction of 1 to 3 ml of CSF was performed by lumbar puncture in those 
patients undergoing clinical relapse. CSF was processed immediately after 
spinal tap, centrifuged after collection and the CSF supernatant was stored at -
80ºC until it was used. 
3.4.3.    Multi-analyte Profiling 
The Luminex xMAP® technology platform was used for the simultaneous 
measurement of multiple plasma analytes in our population study. Plasma 
samples were previously clarified by high-speed centrifugation and the 
commercially available Human cytokine 30-Plex panel (Invitrogen) was 
performed. The current investigation required the assembly of an extensive 
multiplex array consisting of cytokines, chemokines, soluble receptors, growth 
and angiogenic factors, which were evaluated using bead-based 
immunoassays. The following cytokines, chemokines and growth factors were 
studied: IL-1β, IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-
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13, IL-15, IL-17, TNFα, IFNα, IFNγ, GM-CSF, MIP-1α, MIP-1β, IP10, Mig, 
Eotaxin, Rantes, MCP-1, VEGF, G-CSF, EGF, FGF-basic, and HGF.  
This analysis of a broad spectrum of biomarkers enables a comprehensive 
analysis of an individual’s immunological state. The xMAP® technology 
combines the efficiency of the simultaneous analysis of diverse proteins with a 
similar reproducibility to ELISA.  In this technology each analyte-specific assay 
is assigned a microsphere set labeled with a specific fluorescence signature. 
Beads, with defined spectral properties, conjugated to protein-specific capture 
antibodies, are added along with samples and standards into wells of a filter-
bottom plate. Washings are performed by aspiration with gentle vacuum. 
Protein present in samples binds to the capture antibodies conjugated to the 
beads; later protein specific biotinylated detector antibodies bind to the 
appropriate proteins and finally streptavidin conjugated with a fluorochrome 
(R-Phycoerithrin) binds to the biotinylated detector. The analysis with the 
Luminex detection system reveals an amount of fluorescence signature that 
allows the determination of the concentration of the different proteins studied. 
Human samples were diluted by half in this technique. The 96 well plates 
analyzed included samples from all clinical groups of MS and healthy controls 
to minimize inter-assay variation. The inter-assay and intra-assay values are 
reported to be less than 15% by the manufacturer. For data analysis and 
presentation, values that were below the lowest concentration detected in the 
standard curve were replaced with a value that was half of the lowest value 
measured or detection limit. On the other hand, values that their mean relative 
fluorescence was higher than the highest point of the standard curve were 
replaced by a value that was two-fold the measurement of the highest 
concentration detected in the standard curve. The lower detection limits 
expressed in (pg/mL) were the following: VEGF (3.8); IL-1b (20.1); GCSF 
(71.2); EGF (23.7); IL-10 (17.03); HGF (119.5); FGFb (9.4); IFNα (16.2); IL-6 
(7.4); IL-12 (10.4); Rantes (14.2); Eotaxin (4.9); IL-13 (38.4); IL-15 (33.9); IL-
17 (76.1); MIP-1α (15.4); GM-CSF (61.6): MIP-1β (13.4); MCP-1 (6.5); IL-5 
(6.4); IFNɣ (25.2); TNFα (5.8); IL-1RA (36.5); IL-2 (13.2); IL-7 (26.4); IP10 
(6.5); IL-2R (48.8); Mig (44.8); IL-4 (41.2) and IL-8 (8.2). 
 
57 
 
  Material and Methods 
 
 
 
 
 
 
 
Figure 7    Working plan for the evaluation of plasma biomarkers and elaboration of 
a combination of biomarkers with the results of the subjects included in the study.  
HGUGM: Hospital General Universitario Gregorio Marañón. 
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3.4.4.         Enzyme-linked Immunosorbent Assays 
3.4.4.1.  ELISA-sDPP4 
The levels of sDPP4 were measured with the commercial sandwich ELISA 
(human DPPIV/CD26 Duo Set ELISA. R&D Systems) following the supplier’s 
instructions. Briefly, Maxisorp plates (Nunc) were coated with 2 μg/ml of the 
commercial capture antibody in PBS overnight at room temperature. The wells 
were saturated with 300 μl of 1% in PBS for 1 hour. A seven-point standard 
curve was performed with the highest concentration at 2,000 pg/ml. Human 
plasma samples were used at dilution 1/800 while cell culture supernatants at 
dilution 1/2 in 1% of bovine serum albumin (BSA) in PBS. Plates were read in 
a Labsystems Multiskan MS (Thermo) device at a wavelength of 450 nm. 
3.4.4.2.  ELISA-IP10/ CXCL10 
The levels of IP10/CXCL10 present in different samples were measured with a 
homemade sandwich ELISA. Briefly, Maxisorp plates (Nunc) were coated with 
2 μg/mL of the capture antibody in PBS overnight at room temperature. Plates 
were washed twice with PBS. The wells were saturated with 200 μL of 
saturation buffer (PBS-Tween 0.05%-1% BSA) for 1 hour. The rest of the 
washings were done with PBS-Tween 0.05%. The secondary antibody was 
utilized at a concentration of 0.5 μg/mL. Detection limit was 31.25 pg/mL. 
Samples were diluted to 1/3 in saturation buffer PBS-Tween 0.05%-1% BSA. 
Plates were read in a Labsystems Multiskan MS (Thermo) device at a 
wavelength of 450 nm. 
3.4.4.3.  ELISA-IFNα 
The levels of human IFN-α present in cell culture supernatants after 24 hours 
were detected with the commercial sandwich immunoassay VerikineTM Human 
IFN-α ELISA Kit (PBL Interferon Source, NJ, USA) following the manufacters 
instructions. Two different six-point standard curves were performed. The high 
sensitivity standard curve: 12.5–500 pg/mL and the Extended Range curve: 
156–5,000 pg/mL. Cell cultures were used undiluted and plates were read in 
an Opsys MRTM Dynex technologies device at a wavelength of 450 nm.  
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3.4.5.         Analysis of DPP Activity 
The dipeptidylpeptidase (DPP) activity present in patient plasma was 
measured using a luciferase-based assay (DPP4-Glo™ protease Assay; 
Promega), following the manufacter’s instructions. This assay provides a 
luminogenic DPP substrate, Gly-Pro-aminoluciferin. After cleavage of the 
proximal two amino acids from the substrate, the aminoluciferin is free to 
engage luciferase. Relative luminescent units (RLU) are proportional to the 
DPP activity. This assay was performed in all plasma samples, serially diluted 
between 0.025%, 0.25% and 2.5% in 10 mm Tris–HCL pH 8 with 0.1% prionex 
stabilizer. Plates were read using the Tristar LB941 device (Berthold 
Technologies, Oak Ridge, TN, USA). The DPP activity is expressed as relative 
luminescent units (RLU) as results were relative to the background of the 
technique. A dilution of 0.025% gave values that were within the linear range 
of the assay. 
3.4.6.         Sex Hormones Detection 
Serum cortisol was quantified by competitive immunoassay (IMMULITE 2000, 
Diagnostic Products Corporation, Los Angeles, CA, USA). Serum 
testosterone, estradiol and progesterone were determined by a 
chemiluminescent immunoassay (Immuno I, Bayer Leverkusen, Germany), as 
previously described 35.  
3.4.7.         25-Hydroxi Vitamin D Quantitation 
The concentration of 25-hydroxi vitamin D present in serum was measured by 
chemiluminescent immunoassay (LIAISON® 25 OH vitamin D TOTAL Assay, 
DiaSorin Inc, MN, USA), following manufacturer’s instructions. 
3.4.8.     RNA Extraction  
PBMCs were lysed in 1 ml of Trizol (TRIzol® Reagent, Invitrogen), very well 
resuspended with pipette, and stored at -80ºC until use. They were thawed 
once, vortexed and centrifuged to obtain the aqueous phase. Most of the RNA 
samples were extracted with columns of the commercial kit RNeasy Mini Kit 
(QIAGEN, CA, USA) and some of the samples with a number of PBMCs < 1 
million were extracted with RNeasy Micro Kit (QIAGEN, CA, USA). Most RNA 
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concentrations were superior to 100 ng/μL (median [25th-75th] 186.9 [129.6-
246.5]) and the absorbance coefficient 260/280 was between 1.8 and 2. RNA 
in nuclease-free water was stored at -80ºC.  
12 μL of RNA (>1μg) was reversed transcribed to complementary DNA 
(cDNA) with the reverse transcription enzyme RevertAidTM Premium Reverse 
Transcriptase (Fermentas Life Sciences) following the manufacter’s 
instructions with random hexamer primers. cDNA samples were stored at -
30ºC until use. 
3.4.9.        Gene Expression by BiomarkTM HD System  
In our study population, gene expression studies were performed with the 
BioMark™ System (Fluidigm) that enables microarray-like studies using high-
throughput real-time qPCR by performing more than 9,000 qPCR reactions in 
a single assay. This technology allows the performance of 96 different primers 
* 96 different samples or 48 different primers * 48 different samples generating 
a large number of data within one technique. Advantages over conventional 
array based transcriptional profiling profiling are that the Biomark has a CV 
<5% as compared to 25% to 35% for microarrays. 
Samples and primers distribute across 48 or 96 reaction chambers in 9 or 6 nL 
aliquots, respectively. The primers utilized in these techniques were related 
with type I interferon signaling pathway and multiple sclerosis pathogenesis 
(list of genes in Appendix 1). In each Biomark experiment, there were several 
references or housekeeping genes employed: GUS (β-glucuronidase), 
GADPH (glyceraldehyde-3-phosphate dehydrogenase), ACTB (beta-actin), 
HPRT (hypoxanthine-guanine phosphoribosyltransferase), and TBP (TATA 
box-binding protein). cDNA samples were diluted to 1/10 in TE Buffer and 2.7 
μL of cDNA were added to a Sample pre-mix of 0.3 μL GE Sample loading 
reagent (20x) (Fluidigm, PN 85000746) and 3 μL of TaqMan® Universal PCR 
Master Mix (2x) (Applied Biosystems, PN 4304437). Biomark arrays were 
loaded as follows. The assay mix consisted of 3 μL of the primer TaqMan® 
Gene expression assay (20x) and 3 μL of Assay Loading Reagent (2x) 
(Fluidigm, PN 85000736). After the loading of the chip assay inlets were 
loaded with 5 μL of assay mix and sample inlets with 5 μL of sample mix.    
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In order to dissect the unique molecular signature of type I interferon response 
in MS patients using high throughput microarray technology, we focused on up 
to 96 top up- and down-regulated genes to discriminate among MS clinical 
forms. 
Primers and probes of the assays were designed by Thermo Scientific Solaris 
(Solaris qPCR Gene Expression Assays). An image of the 96*96 Biomark chip 
with an amplification of the reaction chambers is shown below (Figure 8).  
 
 
 Figure 8    Dynamic ArrayTM 96*96 IFC © Fluidigm Corporation 
 
The relative level of gene expression for each sample was calculated using 
the 2-ΔΔCT method 354. 
ΔΔCt = (Ct target gene – Ct reference gene) sample – 
 (Ct target gene – Ct reference gene) calibrator 
In the experiments with stimulated cultured PBMCs, an endogenous calibrator 
(unstimulated control) and a reference gene (normally GUS or ACTB) were 
used to normalize the amounts of target gene. In the experiments with 
untreated baseline samples from patients, these were used as calibrators and 
the gene ACTB was used as reference gene to normalize the amounts of 
target gene. Finally, those assays with ex vivo PBMCs, the reference gene to 
normalize the results was ACTB and the calibrator was the mean of the 
threshold cycles (Ct) of the target and reference genes in the group of healthy 
controls, similarly as described in other studies 355. The relative quantitative 
value for each sample was expressed as 2-ΔΔCT method, representing a fold 
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change in gene expression normalized to the endogenous reference gene and 
relative to its respective calibrator. 
3.4.10.        Vitamin D Stimulation 
In a subet of MS patients (n=8) and healthy donors (n=8), 2*106 PBMCs were 
cultured in complete medium (RPMI 1640 containing 10% fetal calf serum 
(FCS), streptomycin 50 U/ml, penicillin 50 U/ml and L-glutamine 2 mM) 
supplemented with 1,25(OH)2 vitamin D3 (Sigma-Aldrich) (100nM), in 6 well 
flat bottom plates. Cells were cultured for 24 hours and 5 days. At 24 hours 
PBMCs were lysed in 1 ml of trizol. After 5 days, supernatants were collected. 
As the reagent 1,25(OH)2 vitamin D3 was diluted in ethanol 99%, in those wells 
without 1,25(OH)2 vitamin D3, the same volume of ethanol 99% was added. 
3.4.11.        Whole Blood Experiments 
Whole blood experiments were performed to evaluate the in vitro production of 
IP10, in response to the stimulation with IFN, in two RR-MS male patients, two 
male PP-MS patients and 4 male healthy controls. Blood from heparinized 
tubes was diluted 1:1 with RPMI supplemented with glutamine. Blood was 
distributed in 24 well flat plates (1ml/well). The following reagents were added 
to whole blood: IFN-α: 1000 IU/ml and 250 IU/ml; IFNβ-1a: 1000 IU/ml and 
250 IU/ml; IFN-ɣ: 1000 IU/ml; TNF-α: 20 ng/ml and no stimulus. TNF-α was 
used as negative control of the assay and IFN-ɣ as positive control. 100 μl of 
blood from each well were collected in tubes for posterior flow cytometry. 
Tubes and plates were incubated overnight at 37ºC and 5% of CO2. The 
following day supernatants were collected from the plates for later ELISA 
experiments. The protein transport inhibitor, containing Brefeldin A, 
GolgiPlugTM (BD Biosciences) was added to the tubes, according to the 
manufacter’s instructions and left in the incubator for 5 hours. The staining for 
flow cytometry is explained in the next section. 
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3.4.12.        Multiparametric Flow-Cytometry 
We studied different relevant marker expression antigens on the surface of 
cells from whole blood in order to preserve the original composition of 
mononuclear cells. 
3.4.12.1.  Characterization and Quantitative Analysis of IP10 
Intracellular Expression 
Whole blood (100 µL) was directly stained with the fluorochrome-conjugated 
monoclonal antibodies (mAbs): CD3 FITC, CD16/CD56PerCP and CD14APC 
(BD Immunocytometry Systems, San Jose, CA, USA). A tube of blood without 
staining was used to establish appropriate settings. Blood directly stained with 
the described mAbs was for 20 min at room temperature in the dark, lysed for 
10 minutes and then washed with the solution Perm/WashTM (BD Biosciences) 
(1600 rpm for 5 minutes), for permeabilization. Cells were stained intracellulary 
with the fluorochrome-conjugated mAB IP10 PE and with the human FcR 
Blocking Reagent (Miltenyi Biotec) in order to increase specificity of the 
staining. After an incubation of 20 minutes at 4ºC in the dark, and two washes 
with Perm/WashTM solution, cells were acquired in a FACSort flow cytometer 
(Becton Dickinson) and analysis was performed with the flow cytometry 
analysis Software, FlowJo (TreeStar, Inc, Ashland, OR, USA). The intracellular 
expression of IP10 was restricted to the population of monocites (CD14+). 
Briefly, lymphocytes and monocytes were gated according to forward and side 
scatter. 20,000 events were acquired. Monocytes were characterized as 
CD14+CD3- and the frequency of monocytes with intracellular expression of 
IP10 was measured. The condition of “no stimulus” was utilized to set the 
markers.  
3.4.12.2.  Characterization and Quantitative analysis of DPP4hi 
and CXCR3+ T cell and NK Subsets 
Whole blood (100 µL) samples from EDTA Vacutainers were labeled by direct 
staining with the appropriate fluorochrome-conjugated monoclonal antibodies 
(mAbs) and isotopic controls for 20 min at room temperature and then lysed 
and washed, as previously described 146. Direct conjugated mAbs: CD3-FITC, 
CD26-PE (DPP4), CD4, CD8, CD16 and CD56 PerCP and CXCR3 APC from 
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Becton Dickinson (BD Immunocytometry Systems, San Jose, CA, USA). 
Acquisition was performed in a FACSort flow cytometer (Becton Dickinson), 
and analysis was performed with the flow cytometry analysis Software, FlowJo 
(TreeStar, Inc, Ashland, OR, USA).  
Lymphocytes were gated according to forward and side scatter and a total of 
20,000 events were acquired. We observed three subsets of CD3+DPP4+ 
cells, with low, medium and high  expression of DPP4 (Figure 9).  
 
 
 
 
 
 
 
 
 
 
 
Figure 9    Subsets of CD3+DPP4+ with low, medium and high expression of DPP4.  
 
Krakauer et al. 281 described the subset of CD4+DPP4hi as memory T cells 
(CD45RO+), with high expression of Th1 chemokines and cytokines, including 
CXCR3. We checked that our subsets of T cells DPP4hi were CD45RO+ 
(Figure 10A), and as described by Krakauer et al. we observed that DPP4hi 
subsets coexpressed largely (>80%) CXCR3 (Figure 10B). 
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Figure 10    (A) Expression of CD45RO in the subset CD3+CD4+DPP4hi. (B) Expression 
of CXCR3 in the different T cell subsets studied. 
 
Therefore we focused our attention on DPP4hi T cells, a memory T cell subset 
with Th1 characteristic molecules 281. Briefly, lymphocytes were gated 
according to forward and side scatter. CD3 positive lymphocytes were 
selected and a gate was set according to DPP4 high (DPP4hi) expression on 
the CD3+ population, and we measured the frequency as a percentage of 
CD3+ lymphocytes and the mean intensity fluorescence (MFI) of DPP4 in this 
subset. Similarly, DPP4hi subsets of CD4+, CD8+ T cells and CD16+CD56+ 
Natural Killer (NK) cells were analyzed as described on CD3+ lymphocytes. An 
alternative plot to DPP4 was done with CXCR3, to analyze CXCR3+ CD3+, 
CD4+, CD8+ T cells and CD16+CD56+ NK cells (Figure 11).  
 
 
Table 4    Monoclonal antibodies employed for the immunophenotyping of DPP4hi 
and CXCR3+ T cell and NK subsets. 
Tubes  FITC PE PerCP APC Subsets 
1 anti-IgG1 anti-IgG1k anti-IgG1 anti-IgG1 Isotipic control 
2 anti-CD3 anti-DPP4 anti-CD4 anti-CXCR3 T CD4+ 
3 anti-CD3 anti- DPP4 anti-CD8 anti-CXCR3 T CD8+ 
4 anti-CD3 anti- DPP4 anti-CD16+ 
anti-CD56 
anti-CXCR3 NK cells 
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3.4.13.  Proliferation Assays 
PBMCs were incubated with different stimuli and their proliferations were 
evaluated by [3H] thymidine incorporation assays and by flow cytometry by 
Carboxyfluorescein succinimidyl ester (CFSE). A total of 100,000 PBMCs were 
seeded per well in 96*96 round bottom plates. 
[3H] Thymidine Incorporation  
After 5 days of cell culture, cells were pulsed with 1μCi/well of tritiated 
thymidine (3H-thymidine) and were incubated overnight. Afterwards, cells were 
filtered by an automatic Filter (Tomtec) and incorporated radioactivity was 
measured in a scintillation counter (Microbeta Trilux, Wallac, Finland). 
Proliferation was calculated as the geometric mean of the counts per minute 
(c.p.m). 
Carboxyfluorescein Succinimidyl Ester 
PBMCs were resuspended in PBS for the staining with CFSE. They were 
incubated with CFSE (1μM) for 10 minutes at 37ºC with continuous shaking 
every minute. PBMCs stained with CFSE were cultured in vitro with the 
appropriate stimulus (Table 5) and after 5 days of culture they were stained 
with mAbs (CD25 PE) and (CD4, CD8 PerCP). The proliferation of different 
cell subsets was observed by flow-cytometry with this method. 
 
Stimulus Concentration Company 
soluble anti-CD3  1 μg/ml Becton Dickinson Co, NJ, USA 
soluble anti-CD28 1 μg/ml Becton Dickinson Co, NJ, USA 
phytohemagglutinin 
(PHA) 
2 μg/ml Sigma-Aldrich® 
PMA 40 ng/ml Sigma-Aldrich® 
Ionomycin 2,000 ng/ml Sigma-Aldrich® 
Poly (I:C) 25 μg/ml Invivogen 
Poly (A:U) 50 μg/ml Invivogen 
IFNβ-1a 1,000 IU/ml or 250 IU/ml Rebif®, Merck Co 
IFNα 1,000 IU/ml or 250 IU/ml Intron® A, Merck Co 
IFNɣ 1,000 IU/ml Immukin®, Boehringer Ingelheim 
1,25(OH)2 vitamin D3 100 nM Sigma-Aldrich® 
Table 5    Reagents and concentrations employed in functional assays. 
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3.5. STATISTICS 
3.5.1. Variable Distribution 
3.5.1.1.  Kolmogorov-Smirnov Test 
This test was employed in order to test the goodness of fit for testing the 
normality of the samples distribution. This test compares the cumulative 
distribution function observed in a variable with a theoretical normal 
distribution. The Z of the Kolmogorov-Smirnov test quantifies the distance (in 
absolute value) between the empirical and the theoretical cumulative 
distribution functions 356. 
3.5.2.         Contingency Tables 
3.5.2.1.   Pearson's chi-squared Test  
Pearson's chi-squared test (χ2) measures the association (contingency) 
between two variables qualitative or categorical. In this test, it is contrasted if 
the variables are independent or not 357. 
3.5.2.2.  Fisher's Exact Test  
This test is a variant of Pearson's chi-squared test for 2*2 contingency tables 
that include the Yates’ continuity correction. It is used as an alternative to 
Pearson's chi-squared test when sample sizes are small.  This test measures 
the association (contingency) between two variables qualitative or categorical  
when simple sizes are small 357. 
3.5.3.         Survival Analysis 
It is a group of statistical techniques that study a subject for a certain time 
when it is observed the presence or absence of a determined event. The 
objective is to describe the probabilities of that event to happen and the 
evolution of the incidence of that event along time 358.  
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3.5.4.         Parametric Tests  
3.5.4.1.  Student's t-Test 
The Student’s t-test is used to contrast hypothesis about means in populations 
with a normal distribution. It also gives approximate results for the contrasts in 
means in samples large enough, when these samples are not normally 
distributed (though in this case, it is preferable to choose a non-parametric 
test). 356. 
3.5.4.2.  Pearson Linear Correlation Coefficient (r) 
This coefficient allows the measurement of the strength of a linear association 
between two variables. This strength will be null (inexistent linear association), 
if r=0, increasing the strength of the association as the value of r is more close 
to -1 or to 1. The sign of the coefficient indicates if the correlation is direct 
(positive) or inverse (negative) 356. 
3.5.5.         Logistic Regression 
The logistic regression model allows the association of quantitative and 
categorical data with binary responses. The dependent variable (Y) is a 
dichotomic variable (positive/negative) and the independent variables (Xi), one 
or several, can be quantitative and/or dichotomical with values 0 and 1. The 
parameters of the model are estimated by the method of maximal likeliness. 
The result of the logistic regression for each independent variable is 
expressed in Odds Ratio (O.R.), which is the factor that multiplies the ratio 
between the probability of a positive response of Y and the probability of a 
negative response of Y 359.  
An OR value greater than 1, called n, and statistically significant (p<0.05) 
indicates that the probability that the response Y appears, is n times higher 
among those who present factor X, than among those who do not present it. 
When the value of OR is lower than 1 and statistically significant (p<0.05), the 
interpretation is the contrary and the probability is 1/n lower. 
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3.5.6.         Non-parametric Tests  
Non parametric statistical tests were used when the simple size was small or 
the distribution of the data in the population was free (data were not from 
normal populations and with the same variations) 356. 
3.5.6.1.   Kruskal-Wallis 
The Kruskal- Wallis test is the non-parametric analogous method to the 
parametric test one-way analysis of variance (ANOVA). This method tests 
whether independent samples originate from the same population compares 
globally more than two samples or groups studied. If the Kruskal-Wallis is 
significant, at least one of the samples differs from the others. To identify the 
statistical differences between sample pairs or groups, the data were analysed 
by Mann-Whitney 356. 
3.5.6.2.  Mann-Whitney U Test 
This test compares if two samples of two populations have the same or 
different distribution. This test is the non-parametric alternative to the 
Student’s t-test. Observations from both samples are combined and classified 
with respect to the mean Rank assigned if values are equal 356. 
3.5.6.3.  Wilcoxon Rank-sum Test  
This test, as Mann-Whitney test, compares the distribution of two samples. It 
is another alternative to the Student’s t-test when the sample data do not 
follow a normal distribution 356. 
3.5.6.4.  Spearman's Rank Correlation Coefficient 
This coefficient is a variant of Pearson linear correlation coefficient. It is a 
measure of the association between two variables and it is calculated from the 
assignation of ranks to ordered values. The association or correlation will be 
null if R=0, increasing if the value of R is closer to 1 or -1. The sign of the R 
coefficient indicates the sense of the association. It is direct is the sign is 
positive and inverse if the sign in negative  356. 
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4.1. DEMOGRAPHIC AND CLINICAL CHARACTERSITICS OF MS 
PATIENTS  
MS patients were recruited during two consecutive years, as detailed in the 
materials and methods. In the total MS study population, 80 out of 129 (62%) 
patients had RR-MS distributed as follows: RR-MS Remission n=23, RR-MS 
Active n=13, RESPONDERS n=20, NON RESPONDERS n=13 and RELAPSES 
n=11 (for 6 was their first clinical episode (CIS), and they were later diagnosed 
as RR-MS), 31 were diagnosed as SP-MS and 18 as PP-MS. RR-MS patients 
and patients at relapse had similar ages, while progressive patients SP-MS and 
PP-MS were around 20 years older (Table 6). The lowest disease duration 
(median 1 year) was in the groups of RR-MS with active disease and patients at 
relapse. In RR-MS at remission and responders and non-responders to IFNβ, 
mean disease duration was about a decade and in the progressive forms (SP-
MS and PP-MS) two decades. SP-MS and PP-MS had the highest EDSS 
compared to the other groups. EDSS in RR-MS Remission and in IFNβ 
RESPONDERS were the lowest (median, 0 and 1, respectively), as expected. 
The progression index (EDSS/Disease duration) was the highest in RR-MS 
Active patients, as they had been recently diagnosed and presented with 
considerable disability. As depicted in Table 6, the patients with highest number 
of relapses in the preceding two years where those under treatment with IFNβ 
(RESPONDERS)  about to start therapy with a DMT (RR-MS Active and NON 
RESPONDERS). 
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4.2. CANDIDATE IMMUNOLOGICAL BIOMARKERS FOR 
MULTIPLE SCLEROSIS 
4.2.1.        Specific Biomarkers in Multiple Sclerosis Patients 
In our cohort of MS patients, we found that the circulating plama levels of the 
analytes: sDPP4, IL-7, IL-1RA and Mig were significantly decreased in MS 
patients with respect to healthy controls. The circulating levels of the different 
analytes and the PBMCs collected for gene expression assays were measured 
in all patients at stable clinical conditions, except in those patients undergoing a 
clinical relapse (n=11). Only RR-MS patients under treatment with IFNβ 
(RESPONDERS) were receiving immunomodulatory treatment, the rest of 
patients included in the study were non-treated. Blood samples from MS 
patients and healthy donors included in this study were drawn at the same time 
point (between 8 and 10 a.m.). 
4.2.1.1.  DPP4 Expression and Activity in Multiple Sclerosis 
Dipeptidylpeptidase 4 (DPP4, also known as CD26) is a multifunctional 
molecule that has been implicated in autoimmune pathophysiology with a 
putative immunoregulatory role. Membrane expression of DPP4 on T cells has 
been associated with MS clinical activity, but there is limited information about 
soluble (sDPP4) in MS. We sought to integrate disparate pieces of data and 
analyze the plasma levels of sDPP4, DPP activity and DPP4 surface expression 
on CD3+, CD4+, CD8+ T-cells and CD16+CD56+ NK-cells in our 129 MS patients 
with different clinical forms and 53 healthy controls from two independent 
cohorts.  
4.2.1.1.1 Validation of sDPP4 as MS Biomarker 
The circulating levels of sDPP4 were measured in all patients at stable clinical 
conditions, except in those patients undergoing a clinical relapse (n=11). 
The Pilot cohort of MS patients (cohort 1) presented significantly lower 
circulating levels of sDPP4 than healthy controls (p=0.01, Figure 12A). This 
finding was reproduced in the Validation cohort (cohort 2) (p=0.01, Figure 12B). 
As the only group of patients under treatment was the long-term IFNβ 
responders (RESPONDERS), this group was excluded from the analysis and 
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we compared the circulating levels of sDPP4 in the rest of MS patients without 
medication with the group of HC. In the Pilot cohort untreated MS patients 
presented lower levels of sDPP4 than HC (p=0.002, Fig. 12A), and in the 
Validation cohort MS patients presented a trend of lower levels of sDPP4 than 
HC (p=0.09, Fig. 12B). In the Validation cohort, most of the RR-MS patients at 
remission had higher levels of sDPP4 (77%: 7 out of 9, where 5 were benign 
forms of RR-MS) than the median in the group of healthy donors, which 
accounts for not achieving statistical significance in this comparison, indeed 
when RR-MS in remission were excluded, differences were statistically 
significant (p=0.02).  
 
 
 
Figure 12    Comparison of sDPP4 between healthy controls (Controls, n=16) and multiple 
sclerosis patients (MS, n=65) or between healthy controls and MS patients when the group 
of patients undergoing treatment with Interferon-β was excluded (MS no treatment, n=54) 
in the Pilot cohort (red, A). The analogous comparison was performed with the Validation 
cohort (Controls, n=37; multiple sclerosis patients, n=64; multiple sclerosis patients without 
treatment, n=55) (blue, B). Mann- Whitney U test comparison, median and individual dots 
shown.  
 
Given the intrinsic heterogeneity of MS, the two cohorts were pooled to increase 
the number of cases and controls. Again circulating levels of sDPP4 were 
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significantly lower in MS patients (705±300 vs 898±292 ng/ml, p<0.0001) and in 
untreated MS patients (731±304 vs 898±292 ng/ml, p<0.0001) as compared to 
healthy donors. The Receiver Operating Characteristic (ROC) curves indicated 
a good performance of plasma sDPP4 to discriminate between MS patients and 
controls (p<0.0001; area under the curve (AUC): 0.713) (Figure 13). A cut-off 
value of 622 ng/mL for plasma sDPP4 showed a sensivity of 48.0% and a 
specifity of 90.5%; positive predictive value (PPV) of 92.5% and a negative 
predictive value (NPV) of 41.7%. Concentrations of sDPP4 <622 ng/mL was a 
classifier for individuals with MS (p<0.0001 Fisher's Exact Test, 2-sided) with an 
Odds Ratio of 8.8 (95% confidence interval: 3.3 - 23.7). Importantly, this cut-off 
value was developed in the Pilot cohort (cohort 1) and could be accurately 
applied to the Validation cohort (cohort 2) (Table 7). 
 
 
 
 
 
 
 
 
 
Figure 13    Receiver Operating Characteristic curve of plasma sDPP4 to discriminate 
between multiple sclerosis patients and healthy controls. AUC: 0.713 p<0.0001 (95% 
confidence interval: 0.638-0.788).  
 
 
sDPP4  
(ng/mL) 
 
AUC 95% CI p value Cut-off Sensitivity Specificity PPV NPV 
Pilot 
cohort  0.709 0.566-0.853 0.01 622 60.0% 75.0% 90.7% 31.6% 
Validation 
cohort  0.648 0.542-0.753 0.01 622 37.5% 97.3% 96.0% 47.4% 
Table 7    Clinical utility of sDPP4 as plasma MS biomarker.  
AUC: Area under the curve, 95% CI: confidence interval, PPV: positive predictive value and 
NPV: negative predictive value.  
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Among the different MS clinical forms studied, there were differences in the 
sDPP4 levels (Figure 14A Kruskal-Wallis test, p<0.0003). In particular, we found 
that the groups of patients under treatment with IFNβ (RESPONDERS), RR-MS 
patients with active disease and SP-MS patients had the lowest levels of sDPP4 
(RESPONDERS: M-W p<0.0001; RR-MS Act.: p<0.001; and SP-MS: p<0.001, 
respectively; comparisons made to healthy donors). Patients at relapse 
(RELAPSES, p<0.02) and those with PP-MS (p<0.02) also had significantly 
lower levels of sDPP4 than healthy controls (Figure 14A). By contrast, RR-MS 
patients in remission had similar levels of circulating sDPP4 to those of healthy 
controls. This was also observed if the two independent cohorts were analyzed 
separately. If the groups of RR-MS patients in remission and those with active 
disease, and recent clinical activity, that were about to start DMTs (RR-MS 
Rem. vs RR-MS Act.) were compared; RR-MS patients with active disease had 
significantly lower levels of sDPP4 than RR-MS patients in remission (p=0.03) 
and healthy controls (p=0.0004) (Figure 14B). 
 
Figure 14    (A) Representation of the circulating levels of sDPP4 in the healthy control 
group (Controls, n=53) and in multiple sclerosis (MS) patients split by clinical forms: 
Recurrent-remitting MS patients in remission (RR-MS Rem, n=23), recurrent-remitting MS 
patients with active disease (RR-MS Act, n=13) patients at relapse (RELAPSES, n=11), 
long time Interferon-β responders (RESPONDERS, n=20), non responders to Interferon-β 
(NON-RESP., n=13), Secondary-progressive MS patients (SP-MS, n= 31), Primary- 
progressive MS patients (PP-MS, n=18) (Kruskal-Wallis test p<0.0003). The groups of RR-
MS Act, RESPONDERS and SP-MS had significantly lower levels of sDPP4 than the 
healthy control group (***p=<0.001). The groups of RELAPSES and PP-MS had also 
significantly lower levels of sDPP4 than the healthy control group (*p=<0.02). 
(B) Comparison between healthy controls (Controls, n=53) and the group of RR-MS split by 
inactive: those in continued clinical remission and non treated (inactive, n=23) and active: 
those with recent clinical activity and about to start disease modifying therapies (active, 
n=13). RR-MS active patients had significantly lower circulating levels of sDPP4 than 
healthy controls (***p=0.0004) and than RR-MS inactive (*p=0.03).  
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When MS patients and HC were analyzed according to sex, we observed a 
higher concentration of sDPP4 in healthy men than in healthy women (p=0.01). 
However, these sex differences in healthy controls were lost in MS patients, 
what favors its use as a biomarker. This lack of differences in the levels of 
sDPP4 between MS men and women persisted if the group of patients on 
treatment was excluded. Healthy men had statistically higher levels of sDPP4 
than MS men (p<0.001) and similarly, healthy women showed higher sDPP4 
than MS women (p<0.01) (Figure 15). These differences were also seen if the 
group on treatment with IFNβ was excluded from the group of MS patients. 
 
 
 
Figure 15    Comparison of men and women levels of sDPP4 in the group of healthy 
controls (n=53, F/M= 29/24) and in the group of MS patients (n=129, F/M= 85/44). Levels 
of sDPP4 were significantly higher in men compared to women in the group of healthy 
controls (A) but not in MS patients (B). When comparing men (C) and women with or 
without the disease, the differences were also significant (C: p<0.001 and D: p<0.01 Mann-
Whitney U test). Medians and individual dots shown. 
 
In order to analyze whether sex differences between healthy men and women 
on DPP4 concentration could be due to sex hormonal variations, we analyzed a 
group of 18 healthy women (age: 36 (32-40) years), evaluating the 
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concentrations of sDPP4 at day 1 of their menstruation cycle and at day 14, the 
time of ovulation. We observed no differences in sDPP4 between these two 
interval time points (Figure 16A). When the sDPP4 levels of healthy men and 
women at day 1 or at day 14 were compared, we found significantly higher 
sDPP4 levels in healthy men than in healthy women (p<0.01, Table 8). No 
correlation between sDPP4 and the serum levels of progesterone, estradiol, 
testosterone and cortisol was found for the population included in this study 
(p>0.05). 
 
Figure 16   (A) Levels of sDPP4 and of (B) dipeptidyl peptidase (DPP) activity in healthy 
women at day 1 and at day 14 of the menstrual cycle (Two-tailed Paired t tests, not 
significant).  
 
 Mena Women D1b Women D14c p value 
sDPP4 (ng/mL) 1133±297.4 
1122 (476.6) 
808.1±223.1 
738.7 (277.7) 
866.2±270.8 
785 (236.4) 
< 0.01a vs b 
< 0.01a vs c 
DPP activity (RLU) 24.18±4.22 
24.47 (7.27) 
20.49±4.81 
18.84 (7.9) 
19.51±5.69 
18.77 (8.53) 
< 0.05a vs b 
< 0.01a vs c 
Table 8    Levels of plasma sDPP4 levels and dipeptidyl peptidase (DPP) activity in 
healthy men (n=17) and healthy women (n=18) at D1 (menstruation) and D14 
(ovulation) of their menstrual cycle. Results expressed as mean±SD and median 
(interquartile range). Significant differences were observed when healthy men were 
compared with healthy women at both time points of the menstrual cycle (Mann-Whitney U 
test). 
 
 
4.2.1.1.2 Lower Dipeptidyl Peptidase Activity in MS patients 
Two of the six DPPs are extracellular – DPP4 and FAP – but the majority of 
plasma DPP activity is due to sDPP4 360. The DPP activity present in the 
plasma of our samples was analyzed in the two independent cohorts of MS and 
healthy controls. We could not pool together the results from different years as 
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the assay technique is relative (measuring enzymatic activity as a function of 
the release of a dipeptide-luciferin molecule), and assays were performed at 
different times.  
MS patients had significantly lower DPP activity than healthy controls (p=0.01, 
Figure 17A) and again, the median value was lower when the group of 
RESPONDERS was excluded (p=0.003 Figure 17A below). In the Pilot cohort, 
differences the same trend was observed (Figure 17A).  
 
 
  
Figure 17    Comparison of DPP activity measured in relative luminescent units (RLU) in 
the Pilot and Validation cohorts. (A) Comparison of DPP activity between healthy controls 
(Controls, n=16) and multiple sclerosis patients (MS, n=65) or between healthy controls 
and MS patients without treatment (MS no treatment, n=54) in the Pilot cohort (red).         
(B) Analogous comparison in the Validation cohort (Controls, n=37; multiple sclerosis 
patients, n=64; multiple sclerosis patients without treatment, n=55) Validation cohort (blue) 
Differences were statistically significant (p=0.01 and p=0.003, respectively Mann-Whitney 
U test comparison). Medians and individual dots shown.  
 
Then, we sought to determine whether DPP activity correlated with clinical MS 
evolution. Similarly to sDPP4, all the medians of DPP activity varied significantly 
among different MS clinical forms (Kruskal-Wallis test, p=0.003) (Figure 18). 
Interestingly, when analyzing the different clinical groups separately, the group 
of long-term responders to IFNβ (RESPONDERS) showed similar DPP activity 
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to the group of healthy controls in both cohorts. This may be a reflection of 
response to therapy, or alternatively the lower levels may account for a patients’ 
responsiveness. Both in the Pilot and Validation cohorts, SP-MS patients 
showed the lowest DPP activity among all MS clinical forms (Figure 18). SP-MS 
patients displayed significantly lower DPP activity compared to healthy controls 
(Pilot cohort: p<0.02, Validation cohort: p<0.001) and to long-term responders 
to IFNβ (Pilot cohort: p<0.005, Validation cohort: p<0.004).  
 
 
Figure 18    Representation of the DPP activity measured in relative luminescent units 
(RLU) in the Pilot and Validation cohorts with the healthy control group (Controls, Cohort 1-
n=16; Cohort 2-n=37) and the MS patients split by clinical forms: Recurrent-remitting MS 
patients in remission (RR-MS Rem, Cohort 1-n=14; Cohort 2-n=9), recurrent-remitting MS 
patients with active disease (RR-MS Act, Cohort 1-n=7; Cohort 2-n=6), at relapse 
(RELAPSES, Cohort 1-n=5; Cohort 2-n=6), long time Interferon beta responders 
(RESPONDERS, Cohort 1-n=11; Cohort 2-n=9), non responders to Interferon beta (NON 
RESP., Cohort 1-n=4; Cohort 2-n=9), Secondary- progressive MS patients (SP-MS, Cohort 
1-n=15; Cohort 2-n=16), Primary- progressive MS patients (PP-MS, Cohort 1-n=9; Cohort 
2-n=9). The group of SP-MS patients had significantly lower DPP activity than the healthy 
control group and the long-term responders to IFNβ in both cohorts (*p<0.02; **p<0.005; 
***p<0.001). Medians and individual dots shown.  
 
Of note, DPP activity correlated negatively with individual clinical disease 
activity score EDSS (rs= -0.315, p=0.01) and with disease duration in years 
(rs= -0.255, p=0.04). 
In order to establish that DPP activity is related to sDPP4 concentrations, but 
also to examine potential differences in the activity per molar concentration, we 
plotted DPP activity as a function of sDPP plasma concentration. The DPP 
activity and plasma concentration of sDPP4 positively correlated both in HC 
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(Pilot cohort: rs=0.638, p=0.007 and Validation cohort: rs=0.383, p=0.01) and 
MS patients without treatment (Pilot cohort: rs=0.385, p=0.004; and Validation 
cohort: rs=0.359, p=0.007). Additionally, the two populations showed a similar 
slope, arguing against the presence of allosteric regulators or genetic variants 
of DPP4 in MS patients (Figure 19). 
 
Figure 19     Correlation between plasmatic sDPP4 and DPP enzymatic activity in the 
Validation cohort (Spearman correlation).  
 
Examining other correlations, we found an inverse relationship between 
circulating levels of 25(OH)-vitamin D and the activity of DPP in MS patients  
(rs= -0.262, p=0.05). This inverse correlation has not been previously described 
and was exclusive found in female patients with MS (rs= -0.444, p=0.009). In 
contrast, male patients showed no correlation (Figure 20). Of note, circulating 
levels of 25(OH)-vitamin D were only measured in the Validation cohort.  
 
 
 
Figure 20    Inverse correlation between circulating 25(OH)-vitamin D (μg/L) circulating 
levels and DPP enzymatic activity in multiple sclerosis patients (A) in multiple sclerosis 
women (B) (Spearman correlation).  
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We observed no differences in DPP activity between women at day 1 
(menstruation cycle) and women at day 14 (ovulation) (Figure 16B). When the 
DPP activity between healthy men and healthy women at these two time points 
of the menstrual cycle were compared, we found significantly higher DPP 
activity in healthy men than in healthy women at day 1 (p<0.05) and at day 14 
(p<0.01) (Table 8).  
As an additional exploratory study, we evaluated sDPP4 concentration and DPP 
activity in the CSF of five patients at a time of relapse. Both measures were 
undetectable, and therefore this line of investigation was not continued (data not 
shown). 
4.2.1.1.3 DPP4 cell surface expression on circulating T cell subsets and 
NK cells  
In order to obtain a more comprehensive and informative picture of the role of 
DPP4 in MS, we studied the DPP4 expression on T cell subsets and NK cells 
(CD3-CD16+CD56+) in our Validation cohort of MS patients.  
Significantly higher frequencies of circulating CD8+DPP4hi T lymphocytes in MS 
patients with respect to healthy controls were noted (p=0.01) (Figure 21A). The 
mean fluorescence intensity (MFI) at the single cell level of DPP4 in 
CD3+DPP4hi and CD4+DPP4hi lymphocytes was also significantly higher in the 
group of MS patients than in healthy controls (p=0.02 and p=0.03, respectively) 
(Figures 21B and C). Among the different MS clinical forms, patients 
undergoing a clinical relapse (RELAPSE), RR-MS Active patients (RR-MS Act.) 
and RR-MS patients that had not previously responded to IFNβ (NON 
RESPONDERS) presented higher frequencies of circulating CD4+DPP4hi T 
lymphocytes compared to RR-MS patients in remission, although not 
statistically significant. In the groups of patients with RR-MS form (RR-MS 
Remission, RR-MS Active, RESPONDERS, NON RESPONDERS and 
RELAPSES) the frequencies of circulating CD4+DPP4hi T lymphocytes 
correlated positively with the clinical disease activity score EDSS (rs= 0.504, 
p=0.008). 
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Figure 21    Significant differences (p=0.01) between the frequencies of circulating 
CD3+CD8+DPP4hi lymphocytes in healthy controls (HC, n=30) and in multiple sclerosis 
patients (MS, n=48) (A). The below figures represent the mean fluorescence intensity (MFI) 
of DPP4 in CD3+DPP4hi (p=0.02) (B) and CD3+CD4+DPP4hi (p=0.03) lymphocytes (C).  
 
The expression of DPP4 was also measured on NK cells characterized as CD3-
CD16+CD56+ cells. As described in the literature 361 the constitutive expression of 
DPP4 on NK cells was low. Nevertheless, we found significant higher circulating levels 
(6.7±5.6 vs 4.8±5.2, p=0.05) and MFI of CD3-CD16+CD56+DPP4+ (35.8±13.1 vs 
31.6±10.4, p=0.03) in MS patients with respect to healthy controls. 
 
4.2.1.1.4 T-cell lymphoproliferation in MS patients after TCR stimulation. 
Association with DPP4. 
In a subgroup of 4 MS patients and 4 healthy controls, PBMCs were stimulated 
in vitro with different mitogens and antigens: soluble phytohemagglutinin (PHA) 
and soluble anti-CD3 and anti-CD28. sDPP4 was quantified from the 
supernatants at day 6. Two out of the 4 patients (P1 and P4, see table below) 
showed a marked proliferative defect to soluble anti-CD3 and anti-CD28 with 
normal proliferation to PHA with respect to the healthy controls included in the 
study. These data reflect a proliferative defect in a subgroup of MS patients 
associated with lower (undetectable) levels of DPP4, while sDPP4 is restored 
by a stronger T-cell proliferation stimulus, and thus discarding an intrinsic defect 
of DPP4 expression and shedding. As depicted in Table 9, low cell proliferation 
was associated with values below the least detectable dose (LDD) of sDPP4 in 
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the cell culture supernatants.  This subgroup was enlarged to 13 MS patients 
and 11 healthy controls and their proliferation under different stimuli was also 
studied by CFSE (see section 4.3).   
 
 NS Anti-CD3+Anti-CD28 PHA 
   [
3H] Thymidine 
incorporation, cpm 
sDPP4 
(pg/mL) 
[3H]Thymidine 
incorporation, 
cpm 
sDPP4 
(pg/mL) 
[3H]Thymidine 
incorporation, cpm 
sDPP4 
(pg/mL) 
P1  1,012 <LDD 583 <LDD 84,977 885 
P2  1,392 178 62,422 439 36,486 770 
P3  2,887 <LDD 55,212 332 79,911 637 
P4  1,706 <LDD 2,309 <LDD 45,514 470 
C1  487 <LDD 27,165 360 57,840 701 
C2  3,183 <LDD 32,887 462 51,463 918 
C3  1,269 122 74,197 440 80,244 653 
C4  3,404 <LDD 70,101 387 46,026 594 
 
Table 9    Comparison between the proliferation of stimulated or non stimulated PBMCs 
and measured concentration of sDPP4 in the cell culture supernatants after 6 days. Note 
that sDDP4 concentrations are in pg/mL. (LDD: least detectable dose). 
 
4.2.1.1.5 sDPP4 and DPP activity correlate with chemokines in MS  
Among chemokines that are cleaved by DPP4, there are some proinflammatory 
chemokines produced by immune cells and CNS glia that are expressed in the 
CNS in MS and EAE initiating immune cells influx into the CNS and the 
inflammatory cascade, such as IP-10/CXCL10, MCP-1/CCL2, MIP-1α/CCL3, 
MIP-1β/CCL4, Rantes/CCL5, MCP-3/CCL7 and Mig/CXCL9 362-373.  
In our study, in untreated MS patients (n=105), sDPP4 directly correlated with 
the chemokines MIP-1α/CCL3 (rs=0.277, p=0.004) and MIP-1β/CCL4 (rs=0.272, 
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p=0.004). In the subgroup of patients with MS relapse there was also a positive 
correlation with DPP activity and IP10/CXCL10 (rs=0.828, p=0.04). 
 
4.2.1.1.6 Vitamin D (1α,25-Dihydroxivitamin D3) stimulates in vitro sDPP4 
expression  
In order to investigate whether in vitro addition of 1,25(OH)2 vitamin D3 (100 nM) 
had any effect in the expression of DPP4 by PBMCs, we stimulated 2*106 
PBMCs of a small subset of 4 healthy donors and 2 MS patients for 24 hours 
and quantified the mRNA DPP4 expression. We observed a remarkable 
increase of the expression of DPP4 in five of the six subjects analyzed (Figure 
22A). We utilized an endogenous positive control gene that is induced by 
Vitamin D: CYP24A1 gene that encodes the mitochondrial enzyme 1,25-
dihydroxyvitamin D3 24-hydroxylase; to check that the effect observed in 
PBMCs was due to the Vitamin D. Those PBMCs stimulated by 1,25(OH)2 
vitamin D3 had an enhanced expression of CYP24A1.  
Our genetic expression findings were confirmed with the increased levels of the 
protein sDPP4 detected in the cell culture supernatants by ELISA after 5 days 
(time point when the highest increase of sDPP4 was detected). Even in the 
healthy control (C3) where there was no increase of genetic expression after 24 
hours (Figure 22B). 
 
 
Figure 22    (A) The in vitro stimulated PBMCs of five out of the six subjects studied 
increased presented a remarkably increased genetic expression of DPP4 after 24 hours 
stimulation with  1,25(OH)2 vitamin D3 100 nM. (B) The levels of sDPP4 increased in the 
cell culture supernatants of PBMCs stimulated with 1,25(OH)2 vitamin D3 after 5 days. NS: 
no stimulus, VitD: 1,25(OH)2 vitamin D3. 
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We stimulated PBMCs with 1,25(OH)2 vitamin D3 for 5 days, of 6 additional MS 
patients and 4 more healthy controls and analyzed sDPP4 levels in cell culture 
supernatants. We observed an increase of sDPP4 levels in all subjects studied 
without differences of sDPP4 expression in MS patients or healthy controls 
(Figure 23). 
 
 
 
 
 
 
Figure 23    The levels of sDPP4 increased in the cell culture supernatants of PBMCs 
stimulated with 1,25(OH)2 vitamin D3 after 5 days in six additional MS patients and four 
healthy controls. NS: no stimulus, VitD: 1,25(OH)2 vitamin D3. 
 
 
To the best of our knowledge these results confirm for the first time that after in 
vitro stimulation of PBMCs with 1,25(OH)2 vitamin D3 100nM, the expression of 
DPP4 in PBMCs is enhanced.  
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4.2.1.2.  Interleukin 7 in Multiple Sclerosis 
Interleukin 7 (IL-7) is a non-redundant cytokine with an essential regulatory role 
in lymphopoiesis and in peripheral T cell homeostasis 374. Recently, decreased 
systemic levels of IL-7 and of sIL-7RA and increased ratio of membrane-bound 
to soluble IL-7RA have been found in MS patients 375 and MS. Serum levels of 
IL-7 predict clinical response to IFNβ therapy in patients with RR-MS and IL-7 
favors Th1 differentiation of human T cells in vitro and in the mouse model in 
vivo 376. 
4.2.1.2.1  Interleukin 7 is decreased in Multiple Sclerosis 
In our cohort of MS patients, we found that circulating levels of IL-7 were 
uniformly decreased in all the groups of MS patients studied, with respect to 
healthy controls (60±55 vs 102±88 pg/mL, p<0.0005) (Figure 24). If the Pilot 
and Validation cohorts were analyzed separately, this diminished concentration 
plasma levels of IL-7 was statistically significant in the Validation cohort 
(p=0.0004).  
 
Figure 24    (A) Circulating levels of IL-7 where higher in the healthy control group (HC, 
n=36) than in multiple sclerosis patients (MS, n=129) (***p<0.0005, Mann-Whitney U test). 
(B) Clinical MS groups differed in IL-7 levels (Kruskal-Wallis test p<0.002). MS patients 
split by clinical forms: Recurrent-remitting MS patients in remission (RR-MS Rem, n=23), 
recurrent-remitting MS patients with active disease (RR-MS Act, n=13) patients at relapse 
(RELAPSES, n=11), long time Interferon beta responders (RESPONDERS, n=20), non 
responders to Interferon beta (NON-RESP., n=13), Secondary-progressive MS patients 
(SP-MS, n= 31), Primary-progressive MS patients (PP-MS, n=18). The group of NON-
RESP. had significantly lower levels of IL-7 than the groups of Controls, RESPONDERS 
and RELAPSES (***p<0.0001, **p=0.007, *p=0.01; Mann-Whitney U test. Medians and 
individual dots shown). 
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All the medians of IL-7 varied significantly among different MS clinical forms 
(Figure 24B; Kruskal-Wallis test, p<0.002). Those patients who had not 
previously responded to IFNβ treatment (NON RESP.) presented significantly 
lower levels than healthy controls (28±29 vs 102±88 pg/mL, p<0.0001), than 
patients under long-term treatment with IFNβ (28±29 vs 76±73 pg/mL, p=0.007) 
and than patients who were undergoing a clinical relapse (28±29 vs 82±74 
pg/mL, p=0.01) (Figure 24B). The groups of patients of RR-MS in remission and 
active phase of the disease and the progressive forms of MS (SP-MS and PP-
MS) had also significantly lower concentration in plasma of IL-7 (p<0.05) than 
healthy controls (Figure 24B). 
The ROC curves indicate a good performance of plasma IL-7 for the 
discrimination of MS (AUC: 0.692, p=0.0004). The cut-off value of 73 pg/mL of 
circulating IL7 showed a sensitivity and specificity of 69.4% both; PPV of 88.7% 
and NPV of 39.7%. Concentrations of IL-7 <73 pg/mL was a classifier for 
individuals with MS (p<0.0005 Fisher's Exact Test, 2-sided) with an Odds Ratio 
of 5.1 (95% confidence interval: 2.3 – 11.5).  
 
4.2.1.3.  Interleukin 1 Receptor Antagonist in Multiple Sclerosis 
The interleukin-1 receptor antagonist (IL-1RA) is a protein encoded in the gene 
IL-1RN (2q) that binds to the IL-1 receptor; inhibiting the binding of the 
proinflammatory cytokines IL-1alpha (IL-1α) and IL-1beta (IL-1β) 377.  
IL-1RA is produced as different isoforms by alternatine mRNA splicing; there is 
a secreted isoform of IL-1RA (sIL-1RA) and other three intracellular isoforms 
378. The IL-1RA blood levels are altered in different immune based diseases and 
the recombinant human IL1R blockers are successfully employed in IL-1 driven 
diseases378, 379. In EAE, the animal model of MS, sIL-1RA prevents the 
induction of the disease 331. In MS patients sIL-1RA serum levels increase after 
treatment with IFNβ 380, 381, glatiramer acetate 382 or steroids 383, indicating that 
these drugs mediate their anti-inflammatory effect by the increase of the sIL-
1RA systemic concentration. 
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4.2.1.3.1 Interleukin-1 Receptor Antagonist is decreased in Multiple 
Sclerosis  
In our cohort of MS patients, we found that all the different clinical groups of 
patients had significantly decreased plasma levels of sIL-1RA compared to the 
healthy controls (403±356 vs 712±884 pg/mL, p=0.02) (Figure 25A). When the 
Pilot and Validation cohorts were analyzed separately, this lower expression of 
sIL-1RA was statistically significant in the Validation cohort (p=0.004). We did 
not observe significant differences of IL-1RA expression among the groups 
studied (Figure 25B). However, the group of RESPONDERS had slightly higher 
levels than the rest of groups. 
 
 
Figure 25    (A) Circulating levels of sIL-1RA where higher in the healthy control group (HC, 
n=36) than in multiple sclerosis patients (MS, n=129) (*p=0.02, Mann-Whitney U test).  
(B) MS patients split by clinical forms: Recurrent-remitting MS patients in remission (RR-MS 
Rem, n=23), recurrent-remitting MS patients with active disease (RR-MS Act, n=13) patients 
at relapse (RELAPSES, n=11), long time Interferon beta responders (RESPONDERS, 
n=20), non responders to Interferon beta (NON-RESP., n=13), Secondary-progressive MS 
patients (SP-MS, n= 31), Primary-progressive MS patients (PP-MS, n=18). No significant 
differences were observed among groups (Medians and individual dots shown). 
 
The ROC curve indicated a good performance of sIL-1RA for the discrimination 
of MS (AUC: 0.625; p=0.023). The cut-off value of 377 pg/mL of circulating sIL-
1RA showed a sensivity of 61.3%, specificity of 63.9%; PPV of 85.4% and a 
NPV of 32.4%. The concentration of sIL-1RA <377 pg/mL was a classifier for 
individuals with MS (p = 0.013 Fisher's Exact Test, 2-sided) with an Odds Ratio 
of 2.8 (95% confidence interval: 1.3 – 6.1). 
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4.2.1.4.  Monokine Induced by Gamma Interferon in Multiple 
Sclerosis 
The Monokine induced by gamma Interferon (Mig), also known as CXCL9, is a 
chemokine of the α/CXC subfamily that attracts neutrophils and activated T and 
NK cells 384. Mig is induced by IFNɣ and shares the receptor CXCR3 with the 
related chemokines IP10/CXCL10 and I-TAC/CXCL11. In MS active 
demyelinating lesions, lymphocytes express CXCR3 and Mig is detected focally 
in microglia 263, 265. Human astrocytes and brain endothelial cells express 
constitutively Mig and their protein secretion is enhanced after IFNɣ stimulation 
alone or synergistically with the combination of IFNɣ and IL-1β or IFNɣ and 
TNFα 385. The CSF levels of Mig/CXCL9 and IP10/CXCL10 are increased in MS 
and in other neurological diseases 263 and the circulating frequencies of 
CD4+CXCR3+ T cells are also augmented in the intathecal compartment with 
respect to peripheral blood 263. This may be reflecting an active recruitment of 
these CXCR3+ T cells into the CNS guided by their chemokine ligands. 
4.2.1.4.1 Monokine induced by Gamma Interferon is decreased in Multiple 
Sclerosis  
Circulating Mig was found in significantly lower levels in MS patients than in 
healthy controls (210±237 vs 302±239 pg/mL, p<0.002) (Figure 26A). This 
finding was also observed when the Pilot cohort and the Validation cohort were 
analyzed separately (p=0.04 and p=0.002, respectively).  
Among the different clinical MS groups there were significant differences in Mig 
circulating levels (Figure 26B, Kruskal-Wallis test, p=0.01). The group of 
patients under treatment with IFNβ had similar circulating levels of Mig than 
healthy controls and significantly higher levels than patients at relapse (p=0.04) 
(Figure 26B). 
92 
 
  Results 
 
 
Figure 26    (A) Circulating levels of Mig were higher in the healthy control group (HC, n=36) 
than in multiple sclerosis patients (MS, n=129)(A)(**p<0.002, Mann-Whitney U test). (B) 
Significant differences were observed among groups (Kruskal-Wallis test, p=0.01). MS 
patients split by clinical forms: Recurrent-remitting MS patients in remission (RR-MS Rem, 
n=23), recurrent-remitting MS patients with active disease (RR-MS Act, n=13) patients at 
relapse (RELAPSES, n=11), long time Interferon-β responders (RESPONDERS, n=20), non 
responders to Interferon-β (NON-RESP., n=13), Secondary-progressive MS patients (SP-
MS, n= 31), Primary-progressive MS patients (PP-MS, n=18). RESPONDERS to Interferon-β 
had significantly higher levels of Mig than patients at RELAPSE (*p=0.04). Medians and 
individual dots shown.  
 
ROC curves analysis was used to assess the accuracy of Mig to identify MS 
patients (AUC: 0.673; p<0.002). The cut-off value of 106 pg/mL of circulating 
Mig showed a sensivity of 52.4%, specificity of 83.3%, PPV of 91.5% and a 
NPV of 33.7%. The concentration of Mig <106 pg/mL was a classifier for 
individuals with MS (p<0.0005 Fisher's Exact Test, 2-sided) with an Odds Ratio 
of 5.5 (95% confidence interval: 2.1 – 14.1). 
4.2.1.5.  Multivariate Logistic Regression Model for MS patients 
and Healthy Controls 
A logistic regression model was carried out including independent selected 
plasma analytes that had survived to the variable selection process between 
MS patients and healthy controls taken as independent variables and the 
conditions (MS disease or non MS) as the dichotomic target variable. The 
model obtained included the three analytes listed in Table 10 as predictors for 
the condition of having MS.  
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 p value O.R. 95% C.I. 
IL-7 (pg/mL) 0.0107 0.9920 0.9860- 0.9981 
Mig (pg/mL) 0.0193 0.9978 0.9960-0.9996 
sDPP4 (ng/mL) 0.0012 0.9978 0.9964-0.9991 
  Table 10  Logistic regression model for MS. (O.R. >/< greater/less probability of MS) 
The odds for a specific subject, i.e. the probability P of developing MS divided 
by the probability of not developing the disease 1-P, according to the model 
are given by the product of 62.9415 and the three odds ratios each elevated 
by the respective predictors’ values measured in this subject. E.g., for a 
subject with values of IL-7: 60 pg/mL; Mig: 95 pg/mL and sDPP4: 605 ng/mL, 
the odds are 62.9415 • 0.992060 • 0.997895 • 0.9978605 = 8.3. Hence the model 
assigns to this subject a probability of being a patient with MS of 8.3 / (1+8.3) 
= 89% (classification performance). 
The analytes IL-7, Mig and sDPP4 are protective factors for MS disease and 
the higher their levels in plasma, the lower the probability of having MS. 
The model gives a sensibility of 96.5%, a specificity of 23.5%, a PPV of 
80.9%, a NPV of 66.7% and an accuracy of 79.7% for the sample. 
4.2.2.        Biomarkers Discriminating among Clinical Forms of 
Multiple Sclerosis 
In this part of the study, a multifaceted evaluation of circulating analytes was 
performed, in order to identify specific biomarkers and/or their combinations 
which might serve as effective tools in the diagnosis and therapeutic targeting of 
MS patients. 
4.2.2.1.  Panel of Plasma Biomarkers that Discriminate between 
Relapsing-Remitting and Progressive Clinical Forms of Multiple 
Sclerosis 
HGF, Eotaxin and MCP-1 were present at significantly lower circulating levels in 
all the groups of RR-MS patients (RR-MS Remission, RR-MS Active, 
RESPONDERS, NON RESPONDERS and RELAPSES) than in SP-MS and 
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PP-MS patients, while Rantes was significantly higher in the progressive clinical 
forms of MS. 
The analysis of the Pilot cohort revealed that HGF, Eotaxin/CCL11, MCP-
1/CCL2, Rantes/CCL5 were present in significantly higher concentrations in the 
progressive MS clinical forms with respect to the inflammatory (RR-MS) phase, 
findings hat were confirmed in the Validation cohort (Table 11). HGF, Rantes 
and Eotaxin/CCL11 differences between these two groups were statistically 
significant in both cohorts analyzed independently. Plasma MCP-1 levels 
showed a trend to be higher in the Pilot cohort (p=0.06), while in the Validation 
cohort, this difference was statistically significant (p=0.0002).  
 
  
RR-MS 
 
 
Progressive 
 
HC 
Pilot cohort    
HGF 218±181b 
 
387±250 
 
116±130a,b 
 
Eotaxin 80±52b 
 
119±65 
 
81±26b 
 
MCP-1 382±198c 
 
483±212 
 
382±170 
 
Rantes 3,480±2,941b 
 
6,366±2,527 
 
3,898±5,949b 
 
EGF 62±58b 
 
16±19 
 
73±38b 
 
MIP-1β 138±70b 
 
75±76 
 
132±64b 
 
Validation cohort     
HGF 364±234b 
 
577±339 
 
771±753a 
 
Eotaxin 95±60b 
 
252±167 
 
199±167a 
 
MCP-1 369±254b 
 
689±357 
 
654±351a 
 
Rantes 4,865±6,176b 
 
16,167±9,986 
 
6,803±7,594b 
 
EGF 109±76c 
 
80±58 
 
146±107b 
 
MIP-1β 144±89c 
 
110±53 
 
198±138b 
 
 
Table 11   Comparisons of the plasma levels of HGF, Eotaxin, MCP-1, Rantes, EGF and 
MIP-1β comparison in the Pilot and Validation cohorts. Note that the Relapsing-remitting 
group (RR-MS) comprises the clinical groups: RR-MS Remission, RR-MS Active, 
RESPONDERS, NON RESPONDERS and RELAPSES. The Progressive group comprises 
Secondary (SP-MS) and Primary-progressive patients. ap<0.05 vs RR-MS, bp<0.05 
PROGRESSIVE vs, cp=0.06.  
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Given the intrinsic heterogeneity of MS, the two cohorts were pooled to increase 
the number of cases and controls. Again, in MS patients globally considered, 
we found that plasma levels of HGF, Eotaxin/CCL11, MCP-1/CCL2 were 
significantly diminished in the inflammatory (RR-MS patients) than in the 
progressive forms (SP-MS and PP-MS) (HGF: 294±221 vs 484±310, p= 0.0002; 
Eotaxin: 87±56 vs 187±143, p<0.0001; MCP-1: 375±227 vs 588±309, 
p<0.0001), while Rantes/CCL5 was significantly higher between both forms 
(Rantes: 11,371±8,800 vs 4,173±4,855, p<0.0001) (Figure 27). Interestingly, the 
levels of HGF, MCP-1/CCL2 and Eotaxin/CCL11 in the progressive MS patients 
were similar to those observed in healthy controls (HGF: 476±652; Eotaxin: 
147±138; MCP-1: 538±315), while Rantes/CCL5 was more elevated in the 
progressive forms with respect to healthy controls (5,518±6,796) and to the rest 
of MS patients. RR-MS patients had significantly lower levels of Eotaxin, MCP-1 
and Rantes than healthy controls (p=0.001, p=0.001 and p=0.0002, 
respectively). 
 
 
Figure 27    Comparison of the plasma levels of HGF, Eotaxin, MCP-1 and RANTES in 
relapsing-remitting (RR-MS, n= 80) and in the group of progressive (SP-MS and PP-MS, 
n=49) patients.  *** p<0.0001, ** p=0.0002, Mann-Whitney U test.  Medians and individual 
dots shown. 
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The ROC analyses indicated a good performance of plasma HGF, Eotaxin, 
MCP-1 and Rantes for the discrimination between RR-MS from progressive 
clinical forms (Table 12). 
 AUC (95% CI) p value 
HGF 0.702 (0.604-0.799) <0.0002 
Eotaxin 0.755 (0.662-0.849) <0.0001 
MCP-1 0.721 (0.626-0.816) <0.0001 
Rantes 0.792 (0.707-0.876) <0.0001 
EGF 0.689 (0.592-0.786) 0.0005 
MIP-1β 0.702 (0.607-0.798) <0.0002 
Table 12 Areas under the curve (AUC), 95% Confidence Interval (95% CI) and p value 
for the analytes HGF, Eotaxin, MCP-1, Rantes, EGF, MIP-1β.  
 
HGF correlated strongly with MCP-1/CCL2 both in MS patients and in healthy 
controls (rs=0.4674, p<0.0001), whilst HGF correlated with eotaxin/CCL11 
(rs=0.5574, p<0.0001) and Rantes/CCL5 (rs=0.3317, p=0.0002) only in MS 
patients. These proteins correlated also with neurological disability measured by 
the EDSS: HGF (rs=0.3254, p=0.0003), MCP-1/CCL2 (rs=0.2714, p=0.003), 
Eotaxin/CCL11 (rs=0.3610, p<0.0001), Rantes (rs=0.4386, p<0.0001). 
EGF and MIP-1β are diminished in Secondary and Primary Progressive 
clinical forms  
Both in the Pilot cohort and confirmed in the Validation cohort, EGF and MIP-1β 
plasma levels were lower in the progressive forms with respect to RR-MS 
patients. In the Pilot cohort, EGF and MIP-1β statistically differed in both 
classification groups (p=0.0001 and p=0.0002, respectively); in the Validation 
cohort, both analytes showed a trend (p=0.06) to be at lower concentrations in 
the plasma of progressive patients (SP-MS and PP-MS) than in RR-MS patients 
(Table 11). 
The pool of both cohorts displayed the same distribution with significantly 
diminished circulating levels of EGF and of the chemokine MIP-1β/CCL4 than in 
RR-MS patients (EGF: 50±54 vs 87±71, p=0.0005; MIP-1β: 93±67 vs 141±79, 
p=0.0002) (Figure 28). RR-MS patients and HC showed similar circulating 
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levels of EGF and MIP-1β/CCL4 (in HC, EGF: 115±92; MIP-1β: 170±116) and 
progressive patients had significantly lower levels of EGF and MIP-1β than 
healthy controls (p<0.0001 and p=0.0002, respectively). The ROC curves of 
plasma EGF and MIP-1β were used to assess the identification potential 
between RR-MS and progressive (SP-MS or PP-MS) clinical forms (Table 12). 
As expected, EGF and MIP-1β correlated negatively with the disability score 
EDSS: EGF (rs= -0.2906, p<0.002, MIP-1β (rs= -0.355, p<0.0001).  
 
 
 
Figure 28    Comparison of the plasma levels of EGF and MIP-1β between patients with 
relapsing-remitting (RR-MS, n=80) and progressive (SP-MS and PP-MS,n=49) MS. EGF 
***p=0.0005; MIP-1β ***p=0.0002,  Mann-Whitney U test.  Medians and individual dots 
shown. 
 
 
We carried out a logistic regression with all these six factors (HGF, Eotaxin, 
MCP-1, Rantes, EGF and MIP-1β) as independent variables and the clinical 
MS-forms (Relapsing-Remitting vs. Progressive) as the dichotomous target 
variable. We obtained a model that included the factors HGF, EGF, Eotaxin and 
MIP-1β as predictors for the clinical form, while Rantes and MCP-1 did not 
reach statistical significance to be included in the model.  
The odds for a specific patient, i.e. the probability P of being classified as 
progressive clinical form of MS divided by the probability of developing a 
relapsing-remitting form 1-P, according to the model are given by the product of 
0.4021 and the four odds ratios each elevated by the respective predictors’ 
values (in pg/mL) measured in an individual patient. For instance, for a patient 
with values [pg/mL] of Eotaxin: 200; HGF: 323; EGF: 17; MIP-1β: 54, the odds 
are 0.4021 · 1.0147200 · 1.0038323 · 0.980817 · 0.987354 = 9.14. Hence, the 
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model assigns to this patient a probability of having a progressive form of 9.14 / 
(1+9.14) = 90.1%. 
HGF and Eotaxin with O.R. > 1 are risk factors for developing a progressive 
clinical form of MS, while EGF and MIP-1β with O.R. < 1 are protective factors 
for developing a progressive clinical form of MS. 
Considering odds >/< 1, i.e. a greater/less probability of having a progressive 
versus RR-MS clinical form according to the model, as a positive/negative 
prognosis, the model gives a sensitiviy of 71.7%, a specificity of 89.9%, a PPV 
of 82.5%, a NPV of 82.7% and an accuracy of 82.6% for our cohort of MS 
patients.  
4.2.2.2.  Progressive Clinical Forms of Multiple Sclerosis present 
High Gene Expression Levels of Clusterin and Low Gene Expression 
Levels of Interferon Regulatory Factor 2 
In order to evaluate whether there were differences in the genetic expression of 
selected genes related with MS pathogenesis and type I Interferon signature in 
the different clinical MS groups, we analyzed the mRNA levels from PBMCs in 
patients at stable conditions (except for those undergoing a clinical relapse).  
The expression levels of the gene clusterin (CLU), also known as 
apolipoprotein-J, were significantly higher in progressive patients (SP-MS and 
PP-MS) compared with controls (p<0.0001) and with all the patients with RR-
MS (p=0.0002), if the group under treatment with IFNβ (RESPONDERS) was 
excluded from the analysis, the differences between untreated RR-MS and 
progressive clinical MS forms remained significant (p=0.003) (Figure 29). 
On the other hand, the interferon regulatory factor 2 (IRF2) was expressed at 
lower mRNA levels in the progressive patients compared to patients with RR-
MS (p=0.007). Again this difference was significant when the group of 
RESPONDERS was not included in the RR-MS patients (p=0.004). Progressive 
patients had lower mRNA expression of IRF2 than healthy controls but this 
difference did not achieve statistical significance (p=0.08) (Figure 29).  
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Figure 29    Comparison of gene expression levels of clusterin (CLU) and interferon regulatory 
factor 2 (IRF2) in the PBMCs from healthy controls (HC, n=46), RR-MS patients (n=76) and 
Progressive MS patients (n=48) (Mann-Whitney U test).  
 
4.2.2.3.  Plasma FGFb can discriminate between Primary and 
Secondary Progressive patients and between Primary Progressive 
patients and Relapsing-Remitting patients undergoing clinical 
relapse  
Plasma FGFb was markedly diminished in PP-MS patients when compared to 
SP-MS (11±10 vs 26±27, p=0.01), patients undergoing a clinical relapse (11±10 
vs 21±11, p=0.01), or healthy controls (11±10 vs 28±31, p=0.02) (Figure 30). 
This distinction is important because MS at onset can be divided into two main 
forms: relapsing-remitting (all relapses were RR-MS patients) and primary 
progressive.  
 
 
 
 
 
 
 
 
Figure 30    FGFb levels were significantly decreased in primary progressive patients (PP-
MS) with respect to healthy controls (HC: * p =0.02) and to secondary progressive (SP-MS) 
and patients undergoing clinical relapse (RELAPSES) (* p=0.01) Mann-Whitney U test. 
Medians and individual dots shown. 
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4.2.2.4.  Low Density Lipoprotein Receptor Gene Expression is 
increased in Primary Progressive patients   
Patients with PP-MS presented higher mRNA expression levels of the Low 
Density Lipoprotein Receptor (LDLR) in their PBMCs than RR-MS patients 
without treatment (including RR-MS patients in remission, with active disease, 
relapses and non responders to IFNβ) (p=0.0003), SP-MS patients (p=0.01) 
and healthy controls (p=0.006) (Figure 31). RR-MS patients with IFNβ treatment 
(RESPONDERS) had similar mRNA expression levels than PP-MS patients, 
probably due to the effect of therapy in the expression of LDLR.   
 
 
 
 
 
 
 
 
 
 
 
Figure 31    Comparison of gene expression levels of low density lipoprotein receptor 
(LDLR) in the PBMCs from healthy controls (HC, n=46), RR-MS patients without treatment 
(n=56), SP-MS patients (n=31) and PP-MS patients (n=17). (*p=0.01; 
**p=0.006,***p=0.0003 Mann-Whitney U test) 
 
4.2.2.5.  VEGF Levels were higher in Secondary Progressive 
than in Relapsing-Remitting MS  
Patients with SP-MS had significantly higher circulating levels of the vascular 
epidermal growth factor (VEGF) than all the patients with RR-MS (32±28 vs 
15±9, p=0.0004) (Figure 32). Patients with PP-MS had also lower circulating 
levels of VEGF than SP-MS, but this difference was not statistically significant. 
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Figure 32    Plasma levels of the vascular growth factor (VEGF) in the Validation cohort, 
were higher in secondary progressive patients (SP-MS, n= 16) than in patients with the 
relapsing-remitting form (RR-MS, n=38) (*** p=0.0004). Mann-Whitney U test. Medians and 
individual dots shown. 
 
The plasma biomarkers significant across MS clinical forms are summarized 
below (Figure 33). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33    Plasma biomarkers significant across MS clinical forms. Findings are 
summarized. Listed biomarkers were found to differ significantly between comparison 
groups. Arrows preceding each biomarker name indicate increased or decreased plasma 
concentrations in MS groups. 
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4.2.2.6.  IP10 and MCP-1 circulating levels are significantly 
higher in Relapsing-Remitting patients that respond to IFN-β 
treatment than in Non Responders  
Significant among the chemokines tested were IP10/CXCL10 and MCP-
1/CCL2, which were significantly higher in RR-MS patients under treatment with 
IFN-β (RESPONDERS) than in those patients who had been previously treated 
with IFN-β and did not respond to therapy and had clinical activity (NON 
RESPONDERS) (IP10: 111±60 vs 96±136, p=0.04 and MCP-1: 446±158 vs 
272±152, p=0.008) (Figure 34). These two cytokines are induced by type I IFN, 
but only IP10/CXCL10 levels were significantly higher in the RESPONDERS 
group when compared to the levels of the group of HC (111±60 vs 86±86, 
p=0.005) and to those levels of the rest of RR-MS patients without treament 
(RR-MS, RELAPSES and NON RESPONDERS) (111±60 vs 75±78, p=0.0003). 
IP10 levels were also increased in the progressive forms of MS (SP-MS and 
PP-MS) than in the rest of RR-MS patients studied: In PP-MS patients, there 
was a modest increase (96±75 vs 75±78, p=0.05), whereas in SP-MS patients 
these differences were more remarkable (102±52 vs 75±78, p=0.0001). SP-MS 
had also higher circulating levels of IP10 than the group of healthy controls 
(102±52 vs 86±86, p=0.01) (Figure 35). 
 
 
Figure 34    Long-term IFN-β treated RR-MS patients presented with higher circulating 
levels of IP10 (*p=0.04) and MCP-1 (**p=0.008). Mann-Whitney U test. Medians and 
individual dots shown. 
 
 
103 
 
  Results 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35    Plasma levels of IP10/CXCL10 in the different clinical groups and healthy 
controls (n=36). The groups of RR-MS patients without treatment (n=58) had significantly 
lower levels of IP10 than long time Interferon-β responders (RESPONDERS, n=19) 
(***p=0.0003), than Secondary-progressive MS patients (SP-MS, n= 31) (***p=0.0001) and 
than Primary-progressive MS patients (PP-MS, n=18) (*p=0.05). Levels of IP10 were more 
increased in RESPONDERS compared to healthy controls (**p=0.005) and in SP-MS with 
respect to healthy controls (*p=0.01).  Mann-Whitney U test. Medians and individual dots 
shown. 
 
In order to analize the ex vivo production of IP10 to IFNβ in MS patients we 
observed the plasma levels of IP10 in a subgroup of patients with RR-MS in the 
active disease that were about to start with IFNβ. Blood was drawn before the first 
injection, after 10 hours, after 32 hours, and after 1 month (10 hours post 
injection). Results are shown in Figure 36. 
 
 
 
 
 
 
 
 
Figure 36    Plasma levels of IP10/CXCL10 were monitored in four patiens starting IFNβ 
therapy.  
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The increase of IP10 plasma levels were not as remarkable as those observed 
by our group in patients with hepatitis C virus (HCV) starting treatment with 
peg–IFN-α2/ribavirin therapy 1. As IFNα and IFNβ share the same receptors 
on the surface of T cells (IFNAR1 and IFNAR2) we expected to find higher 
plasma levels of IP10 after IFNβ treatment. Therefore, we decided to continue 
with this line of investigation and studied the IP10 production in whole blood 
after stimuli with IFNα and IFNβ in two RR-MS male patients and two male 
PP-MS patients and 4 male healthy controls. We observed a similar 
intracellular production of IP10 after stimuli with IFNα (1,000 IU/mL and 250 
IU/mL) and IFNβ (1,000 IU/mL and 250 IU/mL) in all the subjects studied 
(Figure 37) and ELISA IP10 results in the plasma was also very similar in all of 
them after 24 hours at both concentrations, reflecting a normal response to 
type 1 IFN in the MS patients studied. 
 
Figure 37    (A) Intracellular expression of the chemokine IP10 in the peripheral blood 
monocytes of a representative patient after IFNα stimulus (1,000 IU/mL) and (B) IFNβ-1a 
(1,000 IU/mL). The adjacent graph displays the mean protein expression of IP10 in the 
plasma of the blood stimulated.  
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4.2.2.7.  CXCR3 cell surface expression on circulating T cell 
subsets   
The analysis of the cell surface expression of CXCR3, receptor of the 
chemokine CXCL10/IP10, revealed that the different clinical groups had a 
different CXCR3 expression on the surface of their T cells subsets. 
Higher circulating frequencies of CD3+CXCR3+ T cell subset were observed in 
the PP-MS patients with respect to SP-MS patients (p=0.009); RR-MS patients 
in remission (p=0.02); non responders to IFNβ (p=0.02) and to healthy controls. 
PP-MS patients presented the highest circulating frequencies of CD3+CD4+ 
CXCR3+ T cells among clinical forms of MS. Interestingly, frequencies of 
CD3+CD8+ CXCR3+ T cells were the lowest in SP-MS patients (p=0.01 vs PP-
MS; p=0.009 vs Relapses; p=0.02 vs RR-MS Act; p=0.03 vs HC). The 
fluorescence at the single cell level, median fluorescence intensity (MFI), of the 
three cell subsets was higher in the groups at RR-MS patients with active 
disease (p<0.05 vs HC) and relapse (p<0.05 vs progressive forms) (Figure 38). 
 
Figure 38    Circulating frequencies of CXCR3+ T cells and mean fluorescence expression 
in the different clinical forms studied from the Validation cohort.  
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4.2.2.8.  Gene markers in Responder MS patients to IFNβ  
The analysis of a broad arrange of genes related with type I Interferon signature 
and with MS pathogenesis, enabled the search of selective genes stimulated by 
IFNβ in those patients who were under treatment with IFNβ and with a good 
clinical response. The comparison of the mRNA levels from PBMCs of the 
different clinical groups defined in this study enabled the identification of genes 
that were significantly overexpressed in the group of RESPONDERS to IFNβ 
than in the rest of clinical groups and than the cohort of healthy controls studied 
(Figure 39). 
In an additional small cohort (n=4) of patients that were studied before starting 
treatment with IFNβ, after 10, 32 hours from the first injection of IFNβ and after 
1 month (after 10 hours from the last injection); we observed an induction of 
most of the genes observed in the group of long-term responders to IFNβ; 
MCP1, MDA5, RIG-I, MX1, EIF2AK2, IL1RN, RSAD2 and TRIM25. This may 
reflect the maintained effect of IFNβ in gene induction (Figure 40). 
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Figure 39    The genetic expression of different genes was enhanced in the peripheral 
blood mononuclear cells of patients under treatment with IFNβ (***p<0.0005, **p<0.005 
Responders vs healthy controls).   
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Figure 40    Changes in gene expression in patients starting IFNβ treatment. Time points: 
Before therapy, ten hours after the first injection with IFNβ, 32 hours after the first injection 
with IFNβ, and 1 month after the beginning of therapy but 10 hours after the last injection of 
IFNβ.  In the figure are represented two of the patients as representative examples. 
 
The gene expression of STAT (signal transducer and activator of 
transcription) molecules: STAT1, STAT2 and STAT 3; clue molecules in the 
downstream signaling of type I IFNs, was also increased in MS patients 
under long-term therapy with IFNβ (Figure 41). STAT6 gene expression 
was higher than in healthy controls (p=0.03) but not higher than untreated 
MS groups. 
 
Figure 41    Genetic expression of STAT 1, 2 and 3 was enhanced in the peripheral blood 
mononuclear cells of patients under treatment with IFNβ (***p<0.0001, **p<0.005, *p<0.05 
Responders vs healthy controls). 
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4.3. STUDY OF THE TYPE I INTERFERON SIGNATURE BY TLR3 
STIMULATION IN MS   
A series of functional assays with 13 MS patients and 11 HC were performed 
to test the hypothesis of whether the stimulation of TLR3, by different synthetic 
ligands (polyinosinic-polycytidylic acid, poly(I:C) and polyadenylic–polyuridylic 
acid poly(A:U)), in cultured PBMCs from MS patients induced an altered 
production of type I IFN measured by ELISA. 
PBMCs were stimulated in vitro with different mitogens and antigens: soluble 
phytohemagglutinin (PHA) and soluble anti-CD3 and anti-CD28 (1µg/mL) in the 
presence or absence of the ligands of TLR3 (poly(I:C): 25 µg/mL and poly 
(A:U): 50µg/mL). As previously mentioned, we observed that in 61% of MS 
patients (8 out of 13), their PBMCs showed a marked proliferative defect to 
soluble anti-CD3 and anti-CD28 with normal proliferation to PHA (2 µg/mL) 
(Figure 43) with respect to the healthy controls included in the study. This defect 
in proliferation was only observed with soluble anti-CD3 and anti-CD28 at 1 
µg/mL, in conditions with anti-CD3 bound to the plate at 5 µg/mL, the 
proliferation was restored. 
The addition of the ligand of TLR3 poly(I:C) enhanced the proliferation of CD4+ 
T cells only in the patients with defective proliferation to soluble anti-CD3 and 
anti-CD28 (Figure 42). The addition of exogenous IFNα (1,000 IU/mL) to soluble 
anti-CD3 and anti-CD28 TCR stimulus showed anti-proliferative effects in 
patients with normal proliferation. 
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Figure 42    Representative examples of a healthy control with normal proliferation and an 
MS patient with defective proliferation to soluble anti-CD3 and anti-CD28. CD4+ and CD8+ 
T cells under the conditions: no stimulation, soluble anti-CD3 and anti-CD28, anti-CD3 plus 
anti-CD28 plus poly(I:C) (25 µg/mL) and anti-CD3 plus anti-CD28 plus IFNα (1,000 IU/mL). 
A modest increase in the proliferation of CD4+ T cells was observed when the agonist of 
TLR3, poly(I:C) was added to soluble anti-CD3 and anti-CD28. 
 
111 
 
  Results 
 
 
Figure 43    Representative example of the MS patient shown in Figure 39 with normal 
proliferation to PHA. CD4+ and CD8+ T cells under the conditions: no stimulation, PHA, 
PHA and poly(I:C) (25 µg/mL) and PHA plus IFNα (1,000 IU/mL). 
 
The expression of the activation molecule CD69 on T cells was analyzed after 
stimulation of PBMCs with soluble anti-CD3 and anti-CD28, PHA and 
PMA/Ionomycin. CD69 expression on CD4+ and CD8+ T cells stimulated with 
PHA or PMA/Ionomycin was similar in MS patients and healthy controls (Figure 
44), whereas CD69 expression on CD4+ and CD8+ T cells was diminished with 
respect to healthy controls in those patients with a defect in the proliferation to 
soluble anti-CD3 and anti-CD28 (Figure 44). 
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Figure 44    Activation of CD4+ T cells from a healthy control and a patient with MS. CD69 
expression in CD4+ T cells after stimulation with PHA (blue line), PMA/Ionomycin (green line), 
soluble anti-CD3 and anti-CD28 (orange line) or unstimulated (red line). Numbers represent the 
percentage of CD69+ cells. Cells were stimulated for 24 hours.   
 
A single experiment was performed with stimulated PBMCs for 24 hours with 
poly(I:C) and poly(A:U) of an MS patient and a healthy control. The gene 
expression results by BioMark revealed that after 24 hours in the presence of 
the agonists of TLR3, poly(I:C) and poly(A:U),  genes upregulated by type I IFN 
were differentially induced in the patient and the healthy control (ISGs) (Figure 
45). 
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Figure 45    Induction of interferon stimulated genes after stimulation of PBMCs for 24 
hours with the TLR agonists poly(I:C) and poly(A:U). The numbers represent the mRNA 
levels normalized to actin beta and expressed as fold increase.   
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The levels of IFNα after 24 hours in the cell culture from this patient 
supernatants were decreased with respect to the healthy control after 
stimulation with poly(I:C), the levels of I IFNα after stimulation with non 
redundant poly(A:U) were very low, both in the healthy control and the patient 
with MS (Figure 46). 
 
 
Figure 46    IFNα production, measured by ELISA, in PBMC (2*106) in response to 
poly(I:C) and poly(A:U).  
 
The supernatants at 24 hours from different experiments performed were 
analyzed to test whether the production of type I IFN was impaired in the rest of 
MS patients. No differences in the production of IFNα by poly(I:C) stimulated 
PBMCs between the healthy controls and MS patients (Figure 47). 
 
 
 
 
 
 
 
 
 
 
 
Figure 47    IFNα production, measured by ELISA, in PBMC (105) after different stimuli.  
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Multiple sclerosis (MS), the most common cause of neurological disability in 
young population after trauma, represents a significant personal, social and 
economic public health burden. MS is a chronic autoimmune inflammatory 
disorder of the CNS characterized by multiple demyelination lesions, axonal 
degeneration and oligodendrocyte and neuronal loss. Although CNS MRI and 
the presence of oligoclonal bands (OB) in the CSF have greatly helped in the 
diagnosis of MS, they are not capable of discriminating in a reliable and 
reproducible way between the inflammatory and progressive forms at MS onset 
or to predict evolution. The current challenges associated with MS stem from 
the lack of serum biomarkers that enable to distinguish MS patients from 
healthy controls and to discriminate among the different clinical forms of MS. 
Identification of such minimally invasive biomarkers of MS in the individual 
patient is an important issue. These biomarkers can also help to shed light on 
MS pathogenesis.  
The present investigation shows a significantly decreased expression of DPP4 
and DPP activity in the plasma of MS patients with respect to healthy controls, 
which suggests that DPP4 may have a role in the pathophysiology of MS. In 
addition, DPP activity correlated inversely with clinical disability score in MS. 
Among the most relevant analytes capable of differentiating between MS 
patients and healthy controls, the enzyme DPP4, IL-7, IL-1RA and Mig/CXCL9 
were identified in this study. On the other hand, our data demonstrate that the 
divergent clinical and histology-based MS forms are associated with distinct 
profiles of circulating biomarkers, mostly chemokines and growth/angiogenic 
factors (HGF, Eotaxin, MCP-1, Rantes, EGF, MIP-1β, VEGF and FGFb); and 
different gene expression levels in their PBMCs (CLU, IRF-2 and LDLR). 
Finally, responder patients to type I IFN displayed high levels of plasma IP10 
and MCP-1, and a specific expression pattern of IFN stimulated genes.  
The molecule DPP4 is a multifunctional protein with important enzymatic and 
costimulatory acitivies. This is the first study to analyze simultaneously the 
plasma levels of sDPP4, DPP activity and DPP4 expression on T cells, in a 
large cohort of MS patients with different clinical forms. We report that MS 
patients show significantly diminished plasma levels of sDPP4 and lower DPP 
activity than healthy controls. These findings are in agreement with those 
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described in other autoimmune diseases such as systemic lupus erythematosus 
(SLE) 386 and rheumatoid arthritis (RA) 275, and may point out an underlying 
immunoregulatory and T cell activation defect in the pathophysiology of diverse 
autoimmune diseases.  
MRI has dramatically transformed the horizon of MS, enabling an earlier 
diagnosis and treatment, and still only the presence of IgG OB within the CSF is 
used as routine biomarker. OB require a lumbar puncture, which is an invasive 
procedure with high sensitivity up to 95% but with less specificity as OB are 
present in other inflammatory CNS disorders 319. OB are suggested to represent 
an altered B-cell activation within the CNS compartment. To this point, our 
results on plasma sDPP4 would represent an easy, non cruent and reproducible 
biomarker, as we have validated in two independent cohorts of MS patients and 
controls. Low levels of sDPP4 may suggest a T-cell impairment influencing the 
defects in B cell tolerance with subsequent intrathecal B-cell oligoclonal 
expansion. A preliminary cut-off level of 622 ng/mL of sDPP4 in our two 
independent cohorts showed a global PPV of 92.5% for MS. An effort should be 
made to further confirm our findings on the value of sDPP4 in prospective and 
larger series of MS patients and to compare with other non inflammatory 
neurological conditions. 
The classification of MS patients according to their clinical forms has enabled us 
to observe differences in sDPP4 among the MS groups of patients. 
Interestingly, patients at active phase of the disease (RELAPSE and RR-MS 
Active) and progressive forms (SP-MS and PP-MS) had significantly lower 
levels of sDPP4 than non-active MS patients (RR-MS at remission). Moreover, 
DPP activity negatively correlated with EDSS. Accordingly, an inverse 
correlation of sDPP4 and disease activity was also observed in SLE patients 386. 
The sDPP4 molecule may be modified post-translationally by glycosylation or 
sialation. Partial degradation may affect the detection of circulating sDPP4 by 
conventional ELISA. For instance, in RA the reduction in DPP4 activity was due 
to the glycosylation of DPP4 387, whereas in SLE and Sjögren´s syndrome it 
was due to a reduced sDPP4 concentration 386, 387. As circulating levels of 
sDPP4 in our MS patients’ cohort correlated with the DPP activity, the reduced 
DPP activity is likely a reflection of lower levels of sDPP4.  
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Among MS patients, markedly low sDPP4 and the lowest DPP activity was 
found in the SP-MS group, a finding that was observed in both independent 
cohorts. Measuring DPP activity gives additional information to that of sDPP4 
alone, as low DPP activity is associated with the progressive phase of the 
disease.  
The current paradigm on MS pathophysiology states that circulating 
autoreactive CD4+ T cells migrate through the BBB to the CNS. CSF T cells 
express the chemokine receptor CXCR3 that possibly facilitates the entrance of 
T cells into the CNS 37. Immunohistochemical studies of autopsy brain sections 
from MS patients have shown specific CXCR3 expression on most of the 
perivascular lymphocyte infiltrates, together with the expression of its ligand 
IP10/CXCL10. In the later stages of MS, the number of accumulated CXCR3+ 
T-cells in the intrathecal lesions was higher than in the early stages of the 
disease 265. In this study, we found that PP-MS patients presented higher 
circulating frequencies of CD3+CXCR3+ T and CD4+CXCR3+ T cells than 
healthy controls and than the other groups of patients, while SP-MS patients 
had lower circulating frequencies of CD8+CXCR3+ T cells. Balashov et al. 265 
reported that peripheral CXCR3+ T cells with a skewed Th1 phenotype were 
increased in patients with chronic progressive MS. The high frequencies of 
circulating CD3+CXCR3+ T cells in PP-MS may be reflecting a chronic activation 
of the immune system. Moreover, the expression at the single cell level (MFI) of 
CXCR3 in T cells was significantly higher in RR-MS patients with active disease 
and in RR-MS patients undergoing a clinical relapse, what would reinforce the 
role of these cells in immune activation.  A direct correlation in the MS group 
was detected between sDPP4 expression and MIP-1α/CCL3 and MIP-1β/CCL4; 
and between DPP activity and IP10/CXCL10 in MS patients at relapse. 
According to previous findings of the group of Dr. Albert 1, 388, DPP activity 
would mainly affect chemokine gradients and might be driving the effector 
autoimmune response through the impaired regulatory loop. The data 
presented here compel new evidence of an underlying immunoregulatory defect 
in MS that could be playing a role in MS pathophysiology. 
Previous studies have implicated the subset of CD4+DPP4hi T-cells in the 
pathogenesis of MS 281, 286, 289-291. Hafler et al. were the first to describe CD4+ T-
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cells coexpressing DPP4 in the CSF and peripheral blood of patients with 
progressive MS; naming this antigen T-cell–specific activation antigen Ta1+ 389. 
Later on, several studies correlated CD4+DPP4+ and CD4+DPP4hi T-cell subset 
with active MRI lesions and with clinical disease activity 281, 289-291. In our MS 
population, CD4+DPP4hi T-cell subset correlated with clinical disease activity in 
RR-MS patients. In addition, we found significantly higher percentages of 
circulating CD8+DPP4hi T and CD16+CD56+DPP4+ NK cells in MS patients than 
in healthy controls. An altered expression of DPP4 on the surface of NK cells 
has been reported in other diseases such as SLE 390 and chronic fatigue 
syndrome 391. The overexpression of DDP4 on NK cells seems to regulate their 
proliferation and not to affect their cytotoxic function 392. Thus, the increase in 
circulating frequencies of CD16+CD56+DPP4+ NK cells may be reflecting 
activation of these cells in MS patients. Increased percentages of CD8+ T cells 
coexpressing DPP4 have also been noted in other MS studies correlating with 
active MRI lesions 292. This expanded subset of memory CD8+ T-cells 
coexpressing DPP4 may show high migratory capacity, similarly to that 
described for CD4+DPP4+ T cells by Brezinschek et al. 393 given the role of 
membrane DPP4 on a relevant set of chemokines. Indeed, high numbers of 
CD8+ T-cells of MS patients at acute phase of the disease that display more 
increased adhesion capabilities and migratory capacity than CD4+ T-cells have 
been described, underlining a CD4/CD8 dichotomy in MS 394. CD8+ T-cells are 
the final effector cells inducing demyelination and axonal injury 395, 396, and the 
magnitude of the presence of CD8 T-cells at brain MS lesions is the best 
correlate with MS clinical severity 397, 398. Jensen et al. observed that treatment 
with IFNβ decreased the expression of DPP4 on CD8+ T cells. Our group has 
previously shown that, although MS patients disclose higher percentages of 
memory CD8+ T-cells than healthy controls at baseline, IFNβ was able to 
significantly decrease CD45RO+ memory CD8+ T-cell subset while to expand 
CD4+ and CD8+ regulatory T-cells in a prospective 1-year follow-up study 399. In 
our cohort of MS patients, the group under treatment with IFNβ 
(RESPONDERS) showed low levels of sDPP4. In contrast, this group showed 
the highest DPP activity among all groups of MS patients and the highest IP10/ 
CXCL10 concentration. Long-term treatment with IFNβ seems to restore DPP 
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activity to similar levels of those of healthy controls. Although this is a cross-
sectional study and cannot analyze whether DPP activity could be an interesting 
biomarker of response to IFNβ, prospective studies should be performed to 
confirm our preliminary findings. 
Apart from T cell activation marker, DPP4 is an alternative co-stimulatory 
molecule (reviewed by 400). The crosslinking of DPP4 and CD3 with immobilized 
monoclonal antibodies can induce T-cell costimulation with the absence of 
antigen presenting cells 279. In the clinical setting of MS, Fransson et al. 
described that patients with RR-MS in remission had poor proliferative capacity 
to anti-CD3 antibody and suggested that these cells were kept in anergy 401. In 
some MS patients, we have observed a defect in PBMCs proliferation to anti-
CD3 plus anti-CD28 antibodies that was restored after more potent T 
stimulation. In those patients with a T-cell proliferative defect, sDPP4 was 
undetectable in the supernatants of the cell cultures, while sDPP4 was detected 
in the cell cultures that proliferate and at similar concentrations as in healthy 
subjects, further pointing to an impaired T cell fitness in some patients with MS 
and to a secondary down-modulation of sDPP4 shedding. Moreover, the source 
of the sDPP4 present in the cell supernatants most probably came from the 
shedding of the PBMCs in proliferation. The origin of sDPP4 is still unclear, the 
hepatobiliary system and the shedding from peripheral blood T cells have been 
proposed as possible major sources 275. 
sDPP4 concentration shows sex differences in healthy controls, with higher 
circulating levels of sDPP4 in men than in women, but these differences were 
lost in MS patients, which reinforces its use as a biomarker. Durinx et al. 
described that DPP4 activity in healthy men was slightly higher than in healthy 
women in a large population study 402. In this work, we also observed a higher 
DPP activity in men than in women at any point of the menstrual cycle. We 
observed that circulating levels of 25(OH)-vitamin D showed an inverse 
correlation with the activity of DPP in MS patients and this negative correlation 
was skewed for MS women and not for MS men. Therefore, we observed that 
MS women with high vitamin 25(OH)-vitamin D levels had lower DPP activitiy, 
suggesting that vitamin D may affect differently women and men with MS in the 
enzymatic activity of DPP. The in vitro stimulation of PBMCs with the active 
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form 1,25(OH)2 vitamin D3 showed that DPP4 gene and protein expression was 
enhanced. Based on the clinical association between MS and vitamin D 
deficiency, the relationship with DPP activity warrants additional investigation. 
In summary, our data suggest that the evaluation of sDPP4 and of DPP activity 
might provide additional information for clinical activity in MS patients. We can 
hypothesize that lower sDPP4 concentration and DPP activity might drive 
biased chemokine effects and highlight a novel role of this molecule in MS 
pathophysiology. Further larger and prospective studies should be 
accomplished to evaluate the clinical value of sDPP4 as an additional non 
cruent surrogate biomarker for MS. 
In addition to the plasma analyte sDPP4, other proteins presented lower levels 
in MS patients compared to healthy controls, namely IL-7, IL1-RA and 
Mig/CXCL9. 
The interleukin 7 (IL-7) is essential for T cell development and α-chain subunit 
of the receptor of IL-7 (IL-7Rα/CD127) is also present on the surface of B cell 
progenitors 403. Genetic polymorphisms of IL-7Rα are  associated with a higher 
risk of developing autoimmune diseases including rheumatoid arthritis 404, type 
1 diabetes mellitus 405 and MS 86. In the present study, we found that our cohort 
of MS patients disclosed lower plasma IL-7 compared to healthy controls. Our 
results are in agreement with those recently published by Kreft et al. 375 and in 
contrast with other authors that described increased levels of IL-7 in MS 
patients 406. This may be due to the small sample size of published MS series 
and the heterogeneous distribution of patients. In our work, we studied a larger 
number of total patients with different clinical forms and we found that the group 
of non responder patients to IFNβ had the lowest IL-7 levels. In accordance, 
high serum IL-7 together with paired low IL-17F could be good biomarkers to 
identify those patients with Th1-driven MS that could respond to IFNβ treatment 
376.  
On the other hand, we observed that our MS patients uniformly expressed lower 
plasma sIL-1RA than healthy donors, which may be accounting for impaired 
antiinflamatory compensatory mechanism. Indeed, sIl-1RA is involved in the 
regulation of immunoinflammatory reactions as has been shown in IL-1RA 
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knockout mice that develop excessive inflammatory responses 378 and in sIL-
1RA deficient children that present with autoinflammatory syndrome 407. Long-
term responders to IFNβ presented remarkably higher mRNA levels of IL1RN 
(gene than encodes IL-1RA). This is in agreement with an increase in the 
circulating IL-1RA detected ex vivo after therapy with IFNβ 380, 381, 408. 
Finally, circulating Mig/CXCL9 was also found uniformly decreased in MS 
patients, with the exception of patients on IFNβ. By contrast, Mig and its related 
chemokine IP10, have been described to be increased in the CSF of MS 
patients, together with the overexpression of their receptor CXCR3 on T cells 
263, suggesting that these cells might be recruited through a chemokine gradient 
into the CNS. Patients under treatment with IFNβ had higher Mig and IP10 
levels, probably accounting for the effect of the drug in these chemokines.  
The multivariate logistic regression model combining three biomarkers sDPP4, 
IL7 and Mig discriminated between the dichotomous variables MS/non- MS with 
an ameliorated sensitivity than individual proteins of 96.5% and classification 
accuracy of 79.7%. This study proposes the use of combinatorial biomarker 
analysis as an alternative tool with a better discriminating value. The results of 
the proposed model deserve further clinical validation in larger MS series. 
An important goal of this study was to identify biomarkers enabling 
discrimination among clinical MS forms, in particular between RR-MS and 
progressive forms (SP-MS and PP-MS) which may be have relevant clinical 
implications. 
To the best of our knowledge, this study is the first to describe significant 
differences in circulating levels of FGFb, HGF, VEGF, Eotaxin, MCP-1 and 
Rantes discriminating among MS clinical forms. The biomarker analysis 
described herein provides a revealing cross-section of the pathophysiological 
MS conditions. There is an urgent need to recognize and predict outcome in the 
individual MS patient that could enable more focused treatment strategies. 
Therefore, the identification and development of targeted therapies has moved 
to the forefront of the MS translational research. 
This study shows that low expression of FGFb/FGF-2 is a selective marker of 
PP-MS, probably reflecting low remyelination related to progressive 
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neurodegeneration. FGFb is an emerging MS biomarker with a controversial 
role in promoting myelination by oligodendrocytes 315-317, since the knockout 
mice of FGFb in EAE showed that this growth factor has a 
neuroprotective/regenerative role avoiding nerve fiber degeneration and axonal 
loss and favoring remyelination in the CNS 318. In MS, FGFb is increased in the 
CSF and serum of MS patients, with the highest levels in clinically active MS 
patients undergoing relapse and in SP-MS patients with disability progression 
409. FGFb is a main mitogen of oligodendrocyte precursor cells (OPCs), mainly 
expressed at MS periplaques where macrophagic and/or activated microglial 
and perivascular astrocyte-related remyelination, further supporting its role in 
neurorepair and neuroprotection, respectively, as well as in maintaining the 
integrity of the BBB 314.  We found that patients with PP-MS had significantly 
lower levels of FGFb than the other clinical groups, representing a distinctive 
PP-MS feature. In contrast, patients with SP-MS and patients at relapse 
showed similar levels to those of healthy controls. This finding is in agreement 
with the study by Sarchielli et al. who reported an elevation of FGFb in the CSF 
of MS patients, and the highest levels at relapse and in SP-MS patients with 
recent increase in disability 409. FGFb might be playing a compensatory role 
during the inflammatory attack and during the axonal insult that occurs at these 
stages of the disease. We speculate that PP-MS patients with markedly low 
FGFb circulating levels may be pointing to an impaired production with respect 
to other MS clinical forms, suggesting an additional defect in PP-MS to restore 
myelination and explain their rapid disability progression compared to other 
patients. FGFb could be used as a future therapeutic target to induce effective 
migration of MS lesions by olygodendrocite precursor cells and to favor 
remyelination of lesions.  
In addition to plasma FGFb, another distinctive biomarker for PP-MS was the 
higher gene expression in PBMCs of the low density lipoprotein receptor 
(LDLR) compared to that in untreated RR-MS patients, SP-MS patients and 
healthy controls. The protein coded by LDLR gene is a cell surface LDL 
receptor essential in cholesterol homeostasis 410 and also a receptor for HCV 
virus and other viruses 411. We observed an increased mRNA expression in PP-
124 
 
  Discussion 
 
MS patients what may suggest a different pathogenic mechanism in these 
patients that deserves further investigation. 
The SP-MS form was characterized by overexpression of the vascular 
endothelial growth factor (VEGF) with respect to RR-MS and even to PP-MS 
patients, a prominent player in the complex and highly regulated process of 
angiogenesis and a proinflammatory factor 412-415 suggesting its role in the RR-
MS to the SP-MS transition. An increase of VEGF-A in the initial phases of 
relapse is compatible with its pro-inflammatory activity that attracts monocytes 
and lymphocytes, upregulates immunomodulatory adhesion molecules, 
stimulates secretion of proinflammatory cytokines, and increases BBB 
permeability 416, 417. Evidence for the occurrence of neovascularization in MS 
has been observed by contrast-enhanced MRI in the appearance of “ring 
enhancement” at the periphery, but not at the center of chronic lesions 418. 
Another MRI study showed a direct correlation between VEGF levels and the 
magnitude of spinal cord lesions, suggesting that VEGF might be involved in 
MS spinal cord lesions 419. In agreement, increased VEGF and its receptor 
VEGFR-1 are found in astrocytes in MS plaques during the inflammatory phase 
420, 421. As a direct evidence of this, intrastriatal injection of VEGF aggravates 
plaque inflammation at the site of injection 421. Moreover, as VEGF expression 
is highly influenced by inflammatory cytokines and ischemia, the accumulation 
of VEGF may be not only a mediator but the result of MS inflammation. While all 
these findings may suggest that VEGF aggravates MS but may act also as a 
neuroprotective factor, protecting against axonal damage in MS. Thus, the 
precise role of VEGF in MS remains enigmatic. Possibly, VEGF exerts a dual 
role in MS lesions: increased levels of VEGF can amplify vascular permeability 
and thus inflammation through glial cells during the acute phase of the disease, 
but can also stimulate the proliferation of neurons and their axons during the 
chronic phases of the disease 417. Recent evidence described low RNA VEGF 
levels in CSF and blood PBMCs of SP-MS patients with respect to RR-MS 422. 
Of note, here we propose a suitable method for classification of MS clinical 
forms. By using a multivariate logistic regression model combining four relevant 
biomarkers, there was significant overall model fit discriminating a dichotomous 
RR-MS versus progressive forms, with a specificity of 89.9% and classification 
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accuracy of 82.6%. In all the MS patients studied, having normal (similar to HC) 
plasma HGF and Eotaxin levels and low plasma EGF and MIP-1β levels were 
prognostic risk factors for being classified as a progressive patient with MS (SP-
MS or PP-MS). At the RR-MS stage of the disease, HGF levels were diminished 
with respect to progressive clinical forms; and circulating levels of the β-
chemokines MCP-1/CCL2, Eotaxin/CCL11 were diminished with respect to 
progressive clinical forms and to healthy controls, suggesting a potential role for 
these diminished molecules in the initial stages of MS pathogenesis. MCP-
1/CCL2 levels have been reported to be decreased in MS patients 264, 384, 423-425 
although its expression in MS lesions is increased 271. MCP-1/CCL2 stimulates 
in vitro the production of HGF by a mouse macrophage cell line 426 and in vivo 
Müller et al. reported that low levels of MCP-1/CCL2 correlated strongly with low 
levels of HGF at the central compartment 308. We have found that plasma levels 
of the β-chemokines: MCP-1/CCL2, Rantes/CCL5 and Eotaxin/CCL11 correlate 
strongly with plasma HGF in MS, suggesting a physiopathological link between 
HGF and these β-chemokines. The levels of Rantes/CCL5 were markedly 
elevated in the progressive forms with respect to healthy controls and to RR-MS 
patients. Thus, high circulating levels of Rantes/CCL5 might be reflecting a 
more progressive and disabling disease course. Rantes/CCL5 and its receptors 
CCR1, CCR3 and CCR5 have been detected in active demyelinating plaques 
on immune and microglia cells 263, 427. Its expression in serum is higher in RR-
MS patients with active lesions and clinical activity 258, 424, 428 and its 
concentration decreases in CSF after corticosteroid therapy 429.  
On the other hand, we found that plasma EGF and the β-chemokine MIP-
1β/CCL4 were diminished in SP-MS and PP-MS clinical forms with respect to 
RR-MS patients and to healthy controls. Scalabrino et al. found lower levels of 
CSF EGF in RR-MS and SP-MS patients with respect to other non-inflammatory 
neurological diseases, but they found no differences in serum EGF among MS 
clinical forms 313. However, the number of progressive MS patients of the study 
was very limited (10 SP-MS and 9 PP-MS patients). In this study, we did find 
significantly diminished plasma EGF levels in progressive MS compared to RR-
MS and to healthy controls. MIP-1β/CCL4 shares the same chemokine 
receptor, CCR5, with Rantes/CCL5 and with MIP-1α/CCL3. The target cells of 
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MIP-1β are CD8+ T lymphocytes and MIP-1β has been detected in actively 
demyelinating plaques on macrophages and microglia 257, 419. 
Additionally, HGF, MCP-1/CCL2, Eotaxin/CCL11 and Rantes/CCL5 that were 
all at higher levels in progressive MS patients than in RR-MS correlated strongly 
with EDSS, the classical indicator of clinical disability. In contrast, EGF and 
MIP-1β that were diminished in progressive patients inversely correlated with 
EDSS. 
Gene expression studies showed differences in the mRNA levels in PBMCs of 
the gene clusterin (CLU) and of the interferon regulatory factor 2 (IRF2) in RR-
MS patients with respect to the progressive clinical forms (SP-MS and PP-MS). 
Clusterin is encoded by the CLU gene, and is an ubiquitous glycoprotein also 
known as apolipoprotein J and as complement lysis inhibitor (CLI) 430. 
Proteomic analyses have found clusterin in the CSF and blood of MS patients 
and have suggested this protein as a putative biomarker for MS 431, 432. 
Clusterin is overexpressed in neurodegenerative diseases such as Alzheimer’s 
disease and Parkison’s disease with a potential neuroprotective role 433. In this 
study a higher expression of clusterin at the mRNA level was found in the 
progressive forms of MS (SP-MS and PP-MS) compared to both RR-MS 
patients and healthy controls. This high expression of clusterin in progressive 
patients may argue to a possible role of this protein in MS pathogenesis, 
especially in the progressive stage of the disease where neurodegeneration is 
more prominent than in the RR-MS phase. Indeed, there is evidence that 
clusterin can cross the BBB by diverse mechanisms 434 and the subcutaneous 
administration of recombinant clusterin promotes remyelination in experimental 
models 435. Overall, these data indicate that clusterin may have a potential 
neuroprotective role and the results from this study suggest clusterin as a 
putative gene expression biomarker with higher expression in the progressive 
forms of MS.  By contrast, the IRF2, an endogenous negative regulator of type I 
IFN signals 436 and IFN production, was markedly diminished in the progressive 
forms compared to RR-MS patients. IRF2 mRNA has been found in MS lesions 
437. This finding may be relevant in the pathogenesis of the progressive stages 
of MS, where IFNβ therapy is not effective.  
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The high degree of biological and clinical heterogeneity that characterizes MS, 
wherein inflammatory and neurodegenerative pathways vary has hampered the 
clinical effect of targeted therapies and emphasizes the need to identify those 
patients most likely to benefit from a particular treatment. 
IP10/CXCL10 and MCP-1/CCL2 have previously been reported to be at higher 
levels in patients under treatment with IFN-β 327-329, 438 and have been proposed 
as biomarkers for IFNβ response 327, 329. In this work, we observed that long 
term treatment with IFNβ translates into persistent IP10 plasma levels in these 
patients, with significantly higher values than those found in healthy controls 
and in the rest of groups with RR-MS, including non responders to IFNβ. In 
addition, we observed that MCP-1 discriminated between responder and non 
responder patients to IFNβ therapy. Moreover, we observed that SP-MS 
patients had significantly higher circulating IP10 than patients in a RR-MS stage 
and than healthy controls.  IP10 is a chemokine expressed by astrocytes that is 
upregulated and highly expressed in active demyelinating lesions 257, 264. This 
chemokine is increased in serum and in the CSF of MS patients during 
exacerbations (reviewed in 384 and 257). However, in our cohort of patients we 
did not observe higher plasma levels of IP10 in MS patients at relapse. 
Interestingly, we remarked that progressive patients, especially SP-MS had 
increased circulating levels of IP10. Several studies have reported increased 
endogenous production of IFNγ by activated T lymphocytes expressing CCR5 
from progressive MS patients 439, 440. As IP10 is induced by IFN, a high 
endogenous production of the Th1 cytokine, IFNγ, by Th1 CCR5+ lymphocytes 
might be reflecting a positive endogenous loop of IP10 production.  
Gene expression studies have been largely used for the identification of 
differential expression of genes in MS brain lesions and in PBMCs.  As IFNβ 
treatment is a long-term therapy, we focused in comparing the genes induced at 
short term in the patients starting therapy with genes induced at long term. The 
PBMCs gene expression revealed that several genes induced by IFNβ 
treatment in a small group of patients starting IFNβ therapy were also 
overexpressed in the group of long-term responders to IFNβ. Although this is a 
cross-sectional study and the same patients were not followed over time, we 
observed that a set of genes: MCP-1, MDA5, RIG-I, MX1, EIF2AK2, IL1RN, 
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RSAD2 and TRIM25, were induced in the four patients starting therapy and also 
increased in long-term IFNβ responders. 
The search for specific biomarkers of IFNβ bioactivity in patients with MS 
continues to be an interesting topic of research 441. Some genes observed in 
this study as MX1, RSAD2, IP10, MCP-1, ISG15 and EIF2AK2 have been 
reported to be upregulated in MS patients under treatment with IFNβ 329, 441, 442.  
Genes reported in this study, such as MDA5, RIGI or TRIM25, could be further 
evaluated as putative specific biomarkers of IFNβ bioactivity. 
A suboptimal secretion of IFNα and β in response to different viruses and 
alterations in the type I IFN signaling with low expression of ISGs in active MS 
has been reported 443, 444. However, in this study no differences in the 
production of IFNα after TLR3 stimulation of PBMCs were observed in a series 
of patients.  
The present study illustrates the unique and informative role of plasma and 
gene expression profiling in improving our understanding of diverse 
pathophysiological pathways underlying the different MS clinical forms and 
response to treatments. The fact that among a combination of a wide set of 
human cytokines, chemokines, soluble receptors and growth factors, the most 
striking differences were noted for chemokines and growth factors, underlines 
the importance of these proteins in the clinical course and pathophysiology of a 
CNS-specific autoimmune disease, such as MS. Autoreactive immune cells 
have CNS tropism and migrate to their target organ, attracted by chemokines 
either through direct effect or by the activation of their leukocyte integrins 445, 446. 
Growth factors have outstanding relevance peripherally and also in the central 
compartment, where they can participate in neovascularization and 
remyelination to counteract the inflammatory attacks. Our findings suggest that 
factors involved in the chemokine inflammatory response and 
growth/angiogenic factors may differentially account for divergent MS clinical 
courses. It is crucial that ongoing work in the field of non-invasive biomarkers 
will be aimed at unraveling the origins and function of the identified biomarkers, 
which could also favor more focused and personalized therapies.  
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  Conclusions 
1. Plasma dipeptidyl peptidase 4 (DPP4), a key point regulator of chemokines 
antagonism, was significantly lower in our cohort of multiple sclerosis (MS) 
patients than in healthy controls. 
2. Dipeptidyl peptidase activity was significantly decreased in our MS patients 
than in healthy controls and correlated inversely with clinical disease activity 
score in MS (EDSS). 
3. A multivariate logistic regression model with DPP4, interlekin 7 and 
monokine induced by gamma interferon (Mig) allowed the discrimination of 
MS patients with a classification accuracy of 79.7% in our cohort of 129 MS 
patients and 53 healthy controls. 
4. A multivariate logistic regression model with hepatocyte growth factor 
(HGF), eotaxin, epidermal growth factor (EGF) and macrophage 
inflammatory protein-1β (MIP-1β) allowed the discrimination between 
relapsing-remitting and progressive (secondary and primary progressive) 
forms of MS with a classification accuracy of 82.6% in the present study. 
This model might have clinical implications for the individual patient. 
5. Low plasma levels of basic fibroblast growth factor (FGFb) and high mRNA 
expression levels in peripheral blood mononuclear cells of low density 
lipoprotein receptor (LDLR) are distinctive features of primary progressive 
MS in our cohort of MS patients. 
6. High plasma vascular endothelial growth factor (VEGF) appears to identify 
secondary progressive with respect to relapsing-remitting MS patients in this 
study.  
7. The plasma levels and mRNA expression levels in peripheral blood 
mononuclear cells of interferon gamma-induced protein 10 (IP10) and 
monocyte chemotactic protein-1 (MCP-1) are increased in our MS patients 
with good response to interferon β treatment.   
8. An increased mRNA expression levels in peripheral blood mononuclear cells 
of the clusterin (CLU) gene identifies progressive (secondary and primary 
progressive) MS forms in our cohort of patients. 
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 8.1. GENES BIOMARK 
ACTB Actin Beta 
ADAM17 
A Disintegrin 
Metalloproteinase Domain 
17 / Tumor Necrosis 
Factor-α Converting 
Enzyme 
ATG5 Autophagy 5 
ATG12 Autophagy 12 
B2M Beta-2-Microglobulin 
CASP1 Caspase 1 
CCL2 
Chemokine, CC Motif, 
Ligand 2 / Monocyte 
Chemotactic Protein 1 
CCL4 
Chemokine, CC Motif, 
Ligand 4 / Macrophage 
Inflammatory Protein 1β  
CCL11 Chemokine, CC Motif, Ligand 11 / Eotaxin 
CD81 CD81 Antigen / Target of Antiproliferative Antibody 1 
CD27 
CD27 Antigen / Tumor 
Necrosis Factor Receptor 
Superfamily, Member 7 
CLU Clusterin 
CXCL9 
CXC Motif Chemokine 
Ligand 9 / Monokine 
induced by Gamma 
Interferon  
CXCL10 
CXC Motif Chemokine 
Ligand 10 / Interferon-
Gamma-Inducible Protein 
10 
CXCR3 CXC Motif Chemokine Receptor 3 
CYLD CYLD Gene 
CYP24A1 1,25-Dihydroxyvitamin D3 24-Hydroxilase 
DPP4 Dipeptidyl Peptidase / CD26 
EGF Epidermal Growth Factor 
EIF2A Eukaryotic Translation Initiation Factor 2A 
EIF2AK2 
Eukaryotic Translation 
Initiation Factor 2- Alpha 
Kinase 2 
FKBP8 FK506-Binding Protein 8 
GADPH Glyceraldehyde 3 Phosphate Dehydrogenase 
GATA3 Gata-Binding Protein 3 
GUS Beta-Glucuronidase 
HGF Hepatocyte Growth Factor 
HPRT Hypoxantine Guanine Phosphoribosyltransferase 
HSPA8 Heat Shock 70Kd Protein 8 
IFNAR1 Interferon Alpha, Beta and Omega Receptor 1 
IFNAR2 Interferon Alpha, Beta and Omega Receptor 2 
IFNA2 Interferon Alpha 2 
IFNA4 Interferon Alpha 4 
IFNA5 Interferon Alpha 5 
IFNA6 Interferon Alpha 6 
IFNA7 Interferon Alpha 7 
IFNA8 Interferon Alpha 8 
IFNB1 Interferon Beta 1 
IGFBP3 Insulin-Like Growth Factor Binding Protein 3 
IL1B Interleukin 1 Beta 
IL1RN Interleukin 1 Receptor Antagonist 
IL2RA Interelukin 2 Receptor Alpha / CD25 
IL2RB Interelukin 2 Receptor Beta / CD122 
IL2RG Interleukin 2 Receptor Gamma 
IL6 Interleukin 6 
IL6R Interleukin 6 Receptor 
IL7RA Interelukin 7 Receptor Alpha 
IL8 Interleukin 8 
IL10 Interleukin 10 
IL10RB Interleukin 10 Receptor beta 
IL12p35 Interleukin 12 subunit p35 
IL12p40 Interleukin 12 subunit p40 
IL18 Interleukin 18 
IL18BP Interleukin 18 Binding Protein 
IL18RAP Interleukin 18 Receptor Accessory Protein 
IRF2 Interferon Regulatory Factor 2 
IRF3 Interferon Regulatory Factor 3 
IRF5 Interferon Regulatory Factor 5 
IRF7 Interferon Regulatory Factor 7 
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 IRF9 Interferon Regulatory Factor 9 
ISG15 Interferon Stimulated Gene 15 
JAK1 Janus Kinase 1 
LDLR Low Density Lipoprotein Receptor 
MAVS Mitochondrial Antiviral Signaling Protein 
MDA5 
Melanoma Differentiation-
Associated Gene 5 / 
Interferon-Induced Helicase 
C Domain-Containing 
Protein 1 
MX1 Myxovirus Resistance 1 
NDEL1 Nude like protein 1 
p65 NFKB, p65 subunit 
PAFAH1B1 
Platelet-Activating Factor 
Acetylhydrolase, Isoform 
1B, Alpha subunit 
PRF1 Perforin 1 
PGR Progesterone Receptor 
RIGI Retinoic Acid Inducible Gene I 
RNF125 Ring Finger Protein 125 
RSAD2 
Radical S-Adenosyl 
methionine domain 
containing protein 2 
SCARB1 Scavenger Receptor Class B, Member 1 
SMAD7 SMA- and MAD-Related Protein 
SOCS3 Suppressor of Cytokine Signaling 3 
SOCS7 Suppressor of Cytokine Signaling 7 
STAT1 Signal transducer and activator of transcription 1 
STAT2 Signal transducer and activator of transcription 2 
STAT6 Signal transducer and activator of transcription 6 
TBP TATA box binding protein 
TCF7 Transcription Factor 7 
TIMP1 Tissue inhibitor of metalloproteinase 1 
TGFB1 Transforming growth factor beta 1 
TGFB2 Transforming growth factor beta 2 
TLR2 Toll like receptor 2 
TLR3 Toll like receptor 3 
TLR4 Toll like receptor 4 
TLR7 Toll like receptor 4 
TLR8 Toll like receptor 8 
TLR9 Toll like receptor 9 
TNF Tumor Necrosis Factor 
TNFRSF1A 
Tumor Necrosis Factor 
Receptor Superfamily, 
Member 1A 
TNFSF10 
Tumor necrosis factor 
ligand superfamily, member 
10 
TRIM25 Tripartite Motif-Containing protein 25 
TYK2 Tyrosine Kinase 2 
USP18 Ubiquitin-specific protease 18 
VDR  Vitamin D Receptor 
ZNF148 Zinc Finger Protein 148 
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INTRODUCCIÓN 
La esclerosis múltiple (EM) es una enfermedad autoinmune crónica inflamatoria 
y desmielinizante del sistema nervioso central (SNC). La EM es la principal 
causa de discapacidad neurológica no traumática en adultos jóvenes 1. Esta 
enfermedad compromete gravemente la calidad de vida de los pacientes y 
tiene un elevado coste e impacto socioeconómico para los pacientes, sus 
familias y la sociedad en su conjunto. 
Según el Atlas mundial de la EM realizado en 2008 por la Organización Mundial 
de la Salud (OMS), la incidencia media global es de 2,5 casos por cada 
100.000 habitantes (rango 1,1-4,0), mientras que la prevalencia global es de 30 
casos por cada 100.000 habitantes (rango 5-200) 2. La EM es más frecuente en 
Europa, Norteamérica, Australia y Nueva Zelanda con prevalencias mayores a 
60 casos por 100.000 habitantes. 
En la EM episodios repetidos de desmielinización inflamatoria resultan en la 
formación de placas escleróticas con distinto grado de pérdida de axonal  3. 
Patológicamente se caracteriza por la pérdida o alteración de la vaina de 
mielina que cubre los nervios en el cerebro y la médula espinal, produciendo 
lesiones multifocales en el SNC 4 que puede llevar a un degeneración axonal y 
progresiva disfunción neurológica.  
La EM es una enfermedad altamente heterogénea en cuanto a sus síntomas 
clínicos y curso de la enfermedad. Los síntomas más comunes incluyen 
alteraciones visuales, pérdida de equilibrio y coordinación, espasticidad, 
alteraciones sensoriales, incontinencia vesical e intestinal, dolor, debilidad, 
fatiga y parálisis 5. El curso de la enfermedad comienza con en más del 80% de 
los pacientes con un ataque agudo, un síndrome clínico aislado (CIS). Si 
ocurren nuevos ataques, estos se dan con distintas frecuencias pero rara vez 
exceden 1,5 al año 5. Esta forma clínica se conoce como esclerosis múltiple 
recurrente-remitente (RR-MS), y se caracteriza por brotes recurrentes con total 
o parcial recuperación y un curso inflamatorio de la enfermedad que se puede 
modificar con terapia. Después de unos 15 años desde el comienzo de la 
enfermedad 6, la progresión ocurre en aproximadamente un 65% de los 
pacientes que entran en una fase secundaria-progresiva (SP-MS). 
Aproximadamente un 20% de los pacientes tienen un comienzo progresivo sin 
brotes, conocido como esclerosis múltiple primaria-progresiva (PP-MS) 5. Para 
las formas progresivas de la enfermedad (SP-MS y PP-MS) los tratamientos 
existentes en la actualidad son incapaces de detener la progresión y el 
deterioro neurológico. Existen algunos pacientes con la forma menos agresiva 
de la enfermedad, llama EM benigna. Estos pacientes no tienen una elevada 
discapacidad después de diez o más años de enfermedad y tienen actividades 
laborales y domésticas normales. Sin embargo, el adjetivo benigno, no significa 
que estos pacientes carezcan de síntomas de la enfermedad, sino que la 
incapacidad es más lenta y no sucede en todos los pacientes 7. El grado de 
discapacidad de los pacientes de EM suele medirse según la escala EDSS 
(Expanded Disability Status Scale), que se extiende numéricamente de 0 
(examen neurológico normal) hasta 10 (muerte por EM). Esta escala se utiliza 
ampliamente como estándar para evaluar a los pacientes con EM pero 
proporciona mucha importancia a la capacidad para andar y no tiene en cuenta 
el deterioro cognitivo 8. 
La etiología de la EM es aún desconocida. Se considera que la EM es un 
desorden complejo desencadenado en individuos susceptibles genéticamente 
por distintos factores ambientales y estocásticos 9. Entre los factores 
ambientales propuestos destacan la influencia de las migraciones y la higiene 
en la infancia, el posible papel de los virus (familia de los herpes virus) y la 
asociación con la vitamina D. El principal factor genético asociado a EM es el 
HLA-DRB1*15:01 10. 
El diagnóstico de la EM se basa principalmente en la evidencia clínica. Los 
síntomas pueden ser provenir del sistema sensorial, motor y autónomo. Las 
lesiones deben estar diseminadas en el tiempo (al menos dos o más episodios 
de disfunción neurológica separados al menos 30 días) y en el espacio (al 
menos dos lesiones independientes en el SNC) 5. Cuando las manifestaciones 
clínicas no son suficientes para un diagnóstico adecuado, los rasgos 
paraclínicos pueden ayudar a establecer el diagnóstico. Las pruebas 
paraclínicas más utilizadas son las imágenes de resonancia magnética (MRI: 
Magnetic Resonance Imaging) y el examen del líquido cefalorraquídeo (LCR). 
La MRI muestra anormalidades de la sustancia blanca en más del 95% de los 
pacientes con EM y muestra la diseminación anatómica de las lesiones; al 
utilizarse la MRI de manera seriada puede mostrar nuevas placas en ausencia 
de episodios clínicos 5. El gadolinio es un material de contraste que es captado 
por las lesiones y placas recientes, y permite detectar rupturas en la barrera 
hematoencefálica (BHE) 11. El análisis del LCR, obtenido mediante una punción 
lumbar, permite detectar bandas oligoclonales (OB: oligoclonal bands) de 
inmunoglobulina G (IgG) a nivel del SNC y no en el suero de los pacientes. Las 
OB están presentes hasta en el 90% de los pacientes con EM 5. Sin embargo, 
la detección de OB no es exclusiva de pacientes con EM y tiene valor 
diagnóstico una vez que otras causas de inflamación han sido descartadas 12. 
Otras pruebas complementarias del LCR son el cociente de albúmina, el índice 
de IgG y el contaje celular 12. Los criterios generalmente empleados para 
diagnosticar la EM son los criterios de Poser 13 o los criterios revisados de 
McDonald 14 15  que tienen en cuenta síntomas clínicos y pruebas paraclínicas. 
Aunque la etiología de la EM es desconocida, se considera que la EM es una 
enfermedad autoinmune Th1/Th17, donde los linfocitos T autorreactivos 
específicos de mielina alcanzan el SNC, atravesando la BHE y 
desencadenando los eventos patológicos que llevan a una desmielinización y 
daño axonal. Los linfocitos T activados expresan distintos receptores de 
quimiocinas e integrinas que facilitan la migración al SNC. El infiltrado 
inflamatorio de las placas escleróticas está compuesto por una infiltración 
perivascular de linfocitos T (CD8+>CD4+) α/β y ɣ/δ, monocitos, algunos 
linfocitos B y células plasmáticas 16. El grado de daño axonal es proporcional al 
número de macrófagos y linfocitos T CD8+ presentes en las lesiones 17. Los 
linfocitos B son también importantes en la fisiopatología de la EM, ya que se 
activan anormalmente en células plasmáticas que producen intratecalmente 
inmunoglobulinas detectadas como OB 18. La apoptosis es también un 
mecanismo importante de regulación de la inflamación en EM. Regula la 
eliminación de linfocitos T autorreactivos, el anormal funcionamiento de la 
apoptosis puede desembocar en daño y lesión en el SNC 19. 
La EM es una enfermedad altamente heterogénea no sólo en sus formas y 
manifestaciones clínicas, sino también en el curso de la enfermedad y la 
respuesta a terapia. La búsqueda de biomarcadores que ayuden a 
diagnosticar, estratificar y predecir la respuesta al tratamiento y la discapacidad 
clínica se ha incrementado en los últimos años y son especialmente 
necesarios. Los biomarcadores potenciales necesitan ser validados para uso 
clínico y el principal obstáculo en el descubrimiento de biomarcadores es que 
muy pocos han sido estandarizados para su uso clínico 20. La definición de 
biomarcador puede definirse como “una característica medible y evaluada 
objetivamente como indicador de un proceso biológico normal, patogénico o 
una respuesta farmacológica a una intervención terapéutica 21”. En la EM, los 
biomarcadores se pueden clasificar según su uso propuesto como 22: 
predictores del riesgo de presentar la enfermedad, diagnósticos, clasificadores 
del estadio y forma clínica de la enfermedad o predictores de la historia natural 
de la enfermedad o de respuesta al tratamiento. Las citoquinas son muy 
importantes en la regulación de la actividad y la función del sistema 
inmunológico; tienen un claro papel en la patogénesis de la EM y han sido 
ampliamente estudiadas como biomarcadores potenciales. Se han descrito 
biomarcadores candidatos en suero como Fas y MIF de empeoramiento 
neurológico en formas progresivas de EM 23. En los pacientes en brote las 
citoquinas TNFα, IL-12, IL-17 and IFNɣ están aumentadas mientras que IL-10 
está disminuida en el LCR y suero 20. La producción sistémica de IL-12, que 
estimula la producción de otras citoquinas proinflamatorias, es anterior a los 
brotes clínicos y se correlaciona con la actividad clínica 20. Todas estas 
citoquinas dan una idea de la naturaleza Th1 y Th17 del brote inmunológico. 
Las quimiocinas y sus receptores también juegan un importante papel en la 
fisiopatología de la EM. Actúan atrayendo el reclutamiento activo de linfocitos 
autorreactivos desde la periferia al SNC e inducen la secreción de nuevas 
citoquinas proinflamatorias, que promueven la desmielinización final y la 
pérdida neurológica 24,25. Algunas de las quimiocinas más importantes descritas 
en EM son: CXCL8, Rantes/ CCL5 26, CXCL13 27, 28, IP10/CXCL10 29-31 y su 
receptor CXCR3 32,33. La mayoría de las β quimiocinas o de los ligandos de 
quimiocinas CCL se encuentran agrupadas en el cromosoma 17q11.2-12, que 
se ha asociado con EM en distintos estudios 34-36. Una de estas β quimiocinas, 
la eotaxina o CCL11 se ha estudiado en el modelo animal de EM, la encefalitis 
experimental autoinmune (EAE), y niveles elevados de eotaxina se asociaron 
con un fenotipo más leve de la enfermedad, BHE más conservada, una 
especificidad antigénica más reducida y un fenotipo antiinflamatorio Th2 37. La 
molécula multifuncional dipeptidilpeptidasa 4 (DPP4, también conocida como 
CD26) está implicada en la fisiopatología autoinmune con un atribuible papel 
inmunoregulador. DPP4 es una serina proteasa con actividad X-prolil 
dipeptidilpeptidasa expresada en muchos tipos celulares, incluyendo a las 
células del sistema inmunológico 38,39. También existe en forma soluble 
presente en el suero y otros fluidos biológicos como sDPP4 39, 40. En las células 
DPP4 tiene un papel de co-estimulación celular 41, 42, además está implicada en 
la regulación de las células T 43 y timocitos 44. Las quimiocinas reguladas por 
DPP4 son muchas como: MIP-1α/ CCL3, MIP-1β/CCL4, Rantes/CCL5, 
Eotaxin/CCL11, Mig/CXCL9, IP10/CXCL10, I-TAC/CXCL11 y  SDF-1α/CXCL12 
40, 45. Los estudios en EM se han centrado en la caracterización de linfocitos T 
que expresan DPP4 en su superficie 46-50 y los han correlacionado con 
marcadores de actividad de la enfermedad clínica y MRI. Los factores de 
crecimiento tienen también relevancia en los desórdenes del SNC y podrían ser 
considerados como posibles biomarcadores de EM. El factor de crecimiento 
hepático (HGF) tiene multitud de funciones y es producido por la microglía, 
células precursores de oligodendrocitos, astrocitos y neuronas 51-54. Además, el 
HGF periférico muestra efectos inmunomoduladores: promoviendo la adhesión 
de los linfocitos B 55, la migración de las células T 56 y el reclutamiento de 
células dendríticas (DCs) 57, 58. El HGF se ha encontrado aumentado en 
enfermedades del SNC, como EM y la enfermedad de Alzheimer 59. Aunque 
otros estudios encontraron distintos hallazgos 60, 61. El factor de crecimiento 
epidérmico EGF tiene efectos positivos sobre la proliferación y diferenciación 
de neuronas, astrocitos y oligodendrocitos 62, 63 y su coadministración con la 
hormona del crecimiento en EAE mejora el fenotipo y la supervivencia 64. En 
EM se ha encontrado en niveles bajos en el LCR comparado con otras 
enfermedades neurológicas no inflamatorias 65. Por último el factor de 
crecimiento básico de los fibroblastos (FGFb), tiene un papel muy importante 
en el crecimiento, diferenciación, migración y crecimiento de los progenitores 
de la glia del SNC 62, y si expresión está aumentada en las places activas de 
EM 66.  Su papel en EM es controvertido 67-69 pero recientemente el ratón sin 
(knockout) FGFb ha revelado un papel neuroprotector en EAE 70. El IFNβ sigue 
siendo la terapia más utilizada en EM. Sin embargo, todavía hay más de un 
40% de pacientes que no responden a esta terapia 71. Numerosos estudios han 
intentado buscar biomarcadores de expresión génica que permitan predecir la 
respuesta terapéutica al IFNβ 72-74. Las quimiocinas IP10/CXCL10 y MCP-
1/CCL2 se han propuesto como biomarcadores de respuesta al IFNβ 75, 76. 
Finalmente los biomarcadores humorales más utilizados son las bandas 
oligoclonales de IgG 20, otros como los anticuerpos neutralizantes de IFNβ 77 
que pueden ser indicativos de que el tratamiento con IFNβ no está siendo 
eficaz, las cadenas kappa ligeras en el LCR puede correlacionarse con 
pronóstico de discapacidad 78 y los anticuerpos IgG elevados al antígeno 
nuclear del virus Epstein-Barr (EBNA-1) se correlacionan con lesiones que 
captan gadolinio 79.  
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OBJETIVOS 
La esclerosis múltiple se caracteriza por un curso clínico y una respuesta al 
tratamiento heterogénea lo que puede representar distintas etiologías, dados 
los diferentes patrones patológicos que exhiben las distintas formas clínicas. En 
la actualidad, no existen biomarcadores séricos para la EM, lo que sería 
necesario para mejorar el diagnóstico así como la evaluación de la actividad de 
la enfermedad y la respuesta al tratamiento. Una identificación temprana de las 
formas clínicas de la EM, especialmente la primaria progresiva supone hoy día  
un reto para los clínicos. El hecho que las formas de la enfermedad todavía no 
disponen de terapias para frenar la neurodegeneración y la discapacidad hace 
todavía más urgente la necesidad de biomarcadores que puedan anticipar el 
comienzo de la progresión. La identificación de tales biomarcadores de EM en 
el paciente es un aspecto importante que permitiría el establecimiento de 
terapias más personalizadas para la enfermedad. 
El propósito de esta tesis ha sido identificar biomarcadores en sangre periférica 
que pudieran distinguir entre pacientes con EM y controles sanos y reflejar 
diferencias fisiopatológicas en las formas clínicas de EM. 
Objetivos concretos: 
 
I. Identificar biomarcadores plasmáticos que discriminen entre 
pacientes con EM y controles sanos.  
II. Caracterizar la expresión de DPP4 en EM y examinar la hipótesis de 
que DPP4 tiene un papel importante en la fisiopatología de la 
enfermedad, dado que esta enzima DPP4 tiene un papel muy 
importante en la inmunoregulación de quimiocinas clave para la EM. 
III. Identificar biomarcadores plasmáticos que permitan estratificar a los 
pacientes con EM según su forma clínica. 
IV. Identificar biomarcadores relacionados con las vías de señalización 
del interferón de tipo I que podrían ayudar a desarrollar estrategias 
personalizadas en EM y proporcionar información sobre los 
mecanismos fisiopatológicos de la enfermedad. 
APORTACIONES FUNDAMENTALES DE LA TESIS 
DOCTORAL 
El presente trabajo de tesis ha permitido identificar una serie de biomarcadores 
en plasma periférico y a nivel de expresión génica de ARNm (messenger RNA) 
en las células mononucleares de sangre periférica (PBMCs) en pacientes con 
EM. 
Nuestro estudio ha encontrado una expresión disminuida de sDPP4 y una 
reducida actividad dipeptidil peptidasa (DPP) en el plasma de los pacientes con 
EM en comparación con los controles sanos. En concreto, la actividad  DPP 
más baja hallada entre los grupos de pacientes con EM fue en el grupo de 
pacientes SP-MS. La actividad DPP se correlaciona inversamente con la escala 
del estado de discapacidad (EDSS). 
En este trabajo hemos encontrado que las diferentes formas clínicas de EM se 
asocian con distintos perfiles de biomarcadores circulantes, principalmente 
quimiocinas y factores de crecimiento/angiogénicos (HGF, Eotaxina/CCL11, 
MCP-1/CCL2, Rantes/CCL5, EGF, MIP-1β/CCL4, VEGF y FGFb); y también 
con distintos niveles de expresión génica (CLU, IRF2 y LDLR). En concreto, los 
pacientes con RR-MS presentaban niveles circulantes disminuidos de HGF, 
Eotaxina/CCL11, MCP-1/CCL2, Rantes/CCL5, mientras que los pacientes en 
las fases progresivas de la enfermedad (SP-MS y PP-MS) presentaban niveles 
disminuidos de EGF y MIP-1β/CCL4. El grupo de pacientes con PP-MS 
presentaba específicamente niveles en plasma disminuidos de FGFb mientras 
que los pacientes con SP-MS presentaban niveles circulantes más elevados 
del factor de crecimiento vascular VEGF que los pacientes con RR-MS. A nivel 
de ARNm, los pacientes en las fases progresivas de la enfermedad 
presentaban una mayor expresión del gen de clusterina (CLU) que los 
pacientes RR-MS y que los controles sanos. La clusterina se encuentra 
aumentada en enfermedades neurodegenerativas como el Parkinson y el 
Alzheimer, en las que se le ha atribuido un posible papel neuroprotector. En 
nuestros pacientes con EM, aquellos con mayor expresión se encontraban en 
la fase progresiva y con mayor neurodegeneración de la enfermedad. Por otro 
lado, la expresión génica del factor regulador de interferón (IRF2) se 
encontraba disminuida en los pacientes progresivos respecto a aquellos con 
RR-MS. Los pacientes con PP-MS presentaban específicamente niveles de 
expresión génica del receptor de lipoproteínas de baja densidad (LDLR) más 
altos que  el resto de pacientes con EM y los controles sanos. Todos estos 
hallazgos diferenciales en las distintas formas clínicas de EM, apoyan y 
proporcionan nuevos indicios de la heterogeneidad de la enfermedad. En los 
pacientes tratados a largo plazo con IFNβ se han observado en este estudio 
niveles más altos en plasma de IP10/CXCL10 y MCP-1/CCL2 y una expresión 
génica incrementada de distintos genes  como MCP1, IP10, MDA5, RIG-I, 
MX1, EIF2AK2, IL1RN, RSAD2 y TRIM25 respecto a controles sanos y a otros 
grupos clínicos de EM.  
En este trabajo hemos realizado mediante análisis de regresión logística 
multivariante combinaciones de biomarcadores plasmáticos que nos han 
permitido aumentar la exactitud para identificar pacientes con EM o distinguir 
pacientes RR-MS de pacientes progresivos. Un modelo que incluye a DPP4, IL-
7 y Mig como factores de protección de no tener la enfermedad permite la 
discriminación en nuestra cohorte entre pacientes con EM y controles sanos 
con un 79.7%. Por otro lado un modelo que incluye a HGF, Eotaxina como 
factores de riesgo y EGF y MIP-1β como factores de protección de tener una 
forma progresiva de EM; permite una discriminación entre formas RR-MS y 
progresivas (SP-MS y PP-MS) del 82.6%. 
 
 
 
  
 
CONCLUSIONES 
1. Los niveles plasmáticos de dipeptidil peptidasa 4 (DPP4), un regulador 
esencial en el antagonismo de las quimiocinas, estaban significativamente 
disminuidos en nuestra cohorte de pacientes con EM respecto a controles 
sanos. 
2. La actividad dipeptidil peptidasa era significativamente más baja en 
nuestros pacientes con EM que en controles sanos y se correlacionaba 
inversamente con la escala del estado de discapacidad en EM (EDSS). 
3. Un modelo de regresión logística multivariante con DPP4, interleucina 7 y la 
monoquina inducida por el interferón gamma (Mig) permitió la discriminación 
de pacientes con EM con una exactitud en la clasificación del 79.7% en 
nuestra cohorte con 129 pacientes con EM y 53 controles sanos. 
4. Un modelo de regresión logística multivariante con el factor de crecimiento 
hepático (HGF), eotaxina, factor de crecimiento epidérmico (EGF) y la 
proteína inflamatoria de macrófagos 1β (MIP-1β) permitió la discriminación 
entre pacientes con EM recurrente-remitente y pacientes progresivos (EM 
secundaria y primaria progresiva) con una exactitud en el diagnóstico del 
82.6% en el presente estudio. Este modelo puede tener implicaciones 
clínicas para el paciente individual. 
5. En nuestra cohorte de pacientes, niveles plasmáticos bajos del factor básico 
de crecimiento de fibroblastos (FGFb) y altos de la expresión de ARNm en 
células periféricas mononucleares de sangre periférica del receptor de 
lipoproteínas de baja densidad (LDLR) diferencian a los pacientes con EM 
primaria progresiva del resto de formas clínicas. 
6. Niveles plasmáticos elevados del factor de crecimiento vascular endotelial 
(VEGF) parecen identifican pacientes EM secundaria progresiva respecto a 
pacientes con EM recurrente-remitente en este estudio. 
7. Los niveles plasmáticos y la expresión en células periféricas mononucleares 
de sangre periférica de ARNm de la proteína inducida por interferón-gamma 
(IP10) y la proteína quimiotáctica de monocitos 1 (MCP-1) están 
aumentados en nuestros pacientes respondedores al tratamiento con 
interferón β. 
8. Una elevada expresión de ARNm en las células periféricas mononucleares 
de sangre periférica del gen de la clusterina (CLU) identifica a las formas 
progresivas (secundaria y primaria progresiva) en nuestra cohorte de 
pacientes. 
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